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1. Introduction 
1.1. The History and Definition of COPD  
The clinical understanding of chronic obstructive pulmonary disease (COPD) has 
evolved over time, such that one of the first descriptions of emphysema was made by 
the Swiss physician Theophile Bonet in 1679 when he described a condition of 
‘voluminous lungs’ 1. Much later, in 1769, the Italian anatomist Giovanni Morgagni 
described 19 cases of “turgid” from air lungs 2 and only in 1789 Braille’s illustrations 
of emphysematous lungs suggested that emphysema could be a part of a more 
complex disease 3. In 1814, the British doctor Charles Badham used the word 
“catarrh” to describe chronic cough and mucous hypersecretion known today to be 
the characteristics of chronic bronchitis 4. Moving ahead to 1821, Rene Laënnec, the 
French physician and inventor of the stethoscope, described a combination of 
emphysema and chronic bronchitis as; hyperinflated lungs where the bronchus is 
filled with mucus 5.  
 
However, the diagnosis of COPD became possible only in 1846 when John 
Hutchinson invented the spirometer 6; yet, it only measured the vital capacity. It took 
another 101 years until Tiffeneau and Pinelli added the concept of timed vital 
capacity as a measure of airflow 7. Finally, in 1959, physicians at the CIBA Guest 
Symposium formally defined the terms ‘chronic bronchitis’ and ‘emphysema’ 8. 
Couple of years later, Dr. William Briscoe used the word ‘COPD’, he is believed to be 
the first person establishing this term in his discussion at the 9th Aspen Emphysema 
Conference in 1965 9. Today, this is the preferred term for the disease.  
 
In general, COPD is a progressive disorder which is characterized by airflow 
limitation that is not fully reversible 10. It is a heterogeneous disease that affects 
central airways causing chronic bronchitis, peripheral airways leading to small airway 
disease, and lung parenchyma giving rise to emphysema 11. Due to emphysema, the 
airway attachments in COPD patients are disrupted leading to airway closure and 
gas trapping in the alveoli 12. Moreover, the peripheral airways in the patients are 
obstructed by inflammatory cell infiltration, fibrosis and mucus hypersecretion 13. 
 
According to Global Initiative for Chronic Obstructive Lung Disease (GOLD), the 
diagnosis of COPD and of its severity is based on the spirometric criteria,  where the 
ratio of forced expiratory volume in one second  (FEV1) to the forced vital capacity 
(FVC) is estimated 14. FEV1 is the volume expired in the first second of maximal 
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expiration after a maximal inspiration whereas FVC is a maximum volume of air that 
can be exhaled during a forced exhalation. The drop in the FEV1/FVC ratio below 0.7 
(FEV1/FVC ratio <70%) indicates airflow limitation and the possibility of COPD 
15,16. 
Based on the FEV1 degree (GOLD), the spirometric classification of severity of COPD 
includes four stages which are summarized in Table 1 17. 
 
       Disease Severity                                      GOLD  
            Stage I: mild                FEV1 ≥80% of predicted 
        Stage II: moderate         FEV1 50% to < 80% of predicted 
          Stage III: severe            FEV1 30 to < 50% of predicted 
       Stage IV: very severe               FEV1 <30% of predicted 
Table 1. Spirometric classification of COPD severity based on FEV1 (Adapted from Juvelekian and 
Stoller, 2012) 
17
. 
 
1.2. Epidemiology 
The prevalence of chronic obstructive pulmonary disease (COPD) is increasing and it 
is becoming one of the leading causes of morbidity and mortality all over the world 18. 
In 2002, the World Health Organization (WHO) has predicted that COPD will become 
the fifth most common cause of disability and the third most common cause of death 
in the world by 2020 19. However, according to the WHO report in 2012, COPD has 
already become the third leading cause of death worldwide (Fig. 1) 20. In addition to 
increased prevalence and mortality, there is currently no cure for this disease. 
 
1.3. Risk Factors 
Two types of risk factors are responsible for the development of COPD; 
environmental factors and genetic risk factors. The most commonly encountered risk 
factor for COPD is cigarette smoking which accounts for 80%-90% of COPD cases 
21. In smokers, the oxidant burden is enhanced due to the fact that cigarette smoke is 
a mixture of over 4,700 chemical compounds; it contains 1014 oxidants/puff and 3,000 
ppm nitric oxide (NO) per puff 22. Free radicals in cigarette smoke are in the gas and 
tar phase. The gas phase includes short lived oxidants like nitric oxide, peroxide, 
peroxynitrite and nitrogen dioxide, whereas the tar phase includes long-lived radicals 
such as: semiquinones, which react with oxygen to produce ·O2·
-, ·OH and H2O2 
23. 
 
Another environmental factor that contributes to the pathogenesis of COPD is the 
exposure to indoor pollution in poorly ventilated houses due to accumulation of 
particulate matter arising from cooking and heating with biomass fuel 24. In addition to 
this, occupational exposure to gases and fumes increases the risk of COPD 
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development 25. This exposure to other risk factors has a cumulative effect with that 
from cigarette smoking 26. Although smoking remains the main risk factor, genetics 
also plays a role. For instance, people suffering from alpha-1-antitrypsin deficiency, a 
major inhibitor of serine proteases, have a high risk of COPD development 27. 
Environmental and inherited risk factors are summarized in Table 2 14. 
 
Environmental factors Genetic factors 
Cigarette smoke Genetic abnormalities 
Indoor biomass exposure Bronchial hyper-responsiveness 
Occupational exposures Reduced lung growth 
Outdoor air pollution Age 
Table 2. Risk factors for COPD development (Adapted from the Global Initiative for COPD, 2005) 
14
. 
 
1.3.1. Cigarette Smoke vs. Cigarette Smoke Extract 
Cigarette smoke (CS) as was mentioned above is a mixture of a variety of chemical 
components. The exposure of mice to cigarette smoke in order to generate a model 
of human smoking is dated back to 1940s 28 and it continues nowadays, however, 
this method is time consuming as it is of extended duration. Cigarette smoke extract 
(CSE), that is used in this thesis, is an alternative for cigarette smoke as it contains 
most of particulate matter that is found is the cigarette smoke 29-31. This method was 
first published by Miller and colleagues as they introduced cigarette smoke 
components intranasally through CSE exposure 32. CSE is considered as a second 
hand smoke and it consists of 85% of smoke that rises from the tip of the burning 
cigarette between puffs, of 11% of the exhaled smoke from the smoker and from 4% 
of the contaminants diffused through the cigarette paper 33. The CSE method has 
become very popular and it is used now in a wide range of pulmonary and cancer 
studies in order to unravel important biological cellular pathways.  The method for 
generation of CSE is practically similar in most of the studies, however, the 
concentration of CSE, the media and the number of cigarettes used varies. The 
method for CSE generation is described in the methods (section 3.3.2) of this thesis. 
1.4. Pathophysiology 
1.4.1. Chronic Bronchitis 
The presence of chronic productive cough for three months per year in two 
consecutive years is characterized as chronic bronchitis 34. This persistent cough, a 
consequence of chronic irritation caused by gases and noxious particles like cigarette 
smoke, leads to excess mucous production and increased expression of the 
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MUC5AC gene 35,36. Mucous hypersecretion is a result of goblet cell hyperplasia, an 
increase in the size of bronchial submucosal glands and the impairment in the 
mucous clearance 37. Moreover, the accumulation of mucous leads to increased 
susceptibility to infection. The difficulty in mucous clearance is caused by squamous 
metaplasia and as a consequence of ciliary dysfunction leading to airway obstruction 
which is mechanically stimulating coughing 35. The schematic drawings of the normal 
and inflamed bronchus with excess mucous are illustrated in the figure (Fig. 1). 
 
Fig. 1. Normal bronchus vs. narrowed bronchus with excess mucous build-up. 
 
1.4.2. Emphysema 
Emphysema is characterized by the destruction of the alveolar wall and permanent 
enlargement of the airspaces distal to the terminal bronchioles 38. It is caused by the 
protease-antiprotease imbalance or by the inherited α1-antitrypsin deficiency 39,40. 
Thus, continuous exposure to the cigarette smoke inactivates endogenous 
antiproteases triggering macrophages and neutrophils to release a variety of 
proteases, including neutrophil elastase, matrix metalloproteinases (MMPs), and 
cathepsins 41,42. The released proteases bind to the lung extracellular matrix causing 
elastin and collagen degradation 43. This leads to the damage and loss of alveolar 
attachments and consequently to the reduction of the elastic supporting structure of 
the lung resulting in collapse of airways and airflow limitation 44. The comparison of 
the normal alveoli with the emphysematous is illustrated in the Fig. 2. 
 
Fig. 2. Shows the normal alveoli vs. COPD alveoli with disrupted alveolar attachments (surface view). 
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1.5. Pathology 
1.5.1. Airway Epithelium and Cigarette Smoke 
The first line of defence against the harmful inhaled materials is the airway 
epithelium, it releases antioxidants which may be activated or inhibited depending on 
the degree of smoking thus trying to combat and counteract the cigarette-smoke 
induced stress 45. Pulmonary epithelium is not only having a protective role, but it 
also provides communication between different compartments of vascular, interstitial 
and luminal parts of the lung. It is one of the first targets of cigarette smoke which 
disables the receptors and enzymes on the membrane of the epithelium and disrupts 
the tight junctions inducing epithelial changes 46-49. This anti-oxidative capacity of the 
airway epithelium can be overwhelmed leading to inflammation, excess membrane 
permeability and tissue damage leading to disease risk 50. There are several 
mechanisms, by which CSE damages the airway epithelium, one of the ways is that 
cigarette smoke causes the loss of the airway epithelium. Studies have shown that 
exposure of A549, human lung adenocarcinoma cells, and primary alveolar type II 
cells to CSE lead to cell senescence, which is an irreversible growth arrest 51. 
Several other studies have demonstrated apoptosis of alveolar epithelial cells, 
inflammatory and endothelial cells in COPD lungs 52,53. Other studies showed that 
exposure of A549 cells to lower concentrations of CSE demonstrated no apoptosis, 
but necrosis 54. Even though that there is a proportionality between the concentration 
of cigarette smoke and the cell death, apoptosis of alveolar cells can lead to the loss 
of structure of alveoli, contributing to the onset of emphysema. Another possible 
mechanism by which CSE can damage the epithelial layer is by affecting its 
permeability, one of the studies showed that CS induced lung epithelial tight junction 
permeability in the human epithelial bronchial cell line Calu-3, leading to loss of the 
epithelial barrier 50. Another possible mechanism is that CSE could interfere with 
repair mechanism of the lungs thus changing airway architecture and therefore 
contributing to COPD pathogenesis. A study using human bronchial epithelial cells 
(HBE) showed that CS inhibited the HBE proliferation, chemotaxis and the ability to 
remodel the extracellular matrix 55. Another study showed that CS reduced the cell 
attachment, increased cell detachment and decreased cell proliferation in A549 cells 
56. In addition, many cytokines are implicated in the COPD pathogenesis. Human 
bronchial epithelial cells exposed to CS showed an increased inflammatory response 
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by release of pro-inflammatory mediators such as IL-1β, RANTES, IL-6, IL-8, and 
GM-CSF 57. Altogether, cigarette smoke exerts an enormous impact on the epithelia. 
 
1.5.2. Oxidative Stress 
As was mentioned previously, the respiratory epithelium is a major target for 
oxidative injury from oxidants generated either exogenously or endogenously. The 
exogenous oxidants come from cigarette smoke or air pollutants like ozone, nitric and 
sulfur dioxide, whereas endogenous oxidants are generated from reactive oxygen 
(ROS) and nitrogen (RNS) species released from inflammatory/epithelial cells 23,58 or 
formed through mitochondrial respiration 59. ROS and RNS are produced under 
normal conditions as by-products of metabolism, participating in physiological 
processes involved in intracellular signalling, angiogenesis, cell proliferation, and 
gene expression 60.  However, in order to combat the injurious effects of oxidants, the 
body possesses multiple antioxidant systems which are classified into enzymatic and 
non-enzymatic ones. The enzymatic system comprises catalase, superoxide 
dismutase (SOD) and glutathione peroxidase, whereas non-enzymatic includes β-
carotene, mucin, vitamin E, ascorbic acid and albumin 61. Moreover, many 
antioxidant enzymes are under the control of nuclear factor erythroid 2-related factor 
2 (Nrf2). Nrf2 is expressed throughout the lung and is mainly found in epithelial cells 
and macrophages. Nrf2 plays a protective role in the lungs, under normal conditions 
Nrf2 exists in the cytoplasm where it is bound to the Kelch-like ECH-associated 
protein 1 (Keap1) which promotes its ubiquitination and degradation 62. However, 
under stress conditions, Nrf2 dissociates from Keap1 and translocates to the nucleus, 
where it induces the transcription of downstream antioxidant genes (SOD, HO-1, 
thioredoxin reductase) by binding to the antioxidant response element (ARE) 63.  
 
Despite that, any imbalance between oxidants and antioxidants towards pro-oxidant 
system leads to oxidative stress in cells and tissues 64. This stress is not only a result 
of increased oxidants but also of a decreased antioxidative capacity. Chronic 
oxidative stress leads to DNA, lipid and protein damage 65 and is responsible for 
mucous hypersecretion, metaplasia, apoptosis, inactivation of surfactants and anti-
proteases 61. Consequently, the increased burden of oxidative stress is responsible 
for the inflammation and plays an important role in the development and progression 
of COPD 66.  
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Moreover, ROS can oxidize membrane phospholipids when produced close to the 
cell membranes generating lipid hydroperoxide molecules within the membrane 67. 
This leads to tissue permeability, inactivation of membrane-bound receptors and 
impairment of membrane function 67. As a result, reactive aldehydes (acrolein and 4-
hydroxy-2-nonenal (4-HNE)) and other bioactive molecules, such as isoprostanes are 
formed. They are highly diffusible products of lipid peroxidation that can alter the 
function of histone deacetylase HDAC-2 68 and extracellular proteins, such as 
collagen and fibronectin 69 by forming adducts with them due to their high affinity 
towards cysteine, histidine, and lysine residues. This, in turn, affects the cellular 
function.  
 
In addition to this, ROS and RNS maintain the oxidative stress in the lungs through 
the activation of macrophages that in turn recruit other inflammatory cells 
(neutrophils, monocytes, lymphocytes) by releasing cytokines 58. It was reported that 
patients with COPD exhibit high levels of oxidative stress markers in their blood, 
breath, lungs and sputum 70.  
 
1.6. Molecular Mechanisms of COPD Pathogenesis 
COPD is characterized by progressive chronic inflammation. The cells involved in its 
pathogenesis are neutrophils, macrophages and lymphocytes. Cigarette smoke 
activates the immune cells (neutrophils, macrophages and lymphocytes) to release 
pro-inflammatory mediators like cytokines, chemokines and chemoattractants thus 
leading to chronic inflammation 71.  
 
The mechanism of COPD pathogenesis is explained in Fig. 3 72. Inhaled cigarette 
smoke and other irritants stimulate macrophages and epithelial cells to release 
inflammatory mediators. Epithelial cells release TGF-β and FGFs which stimulate 
fibroblast proliferation, inducing fibrosis 72. 
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Fig. 3. Mechanisms of molecular pathogenesis in COPD (From Barnes, J Clin Invest., 2008) 72. 
Macrophages, in turn, release TNF-α, IL-6 and Il-1β which amplify the inflammation in 
COPD. Moreover, alveolar macrophages secrete proteases possessing an elastolytic 
activity such as MMP-9, MMP-12, and cathepsins K, L and S leading to emphysema 
73. In addition to this, alveolar macrophages express CCL2 (also known as monocyte 
chemotactic peptide MCP-1) which is a potent chemoattractant for monocytes acting 
via CCR2 72. CXC chemokines, CXCL1 (also known as GRO-α) and CXCL8, which 
are as well derived from alveolar macrophages and act on CXCR2, are responsible 
for monocyte and neutrophil recruitment 74. Thereafter, monocytes differentiate into 
macrophages in the lung. In addition to this, destructive enzymes such as perforin 
and granzyme B are released from recruited CD8+ lymphocytes (Tc1), resulting in 
apoptosis of the alveolar epithelial cells 75. Neutrophils in turn, release 
chemoattractants like IL-8 and leukotriene B4 (LTB4) to the site of inflammation in 
order to attract other neutrophils 76. In addition to this, neutrophils release proteolytic 
enzymes, including neutrophil elastase (NE), cathepsin G as well as matrix 
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metalloproteinase MMP-8 and MMP-9, that cause the damage of the elastic lung 
tissue 77 and promote mucus hypersecretion 78. 
1.7. Therapeutic Approaches 
Although many approaches have been taken to cure COPD, currently no treatment 
has been found to prevent the progression of the disease. Some approaches that 
can alleviate the symptoms of COPD include: 
 Inhaled steroids: although these locally applied steroids have no effect on the 
systemic inflammation, they can decrease the frequency of exacerbations and 
hence improve the health status of COPD patients 79. 
 Anticholinergics: it was suggested that antagonising the release of 
acetylcholine from macrophages and epithelial cells and therefore blocking the 
activation of neutrophils and macrophages could play a role in decreasing the 
inflammation in COPD. However, it was shown that this only decreases the 
onset of exacerbations and has no effect on serum interleukins (ILs) in COPD 
patients 80. 
 Antioxidant intervention: several antioxidants have been tested as potential 
candidates for treatment, however; none of them protected against oxidative 
stress and consequently against COPD onset. This could be due to the fact 
that most experimental approaches have investigated the effect of a single 
antioxidant agent, whereas COPD is a heterogeneous disease involving many 
antioxidant systems 65. 
 Antioxidative pharmacological mimetics: experimental studies with SOD-
mimicking activity agents showed significant antioxidant and anti-inflammatory 
properties. The studies have only been conducted in models of airway 
inflammation; the challenge is to find SOD mimetics which decrease airway 
inflammation, inflammatory cytokines and lipid peroxidation 81. 
 Thiols: BRONCUS (Bronchitis Randomized on NAC Cost-Utility Study), was 
the largest antioxidant trial in COPD, however; it failed to show any beneficial 
effect of the oral administration of N-acetyl cysteine on the frequency of 
exacerbations and progression of disease 82. 
 
Therefore, new treatment approaches are needed. 
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1.8. Peroxisomes 
1.8.1. Discovery and Morphology of Peroxisomes 
 
Peroxisomes are single membrane-bound organelles that were first discovered 
electron microscopically by Rhodin 83 and named ‘microbodies’ due to the lack of 
knowledge concerning their function and biological importance. Two years later, 
these organelles were identified in rat liver cells by Rouiller and Bernard who 
suggested that these organelles might be precursors of mitochondria 84. Only in 
1960, De Duve and his co-workers recognized them as a novel enzyme-containing 
organelle while doing fractionation experiments for lysosome isolation 85. They 
noticed that this organelle contains catalase, D-amino acid oxidase, and uric acid 
oxidase and that it is different from lysosomes, mitochondria and microsomes. Based 
on the fact that it contains H2O2-degrading enzyme (catalase), as well as H2O2-
producing (flavin-containing oxidases) enzymes, the name ‘peroxisome’ was 
proposed to this organelle 85. 
 
With the introduction of the alkaline 3, 3′-diaminobenzidine (DAB) reaction for 
catalase, the peroxisomal detection became possible under the light and electron 
microscopy 86-88. Using this method, peroxisomes were identified in every examined 
tissue except the spermatozoa 89 and the red blood cells . DAB reaction showed that 
peroxisomes vary in size (ranging from 0,2µm to 1µm in diameter) shape (angular, 
elongated, interconnected, and tubular) and abundance. This variation of the 
peroxisomal shape and the organelle’s enzyme content depends on the organ and 
the cells type and it differs during developmental, environmental and metabolic 
factors.  
 
1.8.2. Biogenesis of Peroxisomes 
All processes involved in the formation of the peroxisomal membrane, import of 
proteins into the peroxisomal matrix and the proliferation of the peroxisomes are 
summarized in the term “peroxisome biogenesis” 90. Peroxisomes either arise de 
novo or multiply by fission from pre-existing peroxisomes 91. However, it’s not clear 
yet how these both pathways contribute to the total number of peroxisomes in the 
wild-type cells 92. Moreover, how the peroxisomal membrane is generated in the 
mammalian cells is still the matter of debate, even though, the membrane was 
described to be synthesized via budding from the endoplasmic reticulum in the yeast 
model 93,94. 
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All proteins required for the biogenesis of peroxisomes are termed “peroxins” (PEX 
proteins) and they are encoded by PEX genes (Pex in the mouse) which are 
numbered according to their date of discovery 90. Moreover, these peroxins can be 
divided into different functional groups. For instance, PEX3, PEX16, and PEX19 are 
involved in the formation of the peroxisomal membrane. Hence, cells that are 
deficient in either of these peroxins have neither peroxisomes nor peroxisomal 
membrane remnants 95,96. PEX5 and PEX7 are responsible for cytoplasmic 
translocation of peroxisomal matrix proteins 97 whereas PEX13, PEX14 and PEX17 
facilitate the docking of receptor/cargo complexes 98. PEX10 and PEX12 are 
important for import of proteins into the peroxisome, PEX11 for budding and fission of 
the organelles and PEX4 for the degradation of the organelle 98. Nowadays, 31 
known peroxins have been discovered, of which 14 peroxins have been identified in 
human 99.  
 
Since peroxisomes do not contain DNA and ribosomes and therefore have no means 
of protein production, peroxisomal matrix proteins are synthesized on free ribosomes 
in the cytosol and then they are post-translationally transported into peroxisomes 97. 
Before being imported into the pre-existing organelle, the synthesized peroxisomes 
are folded into their mature conformation 100.  
   
1.8.3. Peroxisomal Matrix Protein Import 
Peroxisomal matrix proteins possess peroxisomal targeting signals (PTS) that enable 
them to be targeted from the cytosol into the organelle [82]. These peroxisomal 
targeting signals (PTS) are the PTS1 with the amino-acid consensus sequence 
(S/C/A) (K/R/H) (L/M) that is located in protein carboxyl-terminal (C-terminus) 101 and 
the PTS2 that is located in protein amino-terminus (N-terminus) with the consensus 
sequence (R/K)(L/V/I)(X)5(H/Q)(L/A) 102,103. 
 
Cytoplasmic shuttling receptors (PEX5p and PEX7p), that interact with PTS1 and 
PTS2 respectively, bind the peroxisomal matrix proteins in the cytoplasm (Cargo 
Receptor Binding) and translocate them to the docking complex (Docking) in the 
peroxisomal membrane as illustrated in the figure (Fig. 4) 104. The docking complex 
comprises two peroxisomal membrane proteins PEX13 and PEX14 to which shuttling 
receptors bind and subsequently release the cargo into the peroxisome (Cargo 
Release) 104,105. Then, the ubiquitination and recycling of PEX5p occurs 
(Ubiquitination and Translocation, Recycling) and this process requires 
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PEX1p/PEX6p that are anchored to the peroxisomal membrane by PEX26p in 
humans 104,106. 
 
Fig. 4. Schematic representation of the matrix protein import (From Colasante et al., Thromb 
Haemost., 2015) 
104
. 
 
1.8.4. Peroxisomal Topology 
The peroxisomal enzyme content is versatile. It varies from one species to another, 
even within the same species, and from one organ to another 107. Peroxisome 
composition in mammals comprises various enzymes that are divided into different 
groups (Fig. 5A): 
 β-Oxidation enzymes: peroxisomes catalyze the degradation of a variety of 
fatty acids that are not metabolized in the mitochondria. Peroxisomes degrade 
long-chain fatty acids (LCFA), very long-chain fatty acids (VLCFA), long 
branched-chain fatty acids and eicosanoids; by acyl-CoA oxidases (ACOX1, 
ACOX2, ACOX3), multi-functional protein 1 and 2 (MFP1,2) and peroxisome 
3-ketoacyl-CoA Thiolase (ACAA1) 108,109. 
 Antioxidative enzymes: peroxisomes degrade various reactive oxygen 
species (ROS). Catalase, glutathione peroxidase 1 (GPX) and peroxiredoxins 
1, 5 (PRX1, PRX5) decompose H2O2 whereas superoxide dismutase 1 
(SOD1) scavenges superoxide anions.  
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 Ether lipid synthesis enzymes: enzymes responsible for the synthesis of 
plasmalogens are dihydroxyacetone phosphate acyl-transferase 
(DHAPAT=GNPAT (glyceronephosphate O-acyltransferase)) and‐ 
alkylglycerone phosphate synthase (AGPS) 108. 
 Cholesterol synthesis enzymes: 3-Hydroxy-3-methyl glutaryl-CoA 
(HMGCoA) reductase (localized in endoplasmic reticulum as well), Isopentenyl 
diphosphate  delta  isomerase  (IDI1), mevalonate  kinase  (MVK),  phosphor-
mevalonate kinase (PMVK), mevalonate pyrophosphate decarboxylase 
(MPD), isopentenyl-diphosphate isomerase 2 (IPP) and farnesyl diphosphate 
(FPP) 110-112. 
 
Specific transporters (e.g. ABCD1) are responsible for carrying various peroxisomal 
metabolites (VLCFA) across the membrane where these metabolites are broken 
down by peroxisomal oxidases (light purple) (Fig. 5A). During the process of β-
oxidation, H2O2 is generated and further decomposed to H2O and O2 by peroxisomal 
antioxidative enzymes (light blue) (Fig. 5A). Superoxide anions (O ), are scavenged 
by copper-zinc-superoxide dismutase (CuZnSOD) (Fig. 5A). In addition to this, M-LP 
(Mpv17-like protein) (dark blue) is a PMP that is involved in the metabolism of ROS 
113. Nitric oxide (•NO) that is produced from the oxidation of L-arginine by nitric oxide 
synthase (NOS, dark purple), reacts with O  radicals forming a powerful oxidant 
peroxynitrite (ONOO−) (Fig. 5A). Recent study in hepatocytes has shown that iNOS 
is also targeted to peroxisomes through interaction with PEX7 114. 
 
ROS as well as reactive nitrogen species (RNS) are not only scavenged by 
peroxisomes but they are also generated by this organelle (Fig. 5B) 115. Two 
corrections have to be made concerning the diagram, Mn-superoxide dismutase 
(MnSOD) which was used to be recognized as the peroxisome antioxidant enzyme, 
has been found to be actually located solely within the mitochondrial matrix 116 
whereas MPV17 encodes an inner mitochondrial membrane protein 117. 
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Fig. 5. Schematic representation of ROS homeostasis by peroxisomes (Modified from Bonekamp et. 
al., Biofactors,  2009) 
115
. 
1.8.5. Peroxisome Degradation 
Peroxisomes have a half-life of around 2 days 118. Hence, in order to maintain a 
proper functional peroxisome population, dysfunctional organelles have to be 
removed. Peroxisomes are degraded by autophagy, in a process called “pexophagy” 
119. The peroxisomal turnover has three important functions: 1) to recycle the cellular 
components in order to adapt to different environment (non-selective degradation), 2) 
to remove damaged or non-functional organelles (selective degradation) and 3) to 
get rid of exhausted peroxisomes (constitutive degradation) 120. Two different 
mechanisms of pexophagy occur; macropexophagy and micropexophagy as 
illustrated in figure (Fig. 6) 121. Macroautophagy involves the sequestration of the 
organelle by a double-membrane cytosolic structure known as autophagosomes that 
fuses with the vacuole releasing the autophagic bodies inside for further degradation 
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122. In contrast, micropexophagy involves the engulfment of the organelles by 
invagination of the vacuolar membrane and further degradation of the organelle in 
the vacuolar lumen 123. 
 
Fig. 6. Illustration of different mechanisms of peroxisomal degradation (pexophagy) (Modified from  
Manjithaya et. al., FEBS Lett., 2010) 
121
. 
1.8.6. Peroxisomal Disorders 
The cause of the peroxisomal disorders may be associated either with peroxisome 
biogenesis disorders (PBDs) or with single peroxisomal enzyme/transporter 
deficiencies (PEDs).  
  
Peroxisome biogenesis disorders (PBDs) are caused by the mutations in some 
peroxin genes (PEX) which are important for biogenesis of peroxisomes as well as 
for the peroxisomal carrier proteins 124. The mutations of the PEX genes cause 
developmental and/or degenerative pathological disorders known as disorders of the 
Zellweger syndrome spectrum (ZSS) 124. Peroxisome biogenesis disorders (PBDs) 
include; Zellweger syndrome (ZS), neonatal adrenoleukodystrophy (NALD) and 
infantile refsum disease (IRD). The Zellweger syndrome, known as cerebro-hepato-
renal syndrome, is characterized by either a reduced number of functional 
peroxisomes or by a complete lack of peroxisomes 125-127. Children with ZS suffer 
from general hypotonia, muscular weakness and are susceptible to life-threatening 
respiratory problems. They usually die before reaching their 1st year of age from the 
swallowing dysfunction and respiratory compromise or from cardiac problems 128,129. 
Usually, these patients suffer from a decrease in plasmalogens (ether lipids) and 
polyunsaturated fatty acid (PUFA) as well as from the accumulation of branched-
chain and VLC fatty acids 130.  
 
In contrast to peroxisomal biogenesis disorders, in PEDs, peroxisomes are present 
and mostly intact but there is a deficiency in one of the enzymes, thus leading to 
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metabolic abnormality 131. The best known peroxisomal diseases of this group are the 
ones with mutations in the GNPAT and AGPS genes, which encode the enzymes of 
the peroxisomal ether lipid synthesis, leading to the diseases such as; rhizomelic 
chondrodysplasia punctata type 2 and type 3 respectively 132. The other diseases 
include: X-linked adrenoleukodystrophy (X-ALD) and acyl-CoA oxidase deficiency 131. 
1.9. Peroxisomes in the Lungs 
1.9.1. Peroxisomes in the Lung Epithelium 
In the early studies published 30-40 years ago, peroxisomes were visualized with the 
help of DAB reaction in bronchiolar club cells (formerly called Clara cells) and 
alveolar type II cells (AECII) of different species such as man, mouse, rat, hamster, 
guinea pig, rabbit, cat, pig and monkey 133-135. With the discovery of additional 
peroxisomal marker proteins and the introduction of a more sensitive catalase 
detection method, identification of peroxisomes became possible in all pulmonary cell 
types including alveolar type I cells (AECI) and alveolar macrophages of man and 
mice 136,137. However, the distribution, size and protein composition of pulmonary 
peroxisomes showed heterogeneity in distinct cell types indicating the functional 
differences of this organelle. For instance, club cells, AECII cells and macrophages 
express higher levels of catalase as well as possess larger peroxisomes than AECI 
cells. In contrast, higher abundance of β-oxidation enzymes is found in AECI cells 
136,137. The presence of GNPAT in the peroxisomes of AECII cells suggests that they 
are involved in the synthesis and secretion of the surfactant, which is important for 
the alveolar function and prevention of alveolar collapse 138. Moreover, the formation 
of inflammatory lipid mediators (leukotrienes and prostaglandins) as well as platelet 
activating factor (PAF, plasmalogens), secreted by macrophages and neutrophils, 
depends on peroxisomal ether lipid synthesis or peroxisomal β-oxidation 138. 
 
The exposure of lungs to high oxygen concentrations makes them very susceptible to 
injury mediated by oxidative stress 139. Nonenzymatic antioxidants, such as 
glutathione, vitamin C and β-carotene as well as ether lipids (plasmalogens) and 
polyunsaturated fatty acids (PUFA) in the plasma membranes of airway epithelial 
cells or in the surfactant film, covering the alveolar region, are the first line of defence 
against the oxidants 136. Interestingly, the important steps in the synthesis of these 
lipids occur in peroxisomes. The second line of defence against oxidative stress 
includes antioxidative enzymes such as superoxide dismutases, catalase, glutathione 
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peroxidases and peroxiredoxins. The antioxidative enzymes are degrading various 
types of ROS and are localized in distinct intracellular subcompartments as well as in 
different pulmonary cell types 137. Thus, if the balance between the antioxidative 
defensive mechanisms and the ROS production is disturbed, pathological changes 
are induced leading to lung injury and to various airway diseases such as COPD, 
asthma and pulmonary fibrosis 139. Therefore, peroxisomes might protect the 
pulmonary airway epithelium by their high content in different antioxidative enzymes, 
their role in the synthesis of PUFA and plasmalogens and their ability to degrade 
toxic lipid derivatives through the β-oxidation systems 136. 
 
1.9.2. Peroxisome Proliferator-activated Receptors 
Peroxisome proliferator-activated receptors (PPARs) belong to the nuclear hormone 
receptor family that function as ligand-activated transcription factors 140. PPARs play 
a role in the regulation of important processes, such as cellular differentiation, 
inflammation, and wound healing 141. Three different subtypes of PPARs exist: 
PPARα (also known as NR1C3), PPARγ (also known as NR1C1) and PPARβ (also 
known as PPARδ or NR1C2). PPARγ was found to be expressed, within the lung in 
smooth muscle cells, in the epithelia, endothelium, fibroblasts, macrophages, 
eosinophils, dendritic cells, B cells and T cells 45. PPARα was found to be localized in 
the heart, liver, kidneys and intestinal mucosa 142,143 whereas PPARβ is highly 
expressed in adipose tissue, heart, muscle, intestine, and macrophages 143. 
 
PPARγ (peroxisome proliferator-activated receptor gamma) can be activated by 
endogenous as well as exogenous factors (Table 3). Among the endogenous ligands 
(natural) for PPARγ are polyunsaturated fatty acids (such as linoleic acid, arachidonic 
and eicosapentaenoic acid), oxidized lipids (13-HODE and 15-HETE) and 
prostaglandin (PG)-related compounds, such as 15-deoxy-delta12-14-PGJ2 (15d-
PGJ2) 144. The exogenous ligands (synthetic) include thiazolidinediones (TZDs) like 
troglitazone, ciglitazone, pioglitazone and rosiglitazone, non-thiazolidinediones (non-
TZDs) such as isoxazolidinedione JTT-501 and tyrosine-based ligands, like GW-7845 
145,146.  
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Table 3. Some of the important exogenous and endogenous PPARγ activators 
 
1.9.3. PPAR Transcription Machinery 
PPARs have two functional domains that are highly conserved in all the three 
receptors; a DNA binding domain (DBD) (promotes the binding of PPAR to the 
peroxisome proliferator response element (PPRE)) and a ligand-binding domain 
(LBD) (for binding to a wide range of ligands) 147. As illustrated in the figure (Fig. 7) 
148, in an inactive state, PPARs interact with the corepressor having histone 
deacetylase activity thus inhibiting the gene transcription. However, upon binding of 
endogenous or exogenous ligands to the PPAR, the PPAR-ligand bound complex 
heterodimerizes with the retinoid X receptor (RXR) forming a PPAR-RXR 
heterodimer 149. This heterodimer binds to PPRE leading to recruitment of co-
activators that have histone acetylase activity thus inducing the transcription of genes 
149  
 
 
Fig. 7. PPAR gene transcription mechanisms (From Kota et al., Pharmacol Res., 2005). 
148
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1.9.4. Peroxisomes and COPD 
Cigarette smoke or cigarette smoke extract (CSE) contain massive amounts of 
oxidants (ROS and RNS) which provoke oxidative stress by an oxidant/antioxidant 
imbalance 150. Therefore, peroxisomes could be easily affected in airway epithelial 
cells by components of cigarette smoke (e.g. oxidants and NO), since most of these 
organelles are indeed localized directly underneath of the apical surface of ciliated 
cells or in the apical region of club cells of the bronchiolar epithelium 136,137. 
Moreover, peroxisomes are also very abundant in alveolar type II cells 137. 
 
The role of peroxisomes in the bronchiolar epithelium (BE) as well as in the alveolar 
region is not well understood and their possible alterations in COPD patients are 
unknown. However, Karnati and Baumgart-Vogt (2008) 137 suggested that the high 
numerical abundance of peroxisomes in the ciliated cells of the respiratory epithelium 
of bronchi and the bronchiolar epithelium in humans may contribute to the protection 
of the epithelial cells against ROS.  
 
It is of interest that in peroxisomes, lipid and ROS metabolism are intimately linked to 
each other, since they synthesize plasmalogens (ether lipids) that are able to trap 
ROS. It is clear, that oxidative stress in the COPD lungs exerts a major role in the 
aggravation of the disease and that the imbalance of oxidants and antioxidants plays 
a vital role in the molecular pathogenesis of COPD. It was found that oxidative stress 
induces alterations in the peroxisomal compartment, such as tubulation of the 
organelles 151. Therefore, it is most likely, that the peroxisomal compartment is 
affected in the alveolar and bronchiolar region of COPD patients 136. Furthermore, 
altered peroxisomal lipid metabolism, such as a reduced ether lipid synthesis or a 
reduced peroxisomal β-oxidation of eicosanoids, which are important lipid mediators 
of inflammation, might prolong the inflammatory response. In addition to catalase, 
peroxisomes contain a number of antioxidative enzymes, such as SOD1, glutathione 
peroxidase and peroxiredoxins I, V and VI 136. Therefore, the activation of 
peroxisomal genes and peroxisomal proliferation by peroxisome proliferator-activated 
receptors (PPARs), could protect the pulmonary airways against the inflammatory 
onset  152. 
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Since peroxisomes are intimately involved both in the metabolism of ROS and of pro-
inflammatory lipids, alterations in their numerical abundance or in the regulation of 
their metabolic pathways might, therefore, influence the pathogenesis of COPD.  
 
1.9.5. PPARγ and COPD 
Unfortunately, homozygous ablation of PPARγ in vivo has been hindered since the 
deletion of PPARγ caused impaired placental development leading to embryonic 
lethality 153,154. PPARγ null mice demonstrated a lethal effect of placenta dysfunction 
starting from gestational day 9.5 (E9.5) 154, which is actually the time point when the 
lung development in mice begins 155,156. Therefore, the dissection of PPARγ function 
has relied on generation of tissue-specific or isoform-specific knock-out mouse 
models 157-161.  
 
A study with targeted deletion of PPARγ in the airway epithelium of mice led to 
enlargement of airway spaces, exhibited abnormal lung maturation, loss of elastic 
recoil and differences in parenchymal geometry in comparison to control mice 162. 
Another study with PPARγ deletion in the airway epithelium promoted the influx of 
macrophages and produced more severe emphysema, after exposure to cigarette 
smoke, in comparison to mice possessing the PPARγ gene 163. Similarly, activation of 
PPARγ in wild type mice protected against inflammation following the exposure to 
cigarette smoke 164,165. PPARγ is found in immune and inflammatory lung cells, it is 
expressed in monocytes/macrophages, plays a role in differentiation and activation of 
monocytes and in the regulation of inflammatory activity 166,167. Moreover, the release 
of pro-inflammatory cytokines from activated macrophages, eosinophils and airway 
epithelial cells can be inhibited by PPARγ ligands, resulting in anti-inflammatory and 
immuno-modulatory effects 45,168,169. Agonists of PPARγ might regulate epithelial cell 
inflammation by decreasing cigarette smoke-induced mucin synthesis in the airway 
epithelium 170. These PPARγ actions might be pathophysiologically relevant to 
COPD.  
 
Moreover, it was shown that PPARγ expression is impaired in patients with COPD 
171, acute lung injury 172, cystic fibrosis and sarcoidosis 173. It has been suggested that 
PPARγ agonists might have potential for COPD treatment 165,174-176. Therefore, 
PPARs might be novel targets in lung diseases such as; COPD, asthma and acute 
lung injury 45,177. 
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2. Aims of the study 
No information is available so far on the role of peroxisomes in the molecular 
pathogenesis of COPD. As was stated previously in the introduction, the fact the 
peroxisomes are abundant in the airway epithelium and that they could be directly 
affected by cigarette smoke as they are located underneath the apical surface of 
airway epithelia made us hypothesize that they could play a role in COPD.  
Moreover, since peroxisomes are rich in different antioxidative enzymes, and they 
play an important role in β-oxidation of eicosanoids, hereby they could protect the 
pulmonary airway epithelium against ROS and lipotoxicity. 
 
Due to these hypotheses, the aims of the thesis were; 
1. To analyze the possible alterations of the peroxisomal compartment in lung samples 
of COPD patients in comparison to healthy control subjects. 
2. To analyze the possible alterations of the peroxisomal compartment in lung samples 
of a COPD mouse model in comparison to control mice. 
3. To study the functional consequences of cigarette smoke extract on the peroxisomal 
compartment in human HBE cells and mouse C22 cells. 
4. To investigate whether impairment in peroxisomal metabolism could affect the 
molecular pathogenesis of COPD. 
5. To evaluate the changes in the peroxisomal compartment, antioxidative enzymes and 
cytokines following PPARγ overexpression or knockdown in cigarette smoke-treated 
cells. 
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3. Materials and Methods  
 
3.1. General Materials used in the laboratory 
3.1.1. Routine materials used for molecular and morphological experiments  
 
The chemicals used in the experiments and the corresponding suppliers are listed in 
Table 4.  
 
Table 4. The chemicals used in the experiments with the corresponding providers. 
Chemicals Catalogue number Providers 
2X Rapid Ligation Buffer C6711 Promega 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) 
M5655 Sigma-Aldrich 
AccuGENE™ water 51200 LONZA 
Acrylamide  EC 890 ProtoGel 
Agarose  11404 Serva 
Agarose Universal 35-1020 Peqlab 
Allstars negative siRNA  1027280 Qiagen 
Ampicillin A6352 Applichem 
Bradford reagent  B6916 Sigma-Aldrich 
BrdU cell proliferation assay 2750 Millipore 
Bromophenol blue  15375.01 Serva  
Deoxynucleotide Mix (dNTP) 2201210 5 Prime 
Dihydroethidium (DHE) D7008 Sigma-Aldrich 
DNA ladder 10068-013 Invitrogen 
DNA Stain G 39803 Serva 
Dual luciferase reporter assay E1910 Promega 
ElectroMAX™ DH5α-E™ Competent Cells 11319019 Invitrogen 
Ethanol  64-17-5 Merck  
Ethylene diamine tetraacetic acid (EDTA)  O3690 Fluka 
Gene Pulser®/MicroPulser™ Electroporation Cuvettes, 
0.2 
1652086 Bio-Rad 
Glutaraldehyde G7651 Sigma-Aldrich 
Glycerol  GG1 Sigma-Aldrich  
High-Capacity cDNA Reverse Transcription Kit 4368814 ThermoFisher 
Human IL-8 ELISA Ready-SET-Go!® (2
nd
 Generation) 88-8086-22 Affymetrix eBioscience 
Human TNF alpha ELISA Ready-SET-Go!® 88-7346-88 Affymetrix eBioscience 
Immun-Star™ AP Substrate 170-5018 Bio-Rad 
MicroPulser™ electroporator 165-2100 Bio-Rad 
Milk powder T145.3 Carl Roth 
Mouse IL-6 ELISA Ready-SET-Go!® 88-7064-22 Affymetrix eBioscience 
Mouse TNF alpha ELISA Ready-SET-Go!® 88-7324-22 Affymetrix eBioscience 
Mowiol 4-88   17951-500 Polysciences 
3-[N-Morpholino]-propanesulfonic acid (MOPS)  M-8899 Sigma-Aldrich 
N-Propyl-gallate  02370 Sigma-Aldrich 
Neomycin A7002 Applichem 
NucleoBond® Xtra Midi EF REF 740420.50 Macherey-Nagel 
NucleoSpin® Gel and PCR 
Clean-up 
Lot 1601/002 Macherey-Nagel 
Paraformaldehyde (PFA)  604380 Sigma-Aldrich 
Penicillin/Streptomycin  P06-07001 PAN Biotech  
pGL2-basic vector X65323 Promega 
Plasmid PPARγ    IPAKp961L1324Q= RZPD 
pRL-SV40 Renilla luciferase (Rluc) control reporter E2231 Promega 
Precision Plus Protein™ Standards Dual Color 161-0374 Bio-Rad 
Protease inhibitor mix M 39102 Serva 
PVDF membranes IPVH00010 Millipore 
RNAzol® RT R4533 Sigma-Aldrich 
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Rosiglitazone R2408 Sigma-Aldrich 
ScreenFect A S3001 InCella 
siRNA Pex13 GEHC1-000790 (SO-
24886576) 
Dharmacon 
siRNA PPARγ isoform 2 S101385398 Qiagen 
Sodium chloride S6191 Merck 
Sodium dodecyl sulfate (SDS)  L4390 Sigma 
Subcloning Efficiency™ DH5α Competent Cells 18265-017 Invitrogen 
TopTaq DNA Polymerase 200203 Qiagen 
T4 DNA Ligase M1804 Promega 
Tetramethylethylenediamine (TEMED)  A1148,0025 BioChemica  
Trishydroxymethylaminomethane (Tris)  4855.2 Carl Roth 
Triton X-100  T8787 Sigma  
Tween 20  822184 Merck  
Xylene  97133 Carl Roth  
 
3.1.2. Laboratory instruments used 
 
All instruments used for the experimental parts with appropriate manufacturers are 
summarized in Table 5. 
 
Table 5. The chemicals used in the experiments with the corresponding providers. 
Instruments  Suppliers 
Biocell A10 water system                                                Milli Q-Millipore  
Biofuge Fresco   Heraeus 
BioRad electrophoresis apparatus  
(Sub Cell GT) system  
 
 
Bio-Rad  
Centrifuge mini Uni-fuge  Roth 
Dish washing machine (G 78 83 CD)   Miele 
Fusion FX   Fisher Biotec 
Gel-Doc 2000 gel documentation system   BioRad 
Heating and drying table  Medax 
Hera cell 240 incubator   Heraeus 
Hera safe, clean bench KS-12   Heraeus 
Ice machine, Scotsman AF-100   Scotsman Ice Systems 
iCycler PCR machine MyiQ2 optical module   Bio-Rad 
Leica DMRD fluorescence microscope   Leica 
Leica DC 480 camera   Leica 
Leica TCS SP2 confocal laser scanning microscope   Leica 
Leica SM 2000R rotation microtome   Leica 
Microwave oven MB-392445   LG 
Mini-Protean 3 cell system   Bio-Rad 
Mini Trans-Blot® Cell  Bio-Rad 
Multifuge 3SR centrifuge   Heraeus 
NanoDrop™ 8000   ThermoFisher 
Oven HERAEUS T 5050 EKP   Heraeus 
Paraffin tissue floating bath  Medax 
pH meter E163649   IKA  
Pipettes ErgoOne  Starlab 
Potter-Elvehjem homogenizer 8533024   B.Braun 
PowerPac 200  Bio-Rad 
Pressure/Vacuum Autoclave FVA/3   Fedegari 
Pump Drive PD 5001   Heidolph Instruments 
Smartspec
TM
 3000 spectrophotometer  Bio-Rad 
Thermostat Block HBT 130   HLC, BioTech  
Trans-Blot SD semi dry transfer cell   Bio-Rad 
Trimmer TM60  Reichert 
TRIO-Thermoblock   Biometra 
TriStar LB 941 Multimode Reader  Berthold 
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Ultra balance LA120S   Sartorius 
Ultra Turrax T25 basic homogenizer   Junke & Kunkel 
Universal balance  Sartorius 
Vortex MELB 1719  Merck Eurolab  
Water bath shaker GFL 1083   GFL  
 
3.1.3. The materials used for culturing the cells 
 
The general materials and the cell culture medium used for culturing of HBE and C22 
are listed in Table 6. 
 
 Table 6. General materials and the cell culture medium used in the experiments 
Material for cell culture Suppliers 
Cover slips  Menzel-Gläser, Germany  
Culture dish (60mm)  BD Biosciences, Germany  
Multi-well cell culture plates (6 wells) BD Biosciences, Germany 
Multi-well cell culture plates (12 wells)  BD Biosciences,  Germany  
Multi-well cell culture plates (24 wells) BD Biosciences, Germany 
Nalgene syringe filter (0.2µm) ThermoFisher Scientific, Germany 
HBE materials  
Airway Epithelial Cell Basal Medium ATCC, Germany 
Small Airway Epithelial Cell Growth Kit  ATCC, Germany 
C22 media  
DMEM, high glucose, GlutaMAX™ supplement ThermoFisher Scientific, Germany 
Endothelin-1 Peninsula labs, USA 
Recombinant mouse interferon gamma Cell Sciences, USA 
Insulin Sigma-Aldrich, Germany 
Transferrin BD Biosciences, Germany 
Endothelial cell growth supplement (ECGS) Sigma-Aldrich, Germany 
Epidermal growth factor BD Biosciences, Germany 
Hydrocortisone BD Biosciences, Germany 
T3 Triiodothyronine Sigma-Aldrich, Germany 
Fetal ovine serum  ThermoFisher Scientific, Germany  
Penicillin-Streptomycin Life technology, Germany  
 
3.2. Human and animal tissue materials used 
3.2.1. Human tissue samples 
Lung-tissue samples from stage IV COPD patients (age range 50-70; females/males) 
as well as from donors (control) (age range 50-70, females/males) were obtained 
from the Giessen DZL-biobank at the UGMLC (Universities of Giessen and Marburg 
Lung Center). The study protocol was approved by the Ethics Committee of the 
Justus Liebig University school of Medicine (AZ 31/93) in accordance with the 
national law and with the “Good Clinical Practice/International Conference on 
Harmonization”. Informed consent for the study protocol was obtained in written form 
from each subject. For protein extraction, lung tissue was snap-frozen directly after 
explantation. For morphological studies, lung tissue was immersion-fixed and 
embedded in paraffin. 
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3.2.2. Mouse samples 
Paraffin-embedded tissue samples from cigarette smoke-exposed and unexposed 
mice were kindly provided by Dr. Michael Seimetz (Excellence Cluster Cardio-
Pulmonary System, ECCPS) from the group of Prof. Dr. Norbert Weissmann group. 
Briefly, animals were housed under controlled conditions with 12h day and night 
cycle, with food and water supply ad libitum. Animals were randomly assigned to 
smoke-exposed and unexposed groups consisting of 6 mice per group. A group of 6 
wild type mice was exposed to the mainstream smoke of 3R4F cigarettes; (University 
of Kentucky, Lexington, KY, USA) for 6h/day, 5days/week for up to 3 months. The 
control group was kept under identical conditions as smoke-exposed mice but without 
exposure to the smoke 178.  
 
3.3. Methods 
3.3.1. Cell culturing of different cell lines  
3.3.1.1. Cell culture of primary HBE cells 
Human primary bronchial epithelial cells (HBE), isolated from epithelial lining of 
airways, were obtained from ATCC (PCS-300-010). Cells were cultured in Airway 
Epithelial Cell Basal Medium (ATCC, Germany) that was supplemented with the 
Small Airway Bronchial Epithelial Cell Growth Kit (ATCC, Germany) (Table 6). Cells 
were maintained at 37˚C in a humidified environment of 5% CO2. Passages from 2 till 
8 were used. 
 
3.3.1.2. Cell culture of C22 cells  
Mouse club cells are epithelial progenitor lung cells which line the bronchial airways 
down to the alveoli. The mouse C22 club cells are derived from transgenic H-2kb-
tsA58 mice179, which are conditionally immortalized, expressing a temperature-
sensitive Simian Virus 40 (SV40) large T antigen. When the cells are cultured in the 
presence of IFN-γ (Interferon gamma) at 33°C, the expression of the SV40 large T 
antigen is induced and the cells proliferate. Cells were purchased from ECACC (Nb. 
07021401). They were cultured in Dulbecco's modified Eagle's medium (Thermo 
Fisher Scientific, Germany), supplemented with 4% FBS, 0.25μg/ml endothelin-1, 
0.01μg/ml Interferon gamma, 10μg/ml insulin, 5μg/ml tansferrin, 7.5μg/ml endothelial 
cell growth supplement (ECGS), 0.025μg/ml epidermal growth factor, 0.36μg/ml 
hydrocortisone, and 0.02μg/ml T3. The cells were maintained at 33˚C in a 5% CO2 
incubator. 
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3.3.2. Preparation of Cigarette Smoke Extract (CSE) 
Special research cigarettes (3R4F) from the Kentucky Tobacco Research and 
Development Centre (University of Kentucky, Lexington, KY) were used for the 
generation of CSE (Fig. 8). Cigarette smoke from one research cigarette containing 
9.4mg tar and 0.73mg nicotine was bubbled into 15ml of the appropriate medium 
required for each cell line (section 3.3.1.). Each puff being of 3s followed by a 20s 
break. After adjusting the pH of the CSE to 7.4, it was filtered through a 0.2μm filter 
(ThermoFisher). The extract, designated as 100% CSE, was diluted with the 
appropriate media for each cell type, to 2%, 4%, 8% and 16%. The CSE was either 
used immediately or stored at -80°C for a maximum of 3 days. For control 
experiments, air was bubbled into 15ml of the appropriate medium. Cells well treated 
with either DMSO or with different CSE concentrations for 4 hours.  
 
3.3.3. MTT Assay 
In order to measure the cell viability in response to the CSE, the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma, Germany) assay 
was performed. Stock solution was prepared by dissolving 5mg/ml of MTT in a 
medium lacking phenol red (DMEM). The prepared solution was stored at -20°C. 
Prior to use, stock solutions were dissolved to equal 1/10th of the original culture 
volume.  
 
Fig. 8. Cigarette smoke generation apparatus 
consisting of a flask with the appropriate media (A), 
cigarette (B) and a connection to a pressure pump 
(C). 
A 
C 
B 
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Briefly, HBE and C22 cells were seeded in a 12-well plate, after 24h of seeding, the 
cells were treated with different concentrations of CSE (0%, 2%, 4%, 8% and 16%) 
for 4h. Then, the medium was aspirated and the cells were washed once with PBS. 
After that, 1ml of MTT was added to each well, and the cells were incubated in the 
incubator for an additional 2-3h to facilitate the conversion of MTT to formazan 
crystals in living cells by mitochondrial dehydrogenases. After incubation, MTT was 
removed and dark-violet formazan was solubilized by addition of 300µl/well of 
DMSO. The optical density was read at a wavelength of 570nm using a SmartspecTM 
3000 spectrophotometer (Bio-Rad, Germany). 
 
3.3.4. Treatment of cells 
3.3.4.1. PPARγ agonist 
Rosiglitazone (RZG) solution was prepared by dissolving 10mg of the drug in 
dimethyl sulfoxide (DMSO) to obtain a 10mM stock solution. All working solutions 
were prepared fresh directly from stocks by dissolving (RZG) in the culture media to 
get the final concentration of 10uM (RZG) per 1ml of medium. Treatment was 
performed on the cells at 70% confluence after 24h of seeding. The cells were either 
treated with DMSO as a control or with RZG (10μM/ml media) for 24h prior to any 
experiment.  
 
3.3.4.2. Cigarette smoke extract 
The stock, designated as 100% CSE, was further diluted to 2%, 4%, 8% and 16% in 
the culture medium required for each cell line. After establishing the toxicity of CSE 
by MTT assay, the CSE concentration of 8% was further used for all the experiments. 
For the basal condition, the treatment with CSE was done on the cells at 70% 
confluence. The cells were either treated with DMSO as a control or with 8% CSE for 
4h. 
 
For further experiments, the cells that were previously treated with RZG for 24h or 
the cells that were transfected with siRNA (siPex13 or siPPARγ) for 72h were 
thereafter incubated with 8% CSE for 4h or with DMSO as a control. 
 
3.3.5. Transfection 
In order to knockdown Pex13 or PPARγ gene expression in C22 cells as well as in 
order to overexpress the PPARγ gene, the following siRNAs and plasmid were 
purchased: Pex13 siRNA (sense GCUAUAGCCCUUAUAGUUATT, antisense 
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UAACUAUAAGGGCUAUAGCTT), PPARγ siRNA (Qiagen) and PCMV Sport PPARγ 
plasmid (RZPD). Allstars negative siRNA (sequence is proprietary to the company) 
from Qiagen was used as a control. Cells were transfected with ScreenFectA 
transfection reagent (InCella) according to the standard protocol from the 
manufacturer. Cells were seeded 24h prior to transfection in 6-well culture plates. In 
2 separate Eppendorf tubes, the following mixtures were prepared: Tube 1 containing 
(4.5µl of ScreenFect A+120µl of buffer), Tube 2 (30nmol of siRNA+120µl buffer). The 
prepared mixtures were allowed to stand for 5min at RT. Thereafter, the reagents of 
the two tubes were mixed together and allowed to stand for an additional 20min at 
RT. Then, the complexes were transferred to one well of a 6-well plate containing 
1250ul of freshly added medium. A similar protocol was used for the transfection with 
the PPARγ plasmid, where 2ug of the plasmid was used for a single well of a 6-well 
plate. The protein and RNA were collected 72 hours post transfection.  
 
3.3.6. Luciferase activity assay 
3.3.6.1. Transfection 
Cells were seeded in 6-well plates 24h prior to transfection or until 60% confluence. 
In 2 separate Eppendorf tubes, the following mixtures were prepared: Tube 1 
containing (4.5µl of ScreenFect A+120µl of buffer), Tube 2 (30nmol of siRNA+120µl 
buffer). In addition to this, Tube 2 also contained either 3ug of pARE luc and 0.25ug 
of renilla luciferase expression vector pRL-SV40 or 3ug of pGL3 basic vector and 
0.25ug of renilla luciferase expression vector pRL-SV40. The prepared mixtures were 
allowed to stand for 5min at RT. Thereafter, the reagents of the two tubes were 
mixed together and allowed to stand for an additional 20min at RT. Then, the 
complexes were transferred drop by drop to one well of a 6-well plate containing 
1250ul of freshly added medium. The plates were swirled gently to ensure even 
dispersal of the complexes and then incubated for 68h before 4hr CSE- or DMSO-
treatment. 
 
3.3.6.2. Preparation of cell lysates  
The luciferase assay measurements were performed according to the standard 
protocol of the manufacturer (Promega). The growth medium was removed from the 
wells and the cells were rinsed with 1X PBS solution. Then, 150μl of 1X luciferase 
cell culture lysis reagent (CCLR) (5X CCLR provided within the Promega kit was 
mixed with 4 volumes of sterile water to prepare the working concentration 1X) was 
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added to each well of a 6-well plate and the plates were gently shaken for 5min to 
ensure that the complete surface was covered with lysis buffer. Cells were scraped 
and the lysate was transferred to Eppendorf tubes. Before the luciferase activity 
measurements, all samples were incubated on ice for 15s, vortexed afterwards for 
15s and finally harvested by centrifugation at a speed of 13,000g for 30s at RT. 
Thereafter, the firefly or renilla luciferase activities were determined with the 
substrates provided in the dual luciferase reporter assay kit from Promega. 
 
3.3.7. Dihydroethidium (DHE) staining 
To detect the generation of intracellular ROS, the cell permeable dihydroethidium 
(DHE) dye (Sigma) was used. DHE reacts with superoxide forming the ethidium 
product which upon intercalating with DNA produces a red fluorescent color. Cells 
plated on coverslips were incubated with 5μM DHE in medium for 30min at 37°C and 
washed with PBS afterwards. Then, the cells were fixed with PFA for 20min, washed 
with PBS and counterstained with Hoechst 33342 for 10min. Thereafter, the cells 
were washed with PBS and mounted on a slide for further examination with a LEICA 
TCS SP5 confocal microscope (CLSM) (Leica Mikrosysteme Vertrieb GmbH). 
 
 
3.3.8. BrdU cell proliferation assay 
Cells were seeded into sterile 96-well culture plates 24h prior to the treatment. After 
24h, the necessary treatments were performed and the cells were incubated with 
BrdU 2h (Millipore) prior to the end of the test reagent incubation. Thereafter, the 
cells were fixed and the DNA was denatured with 200µl/well of the fixing solution for 
30min at RT. Then, the medium was aspirated and the plate was washed 3 times 
with 1X Wash Buffer. After washing, the buffer was removed and 100ul/well of anti-
BrdU monoclonal antibody was added for 1hr at RT. Following the incubation, the 
microplate was washed again and 100µl/well of goat anti-mouse IgG was added for 
30min at RT. The plate was then washed and incubated with 100µl/well of TMB 
peroxidase substrate for 30min at RT. Finally, the reaction was stopped with 
100µl/well of stop solution and the plate was read at a dual wavelength of 450/550 
nm. 
 
3.3.9. Cytokine and chemokine levels in supernatants  
Cell culture supernatants from different treatment groups were collected and stored 
at −80°C for further analysis. Levels of TNF-α, IL-6, and IL-8 were measured using 
ELISA kits (Affymetrix, eBioscience) according to the manufacturer's instructions. 
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Shortly, following the coating of the 96-well plate with specific capture antibody, the 
plate was washed and incubated with blocking ELISPOT diluent for 1hr at RT. 
Afterwards, the lyophilized standards, as well as supernatant samples, were added 
and the plate was incubated for 2h at RT. Then, the plate was washed and incubated 
for an additional 1hr with the detection antibody. Thereafter, the plate was washed 
and Avidin-HRP was added for 30min at RT. After the incubation, the plate was 
extensively washed and then incubated with TMB solution for 15min. Finally, stop 
solution was added and the absorbance was read at 450nm using a TriStar 
microplate reader (Berthold). 
 
3.3.10. Western Blot 
3.3.10.1. Lung tissue homogenate preparation for Western Blots 
Lung tissue samples from COPD patients as well as from donors (control) (see 
section 3.2.1.) were snap-frozen directly after explantation and stored in liquid 
nitrogen until use. Prior to processing, lung tissue specimens were cut into small 
pieces where 2g of each tissue sample was homogenized with a Potter-Elvehjem 
homogenizer at 1,000rpm (1 stroke, 60s). The homogenization (2g of tissue per 2ml 
buffer) was carried out in an ice-cold homogenization buffer (Table 7) containing 1% 
protease inhibitor mix M (SERVA, Germany). Thereafter, lung homogenates were 
centrifuged (Biofuge Fresco, Heraeus, Germany) at 2,500g for 3min at 4°C and the 
supernatants were collected for further protein analysis. The protein concentration 
was determined by the Bradford method using the Bradford protein assay reagent 
(Sigma) 180. 
 
3.3.10.2. Cell preparation for Western Blots 
After washing HBE or C22 cell cultures once with phosphate buffered saline (1XPBS) 
(Sigma), 100µl of IPB lysis buffer (Table 7) containing 1% protease inhibitor mix M 
was added to each well of a 6 well culture plate. Cells were then scraped thoroughly 
using a rubber policeman and transferred to Eppendorf tubes. The whole isolation 
process was carried out on ice. The isolated protein homogenate was vortexed for a 
couple of times and then centrifuged (Biofuge Fresco, Heraeus, Germany) at 2,500g 
for 10min at 4°C. Supernatants were collected and the protein concentrations were 
measured by the Bradford method using the Bradford protein assay reagent (Sigma) 
180. 
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Table 7. Solutions for isolation of proteins for SDS PAGE and Western blotting 
Tissue homogenization 
buffer 
0.25M sucrose and 5mM MOPS, pH 7.4, 1mM EDTA, 0.1% ethanol, 0.2mM 
DTT, 1mM aminocaproic acid, supplemented with 1% protease inhibitor mix M 
prior to use 
Cell lysis buffer (IPB) 150mM NaCl, 50mM Tris, 1% Triton X-100 (pH 7.4), supplemented with 1% 
protease inhibitor mix M prior to use 
 
3.3.10.3. SDS-PAGE and blotting 
The protein samples (20µg) as well as 5μl of dual color precision plus protein 
Standard® (BioRad, Germany) were separated on 10% SDS-polyacrylamide gels 
using a BioRad gel electrophoresis apparatus. The recipes of the gels used for 
electrophoreses are provided in Table 8. 
 
Table 8. Recipes for two 10% SDS-polyacrylamide gel with a comb thickness of 1.25mm 
Resolving gel buffer 
A 
0.4% SDS 1.5 M Tris-HCl, adjusted to pH 8.8 
Stacking gel buffer B 0.4% SDS, 0.5 M Tris-HCl, adjusted to pH 6.8 
Resolving gel (10%) 3.34ml of dH2O, 10ml of buffer A, 6.68ml of 30% acrylamide,15μl of TEMED, 130μl 
of 10% APS 
Stacking gel 3.75ml of dH2O, 5ml of buffer B, 1.25ml of 30% acrylamide, 8μl of TEMED, 60μl of 
10% APS 
10X Sample buffer 3.55ml dH2O, 1.25ml 0.5M Tris-HCl (pH 6.8), 2.5ml 50% (w/v) glycerol, 2.0ml 10% 
(w/v) SDS, 0.05% bromophenol blue. Prior to use, add 50µl of β-mercaptoethanol 
to every 1ml of 10X Sample buffer 
 
The electrophoresis was performed at a voltage of 150V using the PowerPac 200. 
Thereafter, proteins were transferred to a polyvinylidene membrane (PVDF) 
(Millipore, Germany) using either a semi-dry Trans-Blot® apparatus at a constant 
current of 120mA for 1hr or tank-blotted in cold Towbin buffer at 100V for 1hr.  
 
The membranes were then blocked with 5% non-fat milk powder (Carl Roth, 
Germany) in TBST (TBS + 0.05% Tween-20) for 1hr at RT. Thereafter, the 
membranes were incubated overnight with the specific primary antibodies (Table 10)  
in 5% blocking solution at 4°C. Dilutions of primary antibodies used are listed in 
Table 10. The following day, membranes were washed twice with TBST for 15min 
and incubated with alkaline phosphatase conjugated secondary antibodies (Sigma, 
Germany) for 1hr at RT.  To visualize the bands, membranes were incubated with 
chemiluminescent substrate (ImmunostarTM – AP, BioRad) for 5min and visualized 
with Fusion FX (Fisher Biotec, Australia).  
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Mouse anti-GAPDH antibody (Glyceraldehyde-3-Phosphate Dehydrogenase) (5G4, 
HyTest, Finland) was used to normalize the expression. For detection of different 
target proteins, the membranes were stripped and re-used by re-probing with 
different primary antibodies. All Western blot analyses were performed in triplicates to 
produce reliable results. The buffer recipes used for the Western Blot analysis are 
summarized in Table 9. 
 
Table 9. The composition of the buffers used for western blotting 
10X Electrophoresis buffer 250mM Tris, 2M glycin + 1% SDS  
10X Towbin transfer buffer (tank 
blotting) 
125mM Tris, 192mM glycine adjusted to pH 8.3 in 1l of dH2O 
1X Towbin For 1L: 700ml dH2O, 100ml Towbin, 200ml methanol 
20X Transfer buffer 
(semi-dry transfer) 
Bis-Tris-HCl buffered (pH 6.4) polyacrylamide gel, NuPAGE transfer 
buffer (Invitrogen, Heidelberg, Germany)  
10X TBS 0.1MTris, 0.1M NaCl in 1l dH2O, adjusted to pH 8.0  
1X Washing buffer (TBST) 10 mM Tris/HCl, 0.15 M NaCl, 0.05% Tween 20, pH 8.0 
5% Blocking buffer 5g fat free milk powder in 1X TBST solution  
Stripping buffer (500ml) 62.5mM Tris (pH 6.8), 0.2% SDS, 500ml dH2O, 50ml of 
buffer/membrane in the water-bath at 42°C for 40min with additional 
350μl β-mercaptoethanol 
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Primary antibody against 
antigen 
Host Dilution 
IF 
(Cells) 
Dilution 
IF 
(Tissues) 
Dilution 
(WB) 
Supplier 
Peroxisomal biogenesis and metabolic protein 
Peroxin 13 (PEX13p), mouse Rabbit, polyclonal 1:1,000 1:1,000 1:5,000 Gift from Denis I. Crane; School of Biomol. Biophys. 
Sci., Griffith Univ., Nathan, Brisbane, Australia  
Peroxin 14 (PEX14p), mouse  Rabbit, polyclonal 1:1,000 1:1,000 1:8,000 Gift from Denis I. Crane; School of Biomol. Biophys. 
Sci., Griffith Univ., Nathan, Brisbane, Australia 
Catalase (CAT), mouse Rabbit, polyclonal 1:2,000 1:2,000 1:30,000 Gift from Denis I. Crane; School of Biomol. Biophys. 
Sci., Griffith Univ., Nathan, Brisbane, Australia 
Acyl-CoA oxidases I, mouse Rabbit, polyclonal 1:1,000 1:1,000 1:5,000 Gift from Paul P. van Veldhoven, Dept. of Molecular 
Cell Biology, Pharmacology, Catholic University 
Leuven, Belgium 
Thiolase, human Rabbit, polyclonal 1:1,000 1:1,000 1:5,000 Gift from Nancy E Bravermann; Depts. of Human 
Genetics and Pediatrics, McGill University-Montreal 
Montreal, QC, Canada 
Alkylglycerone-phosphate 
synthase (AGPS), human 
Mouse, 
monoclonal 
- - 1:500 Santa Cruz, Cat no: sc-374201 
Glyceronephosphate O-
acyltransferase (GNPAT), human 
Rabbit, polyclonal 1:500 1:500 1:500 Proteintech, Cat no: 14931-1-AP 
Transcription factors and signalling molecules  
Peroxisome proliferator-activated 
receptor gamma (PPARγ), rabbit 
Rabbit, polyclonal 1:50 1:50 1:500 Santa Cruz, Cat no: sc-7196 
Nuclear factor-erythroid-2 related 
factor 2 (Nrf2), human 
Rabbit, polyclonal - - 1:1,000 Santa Cruz Biotechnology Inc., Heidelberg, Germany, 
Cat. no:sc-722 
Other antioxidative enzymes  
Table 10.  List of primary antibodies used in this study
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Heme oxygenase 1 (HO-1) Rabbit, polyclonal - - 1:1,000 Assay Designs, Inc. Michigan, USA, Cat.no:SPA-895 
Superoxide dismutase 1 (SOD1), 
rat (partially in peroxisomes) 
Rabbit, polyclonal - - 1:1,000 Research diagnostics, Cat no: RDI-RTSODMabR 
Cell type‐specific antigens 
Mucin 5AC, human Mouse, 
monoclonal 
- 1:500 - AbD Serotec, Cat. no: 1695‐0128 
Pro-inflammatory antigens 
Cycloxygenase-2 (COX-2), goat Rabbit, polyclonal - - 1:1,000 
Santa Cruz Biotechnology Inc., Cat. no: sc-1747 
Loading Control 
Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), rabbit 
Mouse, polyclonal - - 1:10,000 HyTest, Finland, Cat. no: 5G4  
Secondary Antibodies  
Secondary detection system Host Dilution 
(WB) 
Dilution (Cells/ 
Tissues) 
Supplier 
anti-Rabbit-IgG alkaline 
phosphatase conjugate 
Goat, polyclonal 1:20,000 - Sigma Aldrich, Cat. no: A0545 
anti-Mouse-IgG alkaline 
phosphatase conjugate 
Goat, polyclonal 1:20,000 - Sigma Aldrich, Cat. no: A3562 
anti-Rabbit-IgG AlexaFluor488 Donkey  - 1:1,000 Molecular Probes/Invitrogen, Cat. no: A21206 
anti-Mouse-IgG AlexaFluor555 Donkey - 1:1,000 Molecular Probes/Invitrogen, Cat. no: A31570 
anti-Goat-IgG AlexaFluor594  Chicken - 1:1,000 Molecular Probes/Invitrogen, Cat. no: A11058 
Counterstaining of nuclei for immunofluorescence 
Hoechst 33342 (1 µg/ml)  - - 1:1,000 Molecular Probes/Invitrogen, Cat. no: 33342 
TOTO®-3 iodide -  1:1,000 Molecular Probes/Invitrogen, Cat. no: T-3604 
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3.3.11. Indirect Immunofluorescence 
3.3.11.1. Immunofluorescence of embedded tissues 
Human and mouse (see section 3.2.1.) paraffin-embedded tissue blocks were cut into 
2-3µm-thick sections using a rotation microtome (Leica RM2135). Table 10 shows the 
dilutions of the primary and secondary antibodies used. The immunofluorescence 
procedure was carried out for 3 days and is summarized in Table 11. The components 
of the solutions used are summarized in Table 12. 
 
Table 11. The experimental procedure of immunofluorescence staining on paraffin-embedded tissue 
sections 
Time Procedure 
     Day 1 Human and mouse tissue sections were placed overnight into a 50°C oven (Heraeus, 
Hanau,Germany) for deparaffinization 
 
 
    Day 2 
 Sections were deparaffinized with xylene and rehydrated in a series of ethanol 
(absolute ethanol, 96% ethanol, 80% ethanol, 70% ethanol, and aqua dest.), each 
step was for 3min at RT 
 For antigen retrieval, sections were subjected to digestion with trypsin buffer for 
10min at 37°C on a heating plate and then microwaved in citrate buffer for 15min at 
900W (Table 12.) 
 Sections were blocked with 4% PBSA at RT for 2h 
 Sections were incubated overnight at RT with the primary antibody diluted (Table 10) 
in 1% PBSA  
 
 
Day 3 
 Sections were rinsed 3X for 5min with 1X PBS  
 Incubated with secondary antibody (Table 10) for 1hr at RT  
 Washed with 1X PBS, 3X for 5min at RT 
 Stained with Hoechst 33342 and TOTO-3 iodide for 10min at RT 
 Washed 3X with 1X PBS for 5min 
 Mounted with cover slips using Mowiol and propylgallate 
 
For negative controls, the sections were incubated with PBSA instead of the primary 
antibody. The samples were analyzed by confocal laser scanning microscopy (CLSM) 
with a Leica TCS SP5 (Leica Mikrosysteme Vertrieb GmbH).  
 
Table 12. Solutions used for immunofluorescence staining of paraffin-embedded tissue sections 
Solution Composition 
10X PBS 1.5M NaCl, 131mM K2HPO4 , 50mM KH2PO4, pH 7.4 
Trypsin (0.01%) Fresh 0.01g trypsin in 100ml of 1X PBS buffer 
Citrate buffer Buffer A: 1mM C6H8O7.H20 
Buffer B: 50mM C6H5Na3O7.2H20 
Final concentration: 0.15mM buffer A + 8.5mM buffer B (pH 6) 
Blocking buffer: 4% PBSA + 0,05% Tween 20 To 8g BSA add 200ml of 1X PBS and 100μl of Tween 20 
Dilution buffer: 1% PBSA + 0,05% Tween 20 To 2g BSA add 200ml of 1X PBS and 100μl of Tween 20 
Mowiol 4‐88 solution Overnight stirring of 16.7% Mowiol 4‐88 (w/v) and 80ml of 1X 
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PBS, add 40ml of glycerol and stir overnight again; centrifuge 
at 15,000U/min for 1hr, take off the supernatant and store at ‐
20°C 
Anti‐fading agent (2.5%) 2.5g N‐propylgallate in 50ml of PBS and add 50ml of glycerol 
Mounting medium 3 parts of Mowiol 4‐88 and 1 part of anti‐fading agent 
propylgallate 
 
 
3.3.11.2. Immunofluorescence of cells  
Cells were plated on coverslips and allowed to grow for 24h. After that, all the 
necessary manipulations (siRNA, plasmids, RZG, CSE) were performed. Thereafter, 
cells were washed with PBS and fixed with 4% paraformaldehyde (PFA) in PBS for 
20min at RT. After fixation, the cells were washed with PBS, pH 7.4 and the coverslips 
containing the cells were incubated in 1% glycine in PBS for 10min. Thereafter, they 
were incubated for additional 10min in 1% glycine and 0.3% Triton X-100 for 
permeabilization. After incubation, samples were rinsed with PBS and incubated for 
30min in 1% BSA and 0.05% Tween 20 in PBS to block non-specific protein binding 
sites. After blocking, the coverslips were incubated with primary antibodies (Table 10) 
at 4°C in a moist chamber overnight. The following day, the cells were washed 
extensively with PBS and incubated with secondary antibodies for 1h at RT. 
Thereafter, the cover slips were washed with PBS and the nuclei were counterstained 
with Hoechst 33342 (1μg/ml) and TOTO-3 iodide for 10min at RT. At last, the 
coverslips were washed with PBS and mounted on the slides. The composition of 
solutions used for immunofluorescence of cells grown on the cover-slips is shown in 
Table 13.  
 
Table 13. Solutions used for immunofluorescence staining of cells grown on coverslips. 
Solution Composition 
Fixative solution 4% PFA in 1X PBS (150mM NaCl, 13.1mM K2HPO4, 5mM KH2PO4), pH 7.4 
Glycine (1%) 1g glycine in 100ml of 1X PBS buffer 
Glycin (1%) + Triton X-100 
(0.3%) 
1g glycine in 100ml of 1X PBS buffer + 0.3ml Triton X-100 
Blocking buffer- 1% PBSA + 
0,05% Tween 20 
To 2g BSA add 200ml of 1X PBS and 100μl of Tween 20 
Mowiol 4-88 solution Overnight stirring of 16.7 % Mowiol 4-88 (w/v) and 80ml of 1X PBS, add 40ml 
of glycerol, stir again overnight; centrifuge at 15,000 U/min for 1h and take off 
the supernatant and store at -20°C 
Anti-fading agent (2.5%) 2.5g N-propylgallate in 50ml of PBS and 50ml of glycerol 
Mounting medium Mowiol 4-88 mixed with anti-fading agent in ratio of 3:1 
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3.3.12. RNA Isolation 
3.3.12.1. RNA isolation from cells 
For RNA isolation, the medium was aspirated from the cells and 1ml of RNAzol 
(RNAzol®, Sigma-Aldrich) was added to each well of a 6 well culture plate.  The lysed 
cells were collected into 2ml tubes. Then, 0.4ml of RNase-free water per ml of RNazol 
was added to each tube and left for 15min at RT. The lysate was then centrifuged at 
12,000g for 15min and the supernatant was transferred to a fresh tube followed by an 
addition of an equal volume of 100% isopropanol for RNA precipitation for 10min at 
RT. Thereafter, the lysate was centrifuged at 12,000g for 10min and the supernatant 
was discarded. The RNA pellet was washed twice with 0.5ml of 75% ethanol per ml of 
supernatant. Then, the RNA was centrifuged at 8,000g for 3min at RT and the ethanol 
was removed thereafter. Finally, the RNA pellet was solubilized in RNase-free water at 
a concentration of 1-2µg/ml. The quantity and integrity of the isolated RNA were 
assessed with the NanoDrop™ 8000 Spectrophotometer. 
 
3.3.12.2. RNA isolation from tissues 
Tissue samples were homogenized at RT with 1ml RNAzol per 100mg of tissue using 
an Ultra Turrax T25 basic homogenizer and allowed to stand for 15min prior to further 
steps. Thereafter, the isolation process was the same as mentioned in section 3.3.7.1. 
 
3.3.12.3. cDNA synthesis 
One μg of total isolated RNA was reverse transcribed to cDNA using the High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Germany) as 
described by the manufacturer. The reverse transcription mix contained 0.8µl of 25X 
dNTP Mix (100mM), 2µl 10X RT buffer, 2µl 10X RT random primers, 1µl MultiScribe™ 
reverse transcriptase, 1µl RNase inhibitor and 3.2µl nuclease-free H2O. Thereafter, 
1ug total RNA in nuclease-free water to a volume of 10ul was pipetted into 10µl 
reverse transcription mix. The reaction was incubated at 25 °C for 10 min, at 37 °C for 
120 min and at 85 °C for 5 min in a Trio-Thermoblock. 
 
3.3.12.4. qRT-PCR 
The qRT-PCR of target genes, described in Table 14-15, was performed in the iCycler 
iQ5™ Real-Time PCR Detection System (BioRad). The reactions were set up with the 
SYBR™ Green PCR mix (Life technologies) according to the manufacturer's protocol. 
The PCR cycle consisted of an initial cycle of 95°C for 3min followed by 42 repeated 
cycles of 95°C for 15s, 60°C annealing temperature for 30s, and the primer extension 
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at 72°C for 30s. Then, 91 repeated cycles at the temperature between 50°C-95°C with 
increased set point temperature after cycle 2 by 0.5°C were performed. All reactions 
were run in triplicates. Mouse Gapdh and human HPRT were used as an endogenous 
reference. The comparison of relative expression values of each gene to the internal 
control gene was analyzed using the equation 2−ddCT, where dCT = (CTtarget gene − 
CTinternal control gene).  
Table 14. Sequences of the human primers used for the qRT-PCR 
Gene name Sense 5’-3’ Antisense 5’-3’ 
ACAA1 GATGCCTTCTTACCCCAACA CCCAACCACTGCATAAGACC 
ACOX1 ATTTCCTTCAGGGGAGCATC GCCAAGTGTCACATCCTGAA 
AGPS AGGGGGATCGTGAGAAGGT CCAAAGCCAAGTCTCGAATG 
CAT CGTGCTGAATGAGGAACAGA TTGTCCAGAAGAGCCTGGAT 
HPRT GAAAAGGACCCCACGAAGTGT AGTCAAGGGCATATCCTACAACA 
GNPAT GTGCAGAAAAACGCCTTAGC GGCTGGTTTTCCTATTGGTG 
IL6 AATTCGGTACATCCTCGACGG TTGGAAGGTTCAGGTTGTTTTCT 
IL8 TTTTGCCAAGGAGTGCTAAAGA AACCCTCTGCACCCAGTTTTC 
PEX5 TGGGAGTCCTTTTCAACCTG CGCCTAGCTTATTCCACAGC 
PEX7 GGCTCATGGGATCAAACTGT ACCTGAGGCTGAAGCAAAAC 
PEX13 CCATGTAGTTGCCAGAGCAG CATCAAGGCTAGCCAGAAGC 
PEX14 CTGCCTTTGGCTTTGATCTC CGTGGTGTCACGGTAGTCAA 
PPARG ATCTTTCAGGGCTGCCAGT TCGTGGACTCCATATTTGAGG 
TNFα CCTCTCTCTAATCAGCCCTCTG GAGGACCTGGGAGTAGATGAG 
 
Table 15. Sequences of the mouse primers used for the qRT-PCR 
Gene name Sense 5’-3’ Antisense 5’-3’ 
Acaa1 CAATGAACTGAAGCGTCGTG CACCACTGTGGCACTCTCTG 
Acox1 CCGCCACCTTCAATCCAGAG CAAGTTCTCGATTTCTCGACGG 
Agps TGTCCTCCGTGTCTGTTCCT CATGGTACAACCTGCCCTTC 
Cat GGAGAGGAAACGCCTGTGTGA GTCAGGGTGGACGTCAGTGAAA 
Cox2 GACTCTGCTCACGAAGGAAC AGCAAGGATTTGCTGCCT 
Ho-1 CGCCTTCCTGCTCAACATT TGTGTTCCTCTGTCAGCATCAC 
Gapdh TGGCAAAGTGGAGATTGTTGCC AAGATGGTGATGGGCTTCCCG 
Il6 CTCTCTGCAAGAGACTTCCATC CTCCGACTTGTGAAGTGGTATAG 
Nrf2 CCAGCAGGACATGGATTTGA ATAGTCCTTCTGTCGCTGACTA 
Pex7 CGACAGCCTGTGTTTGAACT AGAAGCGGATCAGGCTTTG 
Pex5 AATGCAACTCTTGTATCCCGA GGCGAAAGTTTGACTGTTCAATC 
Pex13 TGGATATGGAGCCTACGG CGGTTAAAGCCCAAACCATT 
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Pex14 GCCACCACATCAACCAACTG GTCTCCGATTCAAAAGAAGTCCT 
Pparg TTTTCAAGGGTGCCAGTTTC CATGGACACCATACTTGAGCA 
Sod1 AAAATGAGGTCCTGCACTGG AACCATCCACTTCGAGCAGA 
 
3.3.13. Statistical Analysis 
Each result is a representative of at least three experiments. Data are expressed as 
mean ± standard deviation. Differences between groups were evaluated by the 
analysis of variance (one-way ANOVA) and by the un-paired student t-test. Data were 
considered statistically significant if p≤0.05. 
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4. Results 
 
4.1. Human COPD samples  
4.1.1. Patient sample selection 
There is growing evidence that the prevalence and incidence of COPD increase in the 
elderly and that the onset of COPD is higher in persons over 50 years of age 181-183. 
Therefore, the lung tissue samples analysed in this study belong to the COPD patients 
and donors in the age range of 50-70 years. The samples belong to the patients 
diagnosed with either chronic bronchitis, emphysema, or both. In order to confirm the 
COPD characteristics, samples were analysed for the expression of MUC5AC. It is 
known that excessive mucous hypersecretion is a feature of a variety of chronic airway 
diseases including COPD and that the most abundant mucins present in the airways 
are MUC5B which is constitutively expressed and MUC5AC which is induced in 
response to pathogens and pollutants like cigarette smoke 184-186. As a result, it has 
been shown that the expression of the MUC5AC is increased in the bronchial 
epithelium of COPD patients 187,188. Thus, paraffin-embedded COPD lung tissue 
samples were selected based on MUC5AC upregulation.  
 
Immunofluorescence analysis of COPD samples (Fig. 9) showed a heterogeneous 
distribution of the MUC5AC protein in the bronchial region of different patients, with the 
highest abundance of MUC5AC in patient number 3 (Fig. 9K). For further 
experiments, COPD patients exhibiting similar MUC5AC abundance as patient 3 were 
selected. Similarly, donors showing the absence of MUC5AC (Fig. 9E) were selected 
for further experiments. Interestingly, MUC5AC was detected in donor number 3; this 
could mean that the donor was having an inflammatory airway disease. 
 
Characteristics of the 5 donors and 6 patients selected for further analysis are 
described in Table 16. 
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Gender Age Diagnosis 
Female 58 COPD/Centrilobular emphysema and bronchitis 
Female 52 COPD/ Bronchitis 
Female 58 COPD/Centrilobular emphysema 
Male 55 COPD/Emphysema 
Male 56 COPD/Emphysema 
Male 58 COPD/Centrilobular emphysema and bronchitis 
Fig. 9. CLSM images of IF preparations for mucin 5 (MUC5AC) in 3 human donor lungs (A, E 
and I) and (B, F and J represent the higher magnification) and 3 different COPD patients (C, G 
and K) and (D,H and L represent the higher magnification) in order to show the hyperplasia of 
goblet cell in the bronchiolar epithelium and to confirm the COPD characteristics. Nuclei were 
counterstained with TOTO-3-iodide. Bars represent 60μm for (B, F, J, D, H and L) and 20μm for 
(A, C, E, G, I and K). 
 
Table 16. Characteristics of the selected COPD patients and lung donors as control subjects.  
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Female 70 Donor 
Female 60 Donor 
Male 61 Donor 
Male 58 Donor 
Male 56 Donor 
 
4.1.2. Peroxisomal biogenesis, lipid metabolism and anti-oxidative 
enzymes are altered in COPD patients 
After the selection of five donors and five COPD patients, based on the MUC5AC 
expression, the second step was to analyze the peroxisomal distribution of the COPD 
and donor lung samples. As mentioned previously, cigarette smoke provokes oxidative 
stress by an oxidant/antioxidant imbalance 150. Therefore, peroxisomes could be easily 
affected by components of cigarette smoke, since most of these organelles are indeed 
localized directly underneath of the apical surface of ciliated cells or in the apical 
region of club cells of the bronchiolar epithelium 136,137. Thus, peroxisomal metabolism 
could be altered in COPD patients.  
 
The analysis of paraffin embedded tissue samples revealed a high upregulation and 
proliferation of the peroxisome biogenesis protein PEX14 in the bronchiolar region of 
the COPD patient (Fig. 10C and D) compared to the control (Fig. 10A and B). Tissue 
staining with PEX13 antibody was not performed due to the cross-reactivity of this 
antibody with the elastic fibers of the tissue sample.  Next, the abundance of the 
peroxisomal β-oxidation enzymes; ACOX1 and Thiolase (Acaa1) was analysed. 
ACOX1, the first rate‐limiting enzyme of the peroxisomal β‐oxidation pathway 1 was 
increased in bronchiolar epithelial cells (Fig. 11C and D) as well as in the alveolar 
region (Fig. 11G and H) of COPD patients in comparison to the control samples (Fig. 
11A, B, E and F).  Similarly, Thiolase which is the terminal enzyme of the β-oxidation 
pathway I, was strongly upregulated in the club cells (Fig. 12E), goblet cells (Fig. 
12F), ciliated cells of the bronchiolar region (Fig. 12G) and in macrophages and type II 
cells (Fig. 12H) of the alveolar region in COPD tissue samples as compared to the 
donor samples. Double labelling of rabbit anti‐Thiolase with mouse anti‐MUC5AC; 
which is a marker of goblet cells, showed high abundance of mucin in the bronchi of 
COPD patients.  
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Fig. 10. CLSM images of IF preparations for the peroxisomal biogenesis enzyme PEX14 in the 
bronchiolar (A-D) epithelial regions of human donor (A-B) and COPD patient (C-D) lungs. Nuclei were 
counterstained with TOTO-3-iodide. Bars represent 20μm for (A and C) and 25μm for (B and D). 
Fig. 11. CLSM images of IF preparations for the peroxisomal β-oxidation enzyme ACOX1 in the 
bronchiolar (A-D) and alveolar (E-H) epithelial regions of human donor and COPD patient lungs. 
Nuclei were counterstained with TOTO-3-iodide. Bars represent 20μm for (A, C, E and G) and 60μm 
for (B, D, F and H). 
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Fig. 12. CLSM images of IF preparations for the peroxisomal β-oxidation enzyme Thiolase in 
the bronchiolar and alveolar regions of human donor lungs and COPD patients. Double labelling with 
rabbit anti‐thiolase and mouse anti‐MUC5AC (B and F) or mouse anti-tubulin (C and G). Bars 
represent 20μm for (A and E) and 60μm for (B, C, D, F, G and H). 
 
Fig. 13. CLSM images of IF preparations for the peroxisomal antioxidative enzyme catalase 
(CAT) in the bronchiolar (A-D) and alveolar regions (E-H) of human donor (A, B, E and F) and COPD 
patient lungs (C, D, G and H). Nuclei were counterstained with TOTO-3-iodide. Bars represent 20μm 
for (A, C, E and G) and 60μm for (B, D, F and H). 
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Peroxisomes contain a variety of anti-oxidative enzymes, of which catalase is the most 
abundant one. Therefore, in addition to the above-mentioned biogenesis and β-
oxidizing enzymes, a staining with the peroxisomal anti-oxidative protein CAT revealed 
an upregulation of CAT in the bronchiolar epithelial cells of the COPD patients (Fig. 
13C and D). Moreover, CAT was also upregulated in alveolar macrophages and 
alveolar type II cells of the patients (Fig. 13G and H) in comparison to the donor 
samples (Fig. 13A, B, E and F).  
 
The increase in the abundance of peroxisomal enzymes in COPD patients was 
confirmed by Western blot analyses. Similarly, the increase in the expression of 
peroxisomal genes in the COPD patients was observed at mRNA level with the real-
time PCR analyses. Western blot and real-time PCR analyses showed that the protein 
and mRNA levels of peroxisomal biogenesis proteins involved in matrix protein import 
(such as PEX5, PEX7, PEX13 and PEX14) were increased in their abundance and 
expression in the COPD patients as compared to the control samples (Fig. 14). 
Moreover, the protein and mRNA levels of peroxisomal enzymes in ether lipid 
synthesis (AGPS and GNPAT) (Fig. 15), peroxisomal β-oxidation (ACOX1 and 
ACAA1) (Fig. 16A) and ROS metabolism (CAT) (Fig. 16B) as well as transcription 
factors (Fig. 17) were shown to be significantly upregulated in the total tissue lysates 
and total RNA of the COPD lungs as compared to the lungs from healthy donor 
controls. Next, we analysed the samples on the expression of pro-inflammatory 
cytokines such as IL-6, IL-8 and TNF-α which have been proposed to play an 
important role in the pathogenesis of COPD. Real time PCR revealed a highly 
significant increase of the IL-8 gene and a lower but still significant expression of TNF-
α gene in the total RNA of the COPD patient (Fig. 18). The increase in the expression 
of IL-6 was shown to be insignificant (Fig. 18). 
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Fig. 15. Real-time PCR and Western blot of ether phospholipid synthesis enzyme mRNAs (A) 
and proteins (B) in total lysates and RNAs of healthy donor control and COPD lungs.  P values were 
calculated by the unpaired student t-test.*p ≤ 0.05. 
 
Fig. 14. Expression of peroxisomal biogenesis (PEX13 and PEX14) and peroxisomal targeting 
receptors (PEX5 and PEX7) at the mRNA and (A) protein (B) levels in the control and COPD 
samples by Western blot and real-time PCR analyses. P values were calculated by the unpaired 
student t-test. *p ≤ 0.05, **p ≤ 0.01. 
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To summarize, immunofluorescence, Western blot and real time PCR analyses of 
peroxisomal protein and gene expression levels revealed a strong upregulation of 
peroxisomal biogenesis, anti-oxidative and lipid metabolic (β-oxidation, plasmalogen 
Fig. 17. Real-time PCR and Western blots of the transcription factors (A) on total RNAs and (B) 
lysates of control and COPD lungs. P values were calculated by the unpaired student t-test. *** p ≤ 
0.001 
 
 
Fig. 16. Real-time PCR of peroxisomal β-oxidation gene mRNAs on total RNA of human lung 
tissue (A) and real-time PCR and Western blot of the peroxisomal antioxidant enzyme Catalase (B) 
on total RNAs and lysates of control and COPD lungs. P values were calculated by the unpaired 
student t-test.*p ≤ 0.05, **p ≤ 0.01. 
 
 
 
Fig. 18. Real-time PCR of the pro-inflammatory 
cytokines on total RNA of control and COPD 
lungs. P values were calculated by the unpaired 
student t-test. **p ≤ 0.01, **** p ≤ 0.0001. 
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synthesis) enzymes as well as an increase in the abundance of peroxisome-related 
transcription factors (PPARγ and Nrf2) in the COPD patients, suggesting that the 
peroxisomal function is being more activated. Moreover, the observed increase in the 
level of pro-inflammatory cytokines is a typical characteristic feature of COPD. 
4.1.3. Peroxisomal distribution in various cell types of control and COPD lungs 
The next step was to check the distribution, localization and compartmentalization of 
different peroxisomal enzymes in various cell types of control and COPD lungs. By 
using immunofluorescence for the localization of peroxisomal marker proteins, five 
control and 5 COPD samples were analysed. Table 17 provides a nice summary of 
the results obtained for different peroxisomal markers.  
 
Immunofluorescence analysis revealed that MUC5AC only weakly stained goblet cells 
in the control tissues.  The peroxisomal biogenesis protein PEX14 was highly 
abundant in macrophages in comparison to a much weaker abundance in AECII cells. 
Club cells and ciliated cells showed a similar middle high expression of PEX14. The 
staining for the antioxidative enzyme CATALASE (CAT) showed its high abundance in 
macrophages, club cells, and alveolar epithelial type II cells (AECII) of the control 
samples. Other cell types were only weakly stained for CAT. Acyl-CoA oxidase 1 
(ACOX1), which is known to be responsible for the rate-limiting step of the 
peroxisomal β-oxidation pathway I, was equally and highly abundant in the club cells, 
macrophages and AECII cells whereas a lower abundance was observed in the 
ciliated cells of the control samples. Another β-oxidation enzyme, peroxisomal 3-oxo-
acyl-CoA thiolase (Acaa1) was more prominent in AECII than in any other cell type of 
the control lungs. Interestingly, the pattern of peroxisomal distribution in various cell 
types of the COPD lungs was similar to that of the control lungs. However, the 
peroxisomal protein abundance in cells of COPD lungs was much higher as in the 
control lungs. 
 
Thus, there exists a cell-type specific distribution of the peroxisomal proteins in 
different cells of the control lungs. The distribution pattern is similar in the COPD lungs 
but the abundance of peroxisomes in the COPD patients was observed to be very high 
in comparison to the control samples. 
 
 
 
 
 
49 
 
 
Table 17. Peroxisomal enzymes in various cells of the control and COPD lungs, their localization and 
comparison 
Control lungs Club cells  Ciliated cells Goblet cells Macrophages AECII 
MUC5AC - - + - - 
PEX14 + + - ++ + 
CAT ++ + - ++ ++ 
ACOX1 ++ + - ++ ++ 
THIOLASE 
(ACAA1) 
+ + - + + 
COPD lungs 
MUC5AC - - ++++ - - 
PEX14 +++ +++ - ++++ ++ 
CAT ++++ ++ - ++++ ++++ 
ACOX1 ++++ +++ - ++++ +++ 
THIOLASE 
(ACAA1) 
++ ++ - ++ ++ 
+weak, ++ significant, +++ very significant, ++++ extremely significant 
4.2. COPD mouse model 
4.2.1. Peroxisomal biogenesis, lipid metabolism and antioxidative 
enzymes are altered in COPD mouse model as well 
It was interesting to check whether COPD mouse model displayed a similar pattern of 
peroxisomal alterations as it was observed in the human COPD patients. For this 
purpose, lung tissue samples (obtained from the group of Prof. Weissmann) from the 
wild-type (WT) mice exposed to cigarette smoke for 3 months were analysed and 
compared to the age-matched controls that were kept under identical conditions but 
without smoke exposure178 (refer to section 3.2.2). Immunofluorescence analysis of 
paraffin sections revealed that the peroxisomal biogenesis protein PEX14 was strongly 
up-regulated in the bronchiolar region of the cigarette smoke (CS) exposed mice (Fig. 
19C and D). Similarly, the alveolar region of the COPD mouse model (Fig. 19G and 
H) showed a high abundance of PEX14 when compared to the alveolar region of WT 
controls (Fig. 19E and F). Similar staining pattern was observed for the peroxisomal 
antioxidative protein CAT, such that the COPD mouse model showed a high 
abundance of CAT in the bronchiolar (Fig. 20C and D) and alveolar (Fig. 20G and H) 
regions in comparison to the control lungs (Fig. 20A, B, E and F).  Moreover, the 
expression of peroxisomal mRNA for transcription factors as well as the expression for 
inflammatory mediators were analysed on total RNA by real-time PCR. As shown in 
Fig. 21, the expression levels of peroxisomal biogenesis genes are significantly up-
regulated in the COPD model as compared to the WT controls. Similarly, β-oxidation 
(Acox1 and Acaa1) and ether lipid biosynthesis (Agps) genes are highly expressed in 
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the CS treated model (Fig. 22). The antioxidative genes (Fig. 23A) as well as 
transcription factor mRNAs (Fig. 23B) were as well highly increased in the mouse 
COPD model. It is known that the various inflammatory mediators derived from the 
inflammatory and structural cells of the airways are increased in COPD. This was 
observed in our CS-exposed mice, where the levels of Il-6, Tnfα and Cox-2 in the 
lungs of these mice were highly increased with the Il-6 gene level showing the highest 
expression (Fig. 24). Thus, the results of the qRT-PCR analyses demonstrate that the 
expression levels of most of the peroxisomal genes as well as inflammatory mediators 
and transcription factors are significantly upregulated in the COPD model.  
 
To summarize, in the COPD mouse model similar alterations were present concerning 
the peroxisomal compartment and its associated gene expression levels as in COPD 
patients. 
 
 
 
 
Fig. 19.  CLSM images IF preparations for the peroxisomal biogenesis enzyme Pex14 in the 
bronchiolar (A-D) and alveolar epithelium (E- H) of the mouse control (A, B, E and F) and CS-
exposed lungs (C, D, G and H). Nuclei were counterstained with TOTO-3-iodide. Bars represent 
20μm for (A, C, E and G) and 60μm for (B, D, F and H). 
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Fig. 20. CLSM images of IF preparations for the peroxisomal antioxidative enzyme catalase 
(Cat) in the bronchiolar (A-D) and alveolar epithelium (E- H) of mouse control lungs (A, B, E and F) 
and lungs of the COPD model (C, D, G and H). Nuclei were counterstained with TOTO-3-iodide. 
Bars represent 20μm for (A, C, E and G) and 60μm for (B, D, F and H). 
 
Fig. 21. The expression levels of peroxisomal biogenesis gene mRNAs on total RNA of 
control and CS-exposed mice. P values were calculated by the unpaired student t-test.  *p ≤ 0.05, 
**p ≤ 0.01.   
Fig. 22. Real-time PCR of peroxisomal β-oxidation (Acoox1 and Acaa1) and ether lipid 
synthesis (Agps) gene mRNAs on total RNA of control and CS-exposed mice. P values were 
calculated by the unpaired student t-test.  **p ≤ 0.01.   
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4.3. Human bronchial epithelial cells 
4.3.1. Cigarette smoke exposed human cell culture model  
Following the analysis of human COPD samples and CS-exposed mouse model, our 
next goal was to establish an in vitro model and to determine the effect of CS extract 
(CSE) on peroxisomal alterations in cultured cells.  These cell culture models may 
provide vital information on molecular and functional mechanisms involved in the 
regulation of the peroxisomal or transcription factor alterations. For this purpose, 
primary human bronchial epithelial cells (HBE) were used. 
 
In order to establish an optimal model, we determined the appropriate concentration of 
CSE that was necessary to stimulate the cells but without inducing cell death by 
applying MTT assay (Fig. 25). It was found that CSE reduced the cell viability in a 
Fig. 23. The expression levels of antioxidative (A), and transcription factor (B) gene mRNAs on 
total RNA of control and CS-exposed mice as analysed by qRT-PCR. P values were calculated 
by the unpaired student t-test. ** p≤0.01, *** p≤0.001. 
Fig. 24. The expression levels of inflammatory mediator mRNAs from total RNA of control 
and CS-exposed mice as analysed by qRT-PCR. P values were calculated by the unpaired 
student t-test. **p ≤ 0.01, *** p ≤ 0.001. 
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concentration dependent manner, such that a 4hr exposure to 16% CSE reduced cell 
viability by 50%. Only minor effects were observed with 4% CSE. Therefore, for our 
further experiments, 8% CSE was used because it was the highest concentration that 
showed still only minor cytotoxicity. Two concentrations of 4% and 8% CSE were used 
for the peroxisomal analysis in Western blots in order to detect whether these two 
concentrations affect peroxisome abundance in a concentration dependent manner. 
 
4.3.2. CSE mediates upregulation of peroxisomes in the HBE cell culture 
COPD model 
After determination of the proper CSE concentration, we were interested to find 
whether the results of peroxisomal alterations in the cigarette smoke HBE cell culture 
model would correlate with the results obtained in the human and mouse COPD 
model. For this purpose, HBE cells were cultured until they reached 70% confluency 
and thereafter treated with 8% CSE for 4h. The abundance and expression of 
peroxisomal proteins was then investigated by immunofluorescence, Western blot and 
real time RT-PCR analyses. 
 
Immunofluorescence analysis revealed a significant increase of peroxisomal 
biogenesis (Fig. 26B and D), β-oxidation (Fig. 26F) and ether phospholipid synthesis 
(Fig. 26H) proteins in CSE-treated cells in comparison to DMSO treated controls (Fig. 
26A, C, E and G). Moreover, the peroxisomal antioxidative enzyme Cat was up-
regulated as well in this cell culture COPD model (Fig. 27B).  
Fig. 25.  Cell viability of cigarette smoke 
extract-exposed HBE cells.  The viability is 
determined by MTT assay after a 4h exposure to 
different concentrations of CSE. Results are 
expressed as percentages of the unexposed 
control. P values were calculated by one way 
ANOVA. n=3, ** p ≤ 0.01. 
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Fig. 26.  CLSM images of IF stainings for peroxisomal biogenesis (A-D), β-oxidation (E-
F) and ether lipid synthesis (G-H) proteins in HBE cells.  Human HBE cells were treated 
with DMSO (A, C, E and G) for 4h prior to IF staining. Cells treated with 8% CSE (B, D, F and 
H) for 4h prior to IF. Bars represent 25μm. 
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The upregulation of the peroxisomal compartment was also confirmed on the mRNA 
and protein level by qRT-PCR and Western blot analyses respectively. Significantly 
increased mRNA expression levels of the peroxisome-related genes involved in matrix 
protein import (PEX5, PEX7, PEX13 and PEX14) were observed in the 8% CSE 
treated cells (Fig. 28A-C) in comparison to the control. Similar upregulation of the 
corresponding proteins was observed (Fig. 28D). Moreover, peroxisomal β-oxidation 
genes (Fig. 29) as well as peroxisomal ether phospholipid synthesis genes (Fig. 30A 
and B) and proteins (Fig. 30C) were increased in expression/abundance in the in vitro 
smoke model as compared to DMSO treated cells. Furthermore, peroxisomal 
antioxidative enzyme catalase (CAT) and transcription factor (PPARγ) genes (Fig. 31A 
and C) and proteins (Fig. 31B and D) were highly upregulated in the 8% treated cells. 
Interestingly, Western blot analysis revealed that CSE triggered the upregulation of 
peroxisomal proteins in a concentration dependent manner.  
 
Fig. 27. CLSM images of IF stainings for the antioxidative enzyme CAT in HBE cells.  HBE 
cells were treated with DMSO as a control (A) and with 8% CSE (B) for 4h prior to IF. Bars represent 
25μm. 
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It is known that in COPD, inflammatory cells are activated and produce inflammatory 
mediators like IL-6, IL-8 and TNFα 78,189. Many studies demonstrated the elevation of 
these inflammatory cytokines in COPD patients. Similarly, our CS-exposed HBE cell 
culture model revealed an increase in the expression of inflammatory genes (Fig. 32) 
in comparison to the controls.  Moreover, ELISA analysis of the supernatants from the 
DMSO or CSE treated cells showed a high release of IL-8 from the CSE treated HBE 
cells. In other words, CSE treatment induced IL-8 release into the medium (Fig. 33). 
 
To summarize, our CS-exposed HBE cell culture model demonstrated a significant 
upregulation of the peroxisomal compartment. These results were in agreement with 
the results obtained in the COPD patients and the CS-exposed mouse model. This 
correlates with our goal which was to establish a good cell culture model that will allow 
Fig. 28. The expression levels of peroxisomal gene mRNAs (A-C) and protein abundance 
(D) on total RNA and total lysate respectively. Western blot analyses and qRT-PCR were 
performed on the cells treated either with DMSO as a control or with 4-8% CSE for 4h. P values 
were calculated by the unpaired student t-test. n=3, *p ≤ 0.05, ** p ≤ 0.01. 
Fig. 29. Real-time PCR of peroxisomal β-oxidation gene mRNAs (ACOX1 and ACAA1) on 
total RNA of control and CSE-treated cells. P values were calculated by the unpaired student t-
test. n=3, *p ≤ 0.05, *** p ≤ 0.001. 
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us to maintain as many physiologically-relevant factors as possible and to perform 
functional studies in future experiments.  
 
 
 
 
 
 
 
 
Fig. 30. Real-time PCR and Western blot analyses of peroxisomal ether phospholipid 
synthesis gene mRNAs and proteins on total RNA and total lysate respectively.  Cells were 
either treated with DMSO as a control or with 4-8% CSE for 4h. P values were calculated by the 
unpaired student t-test. n=3, *p ≤ 0.05, *** p ≤ 0.001. 
Fig. 31. Real-time PCR and 
Western blot analysis of 
peroxisomal antioxidative 
(CAT) and transcription factor 
(PPARγ) gene mRNAs and 
proteins on total RNA and total 
lysate respectively.  Cells were 
either treated with DMSO as a 
control or with 4-8% CSE for 4h. 
P values were calculated by the 
unpaired student t-test. n=3, ** p 
≤ 0.01. 
Fig. 32. The expression levels of 
inflammatory mediators mRNA from total 
RNA of control and CS-exposed cells as 
analysed by qRT-PCR. P values were 
calculated by the unpaired student t-test. n=3, 
** p ≤ 0.01, ***p≤0.001.   
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4.3.3. PEX13 knockdown 
The PEX13 gene encodes a peroxisomal biogenesis protein in the peroxisomal 
membrane that belongs to the docking complex and is necessary for peroxisomal 
matrix protein import. Therefore, deletion of PEX13 leads to a loss of matrix protein 
import via the PTS1 and PTS2 targeting signals 190. Knockdown of the PEX13 gene 
disrupts peroxisome biogenesis and would provide a good model to study the role of 
peroxisomes in the pathogenesis of COPD.  
 
Establishment of the conditions for the PEX13 knockdown was done with two different 
PEX13 small interfering RNAs (siRNAs) over a range of 24-96h. We noticed that the 
knockdown drastically affected the survival of the cells even with the lower 
concentration of PEX13 siRNA used (10nmol). The delivery of siRNA into primary cells 
is considered to be challenging because primary cells are hard-to-transfect and after 
couple of unsuccessful attempts, we decided to use the mouse club cell line (C22 
cells) for this purpose. 
 
4.4. Immortalized (Conditionally) Mouse Lung Club Cells (C22) cells 
4.4.1. Cigarette smoke-exposed model 
Similarly like in experiments with HBE cells, it was important to determine the 
appropriate concentration of CSE to be used for the generation of CSE-exposed cell 
model. For this purpose, cell viability was measured with the MTT assay (Fig. 34). The 
results were similar to that of HBE cells where CSE treatment reduced cell viability in a 
concentration dependent manner, such that a 4hr exposure with 16% CSE reduced 
the cell viability by 50%. Only minor changes of cell viability were observed with 4% 
CSE. Therefore, for our further experiments, 8% CSE was chosen to be used because 
it was the highest concentration that still had low cytotoxicity.  
Fig. 33. Cigarette smoke extract induced 
IL-8 production in HBE cells.  The 
supernatants of DMSO and CSE treated 
cells were collected after 4h of treatment 
and analysed by ELISA for the secretion of 
IL-8. P values were calculated by the 
unpaired student t-test. n=3, ** p ≤ 0.01. 
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4.4.2. CSE treated C22 cells reveal an upregulation of peroxisomes 
Before knocking down Pex13, we wanted to confirm that our CSE-exposed C22 in 
vitro model would corroborate the results observed in COPD patients as well as in 
COPD mouse and HBE cell culture model. For this purpose, it was necessary to 
examined whether CSE would induce similar responses, at the protein and mRNA 
levels as the ones observed in the previous models. 
 
Immunofluorescence stainings of C22 cells treated with 8%CSE for 4h demonstrated 
an elevation of the peroxisomal biogenesis protein PEX13 (Fig. 35 B) in comparison to 
the control cells treated with DMSO (Fig. 35A). The increase in PEX14 (Fig. 35D) 
abundance was very slight in comparison to control cells (Fig. 35D). In addition to this, 
the abundance of the peroxisomal antioxidative enzyme CAT (Fig. 36D) as well as the 
peroxisomal β-oxidation enzyme Thiolase (Fig. 36B) was drastically up-regulated in 
the cells stimulated with 8% CSE.  
Fig. 34. Cell viability of cigarette smoke 
extract-exposed cells. The viability is 
determined by MTT assay after a 4hr exposure to 
different concentrations of CSE. Results are 
expressed as percentage of the unexposed 
control. P values were calculated by the one way 
ANOVA. n=3, ** p ≤ 0.01. 
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Fig. 35. CLSM images of IF stainings for peroxisomal biogenesis proteins in C22 cells.  C22 
cells were treated with DMSO as a control (A&C) and with 8% CSE (B&D) for 4h prior to IF. Bars 
represent 10μm. 
Fig. 36. CLSM images of IF stainings for peroxisomal β-oxidation (Thiolase) and 
antioxidative (CAT) proteins in C22 cells.  C22 cells were treated with DMSO as a control 
(A&C) and with 8% CSE (B&D) for 4h prior to IF. Bars represent 10μm. 
 
 
61 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Furthermore, Western blot and real time results were as well in accordance with the 
results shown in the previous models, where CSE induced a drastic upregulation in the 
peroxisomal biogenesis genes and protein (Fig. 37A and B), peroxisomal β-oxidation 
Fig.  39. Real-time PCR and Western blot analysis of peroxisomal ether phospholipid 
synthesis Agps mRNA (A) and protein (B) on total RNA and total lysates respectively. Cells 
were either treated with DMSO as a control or with 4-8% CSE for 4h. P values were calculated 
by the unpaired student t-test. n=3, * p ≤ 0.05. 
Fig. 38. Real-time PCR of peroxisomal β-oxidation gene mRNAs (ACOX1 and ACAA1) on 
total RNA of control and CSE treated cells. P values were calculated by the unpaired student t-
test. n=3, * p ≤ 0.05, **p≤0.01. 
Fig. 37. The expression levels of peroxisomal biogenesis gene mRNAs (A) and protein 
abundance (B) on total RNA and total lysate respectively. qRT-PCR and Western blot were 
performed on the cells treated either with DMSO as a control or with 8% CSE for 4h. P values 
were calculated by the unpaired student t-test. n=3, * p ≤ 0.05. 
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gene mRNAs (Fig. 38) and peroxisomal ether phospholipid synthesis gene mRNA 
(Fig. 39A) and protein (Fig. 39B). Moreover, an increase in the transcription factors 
with 8% CSE in comparison to the DMSO control was observed with the Western blot 
and qPCR analysis (Fig. 40A and B). It is known that the oxidative stress caused by 
cigarette smoke triggers the release of various pro-inflammatory cytokines like IL-8, IL-
6 and TNF-a and that COPD is characterized by abnormal increase of circulating 
cytokines such as CRP, IL-8, TNF-a, IL-6 191,192. Our results were in agreement with 
the COPD cytokine profile described in the previous studies such that; stimulation with 
8%CSE for 4h increased the mRNA levels of pro-inflammatory cytokines, Il-6 and Tnf-
α (Fig. 41A) and elevated the inflammatory protein level of COX-2 (Fig. 41B). 
Moreover, ELISA assay has shown a significant elevation of the secretory proteins 
TNF-α and IL-6 (Fig. 42 A and B). This implies that there is a strong oxidative stress 
which resulted in upregulation of antioxidant genes and enzymes CAT, HO-1 and 
SOD1 as shown by the qPCR and Western blot analysis (Fig. 43A-C). 
 
To conclude, CSE treatment of mouse C22 cells recapitulated the results observed in 
samples taken from COPD patients, CS-exposed mouse model and samples 
generated from CSE-treated HBE cells.  Therefore, C22 cells were used in the further 
knock-down experiments. 
 
 
 
 
 
 
Fig. 40. Gene expression and protein abundance of transcription factors on total RNAs and 
total protein lysates respectively of control and CSE-treated cells as analysed by qRT-PCR and WB. 
P values were calculated by the unpaired student t-test. n=3, * p ≤ 0.05. 
Fig. 41. Real-time PCR and Western blot analysis of pro-inflammatory cytokines (A) and the 
inflammatory marker (B) on total RNAs and total lysate respectively of DMSO control and 4hr 
CSE-treated cells. P values were calculated by the unpaired student t-test. n=3, * p ≤ 0.05, **p≤0.01. 
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4.4.3. Pex13 knockdown in C22 cells 
4.4.3.1. Peroxisome deficiency in Pex13 knockdown in C22 cells 
In order to understand the function of peroxisomes in the pathogenesis of COPD, the 
knock-down of Pex13, a peroxisomal biogenesis gene whose protein product acts as a 
docking factor in the peroxisomal membrane for the import of matrix proteins, was 
performed. Therefore, Pex13 deletion disrupts the peroxisomal biogenesis preventing 
the matrix proteins from being imported into the organelle. Consequently, the matrix 
proteins are mislocalized into the cytoplasm in which many of them (except catalase) 
are degraded. Therefore, mistargeting of catalase to the cytoplasm is an excellent 
proof for the dysfunctional protein import into peroxisomes. 
 
Establishment of the conditions for the Pex13 knockdown was done with Pex13 small 
interfering RNA (siRNA) over a range of 24-96h with a single transfection of siRNA. 
Long times after transfection were necessary since the half-life of peroxisomes was 
estimated to be 3 days (in hepatocytes) and effects on protein levels can only be 
Fig. 43. Real-time PCR and Western blot analyses of antioxidative gene mRNAs and proteins 
on total RNAs and total lysates respectively of control and CSE-treated cells. . P values were 
calculated by the unpaired student t-test. n=3, * p ≤ 0.05. 
Fig. 42. Cigarette smoke extract induced cytokine release in C22 cells.  The supernatants of 
DMSO and CSE-treated cells were collected after 4h of treatment and analysed by ELISA for the 
secretion of IL-6 and TNF-α. P values were calculated by the unpaired student t-test. n=3, **p≤0.01. 
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observed around this time point. We found that the optimal conditions for siRNA 
transfection were as follows: single transfection of Pex13 siRNA (30nmol) and then 
harvesting the cells 72h post transfection. 
 
The cells transfected with siRNA specific for the Pex13 gene and then treated with 
DMSO or 8%CSE, showed a significant reduction in the Pex13 mRNA and protein 
levels after 72h of transfection (Fig. 44A and B). In contrast, a high expression in the 
level of Pex13 mRNA was observed in the cells transfected with scr-siRNA and 
thereafter treated with CSE (Fig. 44A); this result is a confirmation of the previous 
results that CSE triggers upregulation of peroxisomes in un-transfected cells. 
Furthermore, in order to confirm the knock-down, immunofluorescence was performed 
72h post transfection. Immunofluorescence for PEX13 in the Pex13 siRNA transfected 
cells revealed a strong down-regulation in the PEX13 protein abundance in 
comparison to the scr-siRNA transfected cells (Fig. 45B). Moreover, the Pex13 
knockdown induced mistargeting of catalase (CAT), which is normally present in 
peroxisomes, into the cytoplasm of C22 cells as shown by IF (Fig. 46B). As was 
mentioned above, the cytoplasmic localization of peroxisomal matrix enzymes is a 
well-known phenomenon in cells with peroxisome deficiency 193. The level of PEX14, 
which forms the docking complex together with PEX13 on the peroxisomal membrane, 
was not changed on the RNA (Fig. 47A) and protein (Fig. 47B) levels after siRNA 
transfection and this is reasonable as knock-down was Pex13 specific. 
 
 
 
 
 
 
 
 
 
 
 
 
65 
 
 
 
 
 
 
 
 
 
 
     
 
 
Fig. 44. Real-time PCR and Western blot analysis of peroxisomal biogenesis gene mRNA 
and protein of C22 cells transfected with either Pex13-siRNA or scr-siRNA followed by the DMSO 
(0%CSE) or CSE treatment. P values were calculated by the one way ANOVA. n=3, *p≤0.05, ** 
p≤0.01, *** p≤0.001. 
Fig. 45. Effects of Pex13 gene knock-down as shown by immunofluorescence. C22 cells 
were transfected with scr- siRNA as a control (A) or with Pex13 siRNA (B) for 72h prior to IF. 
Bars represent 10μm. 
Fig. 46. Mistargeting of CAT into the 
cytoplasm after Pex13 knock-down as 
shown by immunofluorescence. C22 cells 
were transfected with scr-siRNA as a 
control (A) or with Pex13 siRNA (B) for 72h 
prior to IF. Bars represent 10μm. 
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As was mentioned before, proteins which are to be imported into the peroxisomal 
matrix contain either PTS1 or PTS2 peroxisomal targeting signals. Peroxisomal 
proteins harbouring either PTS1 or PTS2 signals are recognized by the PEX5 and 
PEX7 receptors respectively 194. Once the cargo-receptor complex is formed, the 
complex is translocated to the peroxisomal membrane where it requires the 
peroxisomal membrane proteins (PEX13 and PEX14) for the initial binding step. 
Therefore, the knock-down of Pex13 will affect the import of PTS1 targeted proteins, 
such as catalase or PTS2 proteins, such as Thiolase into the peroxisome 195,196. This 
is shown by the Western blot and real time PCR analyses where the peroxisomal 
antioxidative enzyme catalase (Fig. 48A and C) was reduced by more than 50% at the 
protein and mRNA level following the Pex13 knock-down. In addition to catalase, the 
level of peroxisomal ether phospholipid synthesis enzyme AGPS was also reduced at 
the protein (Fig. 48C) and RNA (Fig. 48B) level after siRNA transfection. The 
peroxisomal β-oxidation enzymes ACOX1 and ACAA1 (Thiolase) (Fig. 49A and B) 
were as well decreased by 80% at the mRNA level in Pex13 siRNA transfected cells. 
Therefore, peroxisome related gene expression and protein expression were strongly 
reduced in the Pex13 knock-down model. How the mRNAs are down-regulated by the 
Pex13 knock-down is not known until now. The degradation of peroxisomal matrix 
proteins in the cytoplasm is probably performed via the proteasome system. 
Fig. 47. Real-time PCR and Western blot analysis of peroxisomal biogenesis gene mRNA and 
protein of C22 cells transfected with either Pex13-siRNA or scr-siRNA followed by the DMSO 
(0%CSE) or CSE treatment. P values were calculated by the one way ANOVA. n=3, *p≤0.05, ** 
p≤0.01. 
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4.4.3.2. Pex13 deletion negatively affects cell proliferation  
To detect the effect of Pex13 siRNA-treatment on cell proliferation, BrdU cell 
proliferation assays were performed. The calculation of the proliferation rate was 
based on measurements of BrdU incorporation during DNA synthesis in comparison to 
the scr-siRNA-treated groups. The Pex13 knock-down together with CSE treatment 
reduced the cell proliferation by 20% in comparison to the DMSO treated scr-siRNA 
transfected cells (Fig. 50). 
Fig. 48. Real-time PCR and Western blot analysis of peroxisomal antioxidant and ether 
phospholipid synthesis gene mRNA and protein of C22 cells transfected with either Pex13-
siRNA or scr-siRNA followed by the DMSO (0%CSE) or 8%CSE treatment. P values were 
calculated by the one way ANOVA. n=3, *p≤0.05, ** p≤0.01. 
 
Fig. 49. Real-time PCR of peroxisomal β-oxidation gene mRNAs (ACOX1 and ACAA1) on total 
RNA of scr-siRNA and Pex13 siRNA transfected cells treated with either DMSO or CSE. P values 
were calculated by the one way ANOVA. n=3, ** p ≤ 0.01. 
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4.4.3.3. The Pex13 deletion and CSE treatment induced a strong increase in 
the expression and the release levels of pro-inflammatory cytokines 
A significant three and two fold increase was observed for the mRNA levels of Il-6 
(Fig. 51A) and Tnf-α (Fig. 51B) respectively in the cells transfected with Pex13 siRNA 
and then treated for 4h with 8% CSE. Moreover, the abundance of the pro-
inflammatory mediator COX-2 was up-regulated at the protein level in the Pex13-
deleted cells (Fig. 51C) in comparison to cells treated with scr-siRNA. The 
upregulation of pro-inflammatory cytokines was confirmed by ELISA which revealed a 
much higher release of IL-6 and TNF-α into the medium after Pex13 deletion and 
treatment with CSE. The supernatant of the cells transfected with Pex13 siRNA for 
68h showed a 3-fold increase in the released IL-6, from 44pg/ml in the unstimulated 
cells to 160pg/ml after CSE stimulation (Fig. 52A). Furthermore, the concentration of 
the released IL-6 in the supernatant of the cells transfected with Pex13 siRNA and 
treated with CSE was 25% higher (160pg/ml) than in the supernatant of the cells 
transfected with scr-siRNA and thereafter treated with CSE (102pg/ml). In addition to 
this, the same pattern was observed for released TNF-α (Fig. 52B) where the 
transfected and then CSE treated cells showed a strong upregulation in TNF-α to 
approximately 1500pg/ml in comparison to 460pg/ml in the supernatant of Pex13 
siRNA transfected but untreated cells. Moreover, the TNF-α released was two-fold 
higher in the supernatant of Pex13 deleted cells followed by CSE treatment than in the 
supernatant of the cells transfected with scrambled siRNA and treated with CSE 
(700pg/ml). In summary, the knock-down of Pex13 together with CSE stimulation 
triggered a much higher release of pro-inflammatory mediators and this expression 
and release of the mediators was more significant than in scr-siRNA transfected and 
then CSE treated cells.  
Fig. 50. Percentage of BrdU positive cells 
after either DMSO or CSE treatment following 
scr-siRNA or Pex13 siRNA transfection. The 
extent of cell proliferation was measured by 
absorbance at 450nm. P values were calculated 
by the one way ANOVA. n=3, ** p ≤ 0.01. 
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4.4.3.4. Peroxisomal deficiency induces a much higher ROS production 
after CSE treatment 
As was shown above, the deletion of Pex13 leads to downregulation of peroxisomal 
enzymes, decreases proliferation and induces the release of inflammatory mediators. 
In addition to this, the ROS production was analysed from differently treated cells by 
using dihydroethidium (DHE) staining. The ROS activity of scr-siRNA transfected cells 
treated with CSE (Fig. 53B and B’) was increased by 30% in comparison to the 
DMSO treated scr-siRNA transfected cells (Fig. 53A and B’), suggesting that the 
intracellular stress is caused by CSE. A slight increase in the ROS activity was already 
observed in Pex13 siRNA transfected cells treated with DMSO (Fig. 53C and B’) in 
comparison to scr-siRNA transfected cells treated with DMSO (Fig. 53A and B’). 
However, in comparison to the value of scr-siRNA transfected and CSE treated cells, 
the Pex13 knock-down and deficiency of the peroxisomal compartment lead to a 
further 80% increase in ROS suggesting that this increase was indeed exerted by the 
peroxisome deficiency (Fig. 53D and B’). 
Fig. 52. Cigarette smoke extract induced the release of pro-inflammatory cytokines (IL-6 and 
TNF-α) in the supernatant of siRNA-Pex13 transfected cells as shown by ELISA assay. The C22 cells 
were transfected with either Pex13 siRNA or scr-siRNA for 68h and then treated with DMSO or 
8%CSE for 4h prior to supernatant collection. The released mediators were measured by ELISA. P 
values were calculated by the one way ANOVA. n=3, ** p ≤ 0.01, *** p≤0.001, **** p≤0.0001. 
Fig. 51. CSE increased the expression of pro-inflammatory mediators at the mRNA level on total 
RNA of scr-siRNA and Pex13 siRNA transfected cells, treated with either DMSO or CSE as estimated 
by qRT-PCR. P values were calculated by the one way ANOVA. n=3, ** p≤0.01, *** p≤0.001. 
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4.4.3.5. Peroxisomal dysfunction due to Pex13 knockdown induced an 
oxidative response 
Oxidative stress mediates the expression of protective genes like Nrf2, Pparγ, Ho-1 
and Sod1. Moreover, it is known that Pparγ may modulate the expression of anti-
inflammatory genes, apparently including antioxidant nuclear factor Nrf2 in response to 
oxidative stress 197.  
 
It was found that Pex13 deletion led to the upregulation of both transcription factors 
PPARγ and Nrf2. It also induced the protein expression and transcription of Nrf2 
downstream genes HO-1 and SOD1. The highest increase in PPARγ was observed at 
the mRNA (Fig. 54A) and protein (Fig. 54C) level in the cells treated with 8% CSE 
after Pex13 deletion. A similar pattern was detected at the mRNA (Fig. 54B) and 
protein level (Fig. 54C) for the transcription factor Nrf2 since it was strongly expressed 
in the cells treated with CSE following Pex13 deletion. Indeed, the expression of these 
transcription factors was higher in Pex13 transfected and CSE treated cells rather than 
in scrambled cells treated with CSE. The NRF2 regulated antioxidative enzymes 
SOD1 and HO-1, were as well highly expressed in Pex13 knock-down cells treated 
with CSE at the mRNA (Fig. 55A and B) and protein levels (Fig. 55C). It is known that 
Nrf2 is a transcription factor that responds to oxidative stress by binding to the 
antioxidant response element (ARE). Therefore, a luciferase gene reporter assay was 
Fig. 53. Measurement of ROS by dihydroethidium (DHE) staining after different siRNA 
treatments (A’). Images were analyzed for DHE intensity using ImageJ (B’). The cells were 
transfected once with Pex13-siRNA and scr-siRNA. Following the siRNA transfection, the cells were 
treated with CSE and then stained with DHE for 30 min. The bars represent 10μm. P values were 
calculated by the one way ANOVA. n=3, ** p≤0.05, **** p ≤ 0.0001. 
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performed with a reporter vector containing the antioxidant response element (ARE) 
(pARE-luc), the DNA-binding element for NRF2, in order to confirm that the Pex13 
knock-down induces oxidative stress. The results revealed that peroxisome deficiency 
by the Pex13 knock-down, induced the activation of ARE (Fig. 56). This activation was 
the highest in cells treated thereafter with CSE. Similarly, the Pex13 knock-down 
without CSE stimulation was also able to induce the ARE activity but to a lower extent 
than in the cells treated with CSE as demonstrated by the luciferase assay. In 
summary, the Pex13 deletion induced peroxisome deficiency leading to reduction of 
the cell proliferation, a higher ROS production and oxidative stress. 
 
 
 
Fig. 54. Cigarette smoke extract induced the mRNA 
expression and protein abundance of transcription 
factors in siRNA-Pex13 transfected cells as shown by 
qRT-PCRs and Western blots. C22 cells were transfected 
with either Pex13 siRNA or scr-siRNA for 68h and then 
treated with DMSO or 8%CSE for 4h prior to collection. P 
values were calculated by the one way ANOVA. n=3, * 
p≤0.05, ** p≤0.05, *** p ≤ 0.001. 
Fig. 55. Cigarette smoke extract induced the mRNA 
expression and protein abundance of Nrf2 regulated 
antioxidative enzymes SOD1 and HO-1 in Pex13 
siRNA transfected cells as shown by qRT-PCRs and 
Western blots. C22 cells were transfected with either 
Pex13 siRNA or scr-siRNA for 68h and then treated with 
DMSO or 8%CSE for 4h prior to RNA and protein 
collection. P values were calculated by the one way 
ANOVA. n=3, * p≤0.05, ** p≤0.05, *** p ≤ 0.001.  
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4.4.3.6. Pparγ regulates the Pex13 expression 
As shown above, the cells with Pex13 knock-down were strongly affected by CSE 
treatment. This effect was significantly stronger than the one observed in the cells 
transfected with scr-siRNA stimulated with CSE. Moreover, these Pex13 knock-down 
cells exhibited an elevation in oxidative stress, pro-inflammatory mediators, ROS 
levels and a decrease in proliferation. Therefore, we hypothesised that the activation 
and induction of peroxisomes could improve the cellular stress in COPD patients and 
therefore would reduce the severity of COPD symptoms. For this reason, it was 
important to prove that the peroxisome proliferator-activated receptor gamma (Pparγ) 
is upstream of the Pex13 gene which would imply that the induction of PPARγ might 
activate the peroxisomal compartment. Therefore, a Pparγ knock-down was performed 
in order to check whether Pex13 would be affected. As shown by the results, the 
knockdown was successful to silence 70% of the Pparγ gene in the cells transfected 
with Pparγ siRNA (Fig.  57A). A down-regulation of Pparγ was also observed at the 
protein level (Fig. 57B). 
 
 
 
Fig. 57. PPARγ knock-down as shown by qRT- PCR and Western blot analysis. C22 cells 
transfected with either Pparγ-siRNA or scr-siRNA followed by the DMSO (0%CSE) or 8% CSE 
treatment. The RNA and protein was collected 72h post-transfection. P values were calculated by 
the one way ANOVA. n=3, ** p≤0.01. 
Fig. 56. Increased ARE response element activity in Pex13 
knock-down cells. Luciferase reporter activity of ARE promoter 
element in cells transfected with either Pex13-siRNA or scr-
siRNA together with either pARE-luc or empty vector and 
thereafter followed by DMSO (0%CSE) or 8% CSE treatment as 
measured by luciferase assays. 72h post transfection cell lysates 
were collected and assayed for luciferase activity. The activity of 
firefly luciferase was measured in cell lysates and normalized to 
the activity of renilla luciferase. P values were calculated by the 
one way ANOVA. n=3, *p≤0.05, ** p≤0.01. 
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The Pparγ siRNA silencing also reduced the Pex13 gene expression (Fig. 58A) and 
reduced strongly its protein abundance (Fig. 58B) as shown by qRT-PCR and 
Western blot analyses.  
 
 
 
 
4.4.3.7. Pparγ silencing provoked a similar response of antioxidative 
enzymes as was observed after Pex13 knock-down 
Pparγ knock-down induced a similar pattern of the antioxidant response as was 
observed after Pex13 knock-down. Catalase (CAT), a major peroxisomal antioxidative 
enzyme was analysed in Pparγ silenced cells. The results revealed a drastic down-
regulation in peroxisomal CAT expression (Fig. 59A) and abundance (Fig. 59B) in the 
Pparγ silenced cells. This decrease in the level of CAT corroborated the strong down-
regulation of the peroxisomal biogenesis protein PEX13 induced by the Pparγ knock-
down. 
 
 
 
 
In contrast to catalase, Pparγ silencing provoked a different response of Nrf2 and its 
downstream genes Ho-1 and Sod1. Interestingly, the deletion of Pparγ led to the 
upregulation of the transcription factor Nrf2 and induced the protein expression and 
Fig. 58. Pparγ knock-down downregulated Pex13 as demonstrated by the qRT-PCR and Western 
blot. C22 cells transfected with either Pparγ -siRNA or scr-siRNA followed by the DMSO (0%CSE) or 
CSE treatment. The RNA and protein was collected 72h post-transfection. P values were calculated 
by the one way ANOVA. n=3, * p≤0.05. 
Fig. 59. Pparγ knock-down reduced the expression and abundance of the peroxisomal 
antioxidative enzyme catalase (CAT) as shown by qRT-PCR and Western blot. The C22 cells 
were transfected with either Pparγ siRNA or scr-siRNA for 68h and then treated with DMSO or 
8%CSE for 4h prior to collection. P values were calculated by the one way ANOVA. n=3, * p≤0.05. 
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transcription of the Nrf2-regulated genes encoding the antioxidative enzymes HO-1 
and SOD1. A high increase in Nrf2 was observed at the mRNA (Fig. 60A) and protein 
(Fig. 60B) levels in the cells treated with 8% CSE after Pparγ deletion, whereas a 
slight increase in the abundance was seen in cells transfected with Pparγ and treated 
with DMSO thereafter in comparison to the cells transfected with scr-siRNA. A similar 
pattern was detected at the mRNA (Fig. 61A and B) and protein level (Fig. 61C) of 
Nrf2-regulated antioxidative enzymes SOD1 and HO-1, which were as well highly 
expressed in Pparγ knock-down cells treated with CSE. Moreover, Pparγ silencing 
provoked a drastic upregulation of COPD pro-inflammatory markers (Il-6 and Tnf-α) 
(Fig. 62), suggesting an increase of the inflammatory response.  
 
 
 
 
 
 
 
Fig. 60. Cigarette smoke extract induced expression and abundance of Nrf2 in Pparγ siRNA 
transfected cells as shown by qRT-PCR and Western blot analyses. The C22 cells were transfected 
with either Pparγ siRNA or scr-siRNA for 68h and then treated with DMSO or 8%CSE for 4h prior to 
collection. P values were calculated by the one way ANOVA. n=3, *p≤0.05. 
Fig. 61. Cigarette smoke extract induced 
expression and abundance of Nrf2-regulated 
antioxidative enzymes SOD1 and HO-1 in siRNA-
Pparγ transfected cells as shown by qRT-PCR and 
Western blot. The C22 cells were transfected with 
either Pparγ siRNA or scr-siRNA for 68h and then 
treated with DMSO or 8%CSE for 4h prior to RNA 
and protein collection. P values were calculated by 
the one way ANOVA. n=3,* p≤0.05, ** p≤0.01. 
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The ARE-luc reporter gene assay was already used to confirm that the Pex13 knock-
down induced the activation of the antioxidant response element (ARE) which upon 
Nrf2 binding leads to the expression of antioxidative enzymes and corresponding 
transcription factor genes (Fig. 63). In pro-oxidant conditions, Nrf2 binds to the 
antioxidant-responsive element (ARE) in the promoter region which activates the 
transcription of antioxidative genes, e.g. Ho-1 and Sod1.  
 
 
 
 
 
Our result on cell proliferation, could suggest that the knock-down of Pparγ is exerting 
a strong effect on the cells’ ability to repair oxidative stress-induced damage caused 
by CSE, compromising cell proliferation as shown by the BrdU assay (Fig. 64), in 
which cell proliferation was reduced by 40% in comparison to the cells transfected with 
either scr-siRNA or Pex13 siRNA. 
Fig. 63. Increased ARE response element activity in PPARγ knock-down cells. Luciferase reporter 
activity of ARE promoter element in cells transfected with either Pparγ -siRNA or scr-siRNA together 
with either pARE-luc or empty vector and thereafter followed by DMSO (0%CSE) or CSE treatment as 
measured by the luciferase assay. 72h post transfection cell lysates were collected and assayed for 
luciferase activity. The activity of firefly luciferase was measured in cell lysates and normalized to the 
activity of renilla luciferase. P values were calculated by the one way ANOVA. n=3, ** p≤0.01. 
Fig. 62. Pparγ  knock-down and CSE treatment increased the expression of the pro-inflammatory 
mediators Il-6 and Tnf-α at the mRNA level on total RNA of scr-siRNA and Pparγ siRNA transfected 
cells, treated with either DMSO or CSE as estimated by qRT-PCR. P values were calculated by the 
one way ANOVA. n=3, ** p≤0.01, *** p≤0.001. 
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4.4.4. PPARγ stimulation induces the elevation of peroxisomes 
Since peroxisomal genes and proteins were down-regulated by the knock-down of 
Pparγ, the next step was to stimulate PPARγ in order to modulate the expression of 
peroxisomes in opposite direction and to check whether this would influence COPD 
markers. For this purpose, the treatment with rosiglitazone (RZG), a drug belonging to 
the class of thiazolidinediones was selected. RZG is a ligand for the nuclear receptor 
peroxisome proliferator-activated receptor gamma (PPARγ) which induces its 
activation. RZG-treatment was performed 24h before the CSE stimulation. The qRT-
PCR (Fig. 65A) and Western blot (Fig. 65B) analyses revealed that the cells treated 
with RZG for 24h and then stimulated with 8% CSE showed a significant upregulation 
of the Pex13 gene and PEX13 protein (Fig. 65B) in comparison to the DMSO treated 
and then CSE stimulated cells. 
 
 
 
 
Peroxisomal catalase as well exhibited a similar upregulation at the mRNA and protein 
levels (Fig. 66A and B) after RZG treatment and CSE stimulation as was observed 
with PEX13. Interestingly, RZG was only able to induce the higher upregulation of 
peroxisomes when the CSE treatment was applied whereas no clear difference was 
observed in peroxisomes in DMSO and RZG only treated groups. The cells treated 
Fig. 64. Percentage of BrdU positive cells after 
either DMSO or CSE treatment following scr-siRNA or 
Pparγ siRNA transfection. The extent of cell 
proliferation was measured by absorbance at 450nm. 
P values were calculated by the one way ANOVA. n=3, 
*** p≤0.001, **** p≤0.0001. 
Fig. 65. RZG treatment induced the expression and abundance of PEX13 in the CSE treated 
cells as shown by qRT-PCR (A) and Western blot (B). Protein levels relative to GAPDH were 
quantified by densitometry with ImageJ. The C22 cells were treated with either DMSO or RZG for 24h 
and then stimulated with either 8%CSE or DMSO for 4h prior to protein and RNA collection. P values 
were calculated by the one way ANOVA. n=3, * p≤0.05, ** p≤0.01, *** p≤0.001, **** p≤0.0001. 
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with DMSO as well as the cells stimulated with RZG showed no significant difference 
at the mRNA and protein levels for PEX13 and CAT. 
 
 
 
 
 
As was demonstrated by further experiments, RZG induced a significant upregulation 
of peroxisomal β-oxidation (Fig. 67A) and ether phospholipid synthesis enzyme (Fig. 
67B and C) mRNAs and proteins when the CSE treatment was applied in comparison 
to the cells stimulated with CSE alone as shown by the qRT-PCR and Western blot 
analyses. Thereafter, it was interesting to check the Nrf2-mediated antioxidant 
response following CSE-treatment. Indeed, Nrf2 was significantly up-regulated at the 
mRNA and to a lesser extent at the protein level following the RZG treatment and CSE 
stimulation (Fig. 68A and B). This led to the drastic elevation of Nrf2-regulated genes 
encoding the antioxidative enzymes (HO-1 and SOD1) following RZG treatment and 
CSE stimulation at the mRNA (Fig. 68C) and protein levels (Fig. 68D). To summarize, 
the samples treated with RZG and then stimulated with CSE showed a significant 
upregulation of the peroxisomal compartment at the mRNA and protein levels in 
comparison to the samples stimulated with CSE alone. Similar results were observed 
for Nrf2 and its regulated genes Ho-1 and Sod1. Thereafter, we checked the ARE 
activity by luciferase assays and found that the activity of the ARE-element-regulated 
promoter as well was significantly activated in the cells treated with CSE following the 
incubation with RZG (Fig. 69).  
Fig. 66. RZG treatment induced the expression and abundance of antioxidative enzyme CAT in 
the CSE treated cells as shown by qRT-PCR (A) and Western blot (B). Protein levels relative to 
GAPDH were quantified by densitometry with ImageJ. The C22 cells were treated with either DMSO 
or RZG for 24h and then stimulated with either 8%CSE or DMSO for 4h prior to protein and RNA 
collection. P values were calculated by the one way ANOVA. n=3, ** p≤0.01, *** p≤0.001, **** 
p≤0.0001. 
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Fig 67. RZG stimulation induced the peroxisomal β-oxidation (A) and ether phospholipid 
synthesis enzymes (B and C) as shown by qRT-PCR and Western blot. Protein levels relative to 
GAPDH were quantified by densitometry with ImageJ. The C22 cells were treated with either DMSO or 
RZG for 24h and then stimulated with either 8%CSE or DMSO for 4h prior to protein and RNA collection. 
P values were calculated by the one way ANOVA. n=3, * p≤0.05, ** p≤0.01, *** p≤0.001, **** p≤0.0001. 
Fig. 68. RZG activation induced the expression (A) and abundance of the Nrf2 (B) and Nrf2 
regulated antioxidant enzymes (C and D) as shown by qRT-PCR and Western blot. Protein levels 
relative to GAPDH were quantified by densitometry with ImageJ. The C22 cells were treated with either 
DMSO or RZG for 24h and then stimulated with either 8%CSE or DMSO for 4h prior to protein and RNA 
collection. P values were calculated by the one way ANOVA. n=3, * p≤0.05, ** p≤0.01, *** p≤0.001, **** 
p≤0.0001. 
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4.4.4.1. RZG treatment reduced the CSE induced pro-inflammatory and pro-
oxidant reaction in the cells 
Il-6 and Tnfα were significantly downregulated by RZG treatment in the CSE 
stimulated cells (Fig. 70A). Similarly, RZG reduced the abundance of pro-oxidant 
COX-2 in the cells that were stimulated with CSE (Fig. 70B).  
 
 
 
 
For the confirmation of the beneficial effects of RZG, ELISAs were performed on the 
supernatants of the 3 groups for the detection of proinflammatory cytokines. As shown 
by ELISA, pre-treatment of cells with RZG attenuated the secretion of proinflammatory 
cytokines into the media when CSE stimulation was applied (Fig. 71). 
 
 
 
 
 
Fig. 69. Increased ARE response element activity in 
RZG treated cells. Luciferase reporter activity of ARE 
promoter element in cells treated with either RZG or DMSO 
followed by CSE stimulation as measured by the luciferase 
assay; cell lysates were collected and assayed for 
luciferase activity. The activity of firefly luciferase was 
measured in cell lysates and normalized to the activity of 
renilla luciferase. P values were calculated by the one way 
ANOVA. n=3, * p≤0.05, ** p≤0.01, *** p≤0.001. 
Fig. 70. RZG treatment reduced the expression of pro-inflammatory mediators and prooxidant 
COX-2 at the mRNA (A) and protein (B) level after incubation with RZG for 24h, cells were stimulated 
with CSE and the RNA and protein was collected thereafter.  P values were calculated by the one way 
ANOVA. n=3, ** p≤0.01, *** p≤0.001. 
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4.4.4.2. RZG treatment attenuates the oxidative stress in the cells 
stimulated with cigarette smoke extract 
As was already shown above, CSE induced a drastic increase in oxidative stress as 
demonstrated by the elevation in DHE staining (Fig. 72B). In contrast, when RZG 
treatment was applied, this oxidative stress was reduced (Fig. 72D) to control level 
(Fig. 72A).  
 
To summarize, RZG was able to attenuate the release of CSE induced pro-
inflammatory and pro-oxidant mediators and it was as well capable to reduce the 
oxidative stress induced by CSE. We assume that the beneficial effect of RZG in 
protecting the cells against the CSE induced stress was due to its ability to upregulate 
the peroxisomal β-oxidation, ether phospholipid and antioxidative enzymes. In addition 
to this, peroxisome proliferator-activated receptor gamma upregulated Nrf2 and its 
antioxidative response element ARE which is a major defensive mechanism against 
oxidative stress. The upregulation of peroxisomal and antioxidative enzymes was 
much higher than the increase that was induced by the CSE treatment. This could 
suggest that this high upregulation was to protect the cells against inflammation and 
oxidative stress. In other words, CSE-induced upregulation of peroxisomes and 
antioxidative enzymes wasn’t enough to battle or counteract the stress because the 
pro-oxidative effect was much stronger. However, the RZG induction of peroxisomes 
and antioxidants to the level that was higher than that caused by CSE was able to 
counteract the drastic CSE effects. To sum up, RZG by its upregulation of 
peroxisomes and other antioxidants induced the protective response. 
Fig. 71. RZG attenuated the release of pro-inflammatory cytokines (IL-6 and TNF-α) in the 
medium of CSE treated cells as shown by ELISA assays. C22 cells were incubated with RZG for 
24h prior to a 4hr treatment with DMSO or 8%CSE, the supernatants were collected thereafter.  
The released mediators were measured by ELISA. P values were calculated by the one way 
ANOVA. n=3, ** p≤0.01, *** p≤0.001. 
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4.4.5. PPARγ overexpression blocks the CSE-induced oxidative stress 
response 
We were wondering whether the overexpression of PPARγ would lead to comparable 
results as was observed with the PPARγ agonist RZG. For this purpose, we used the 
PCMV Sport PPARγ plasmid in order to overexpress PPARγ in C22 cells; PCMV-
Sport6-GFP3b was used as a control vector. C22 cells were transfected either with the 
PPARγ overexpression plasmid or with the control plasmid for 68h prior to CSE or 
DMSO treatment. The first step was to examine mRNA expression levels of PPARγ. 
The qRT-PCR results showed a tremendous several hundred fold increase in Pparγ 
transcription factor mRNA expression (Fig. 73A). Western blot analysis as well 
revealed a much higher abundance of the PPARγ protein following the plasmid 
transfection in comparison to the control group (Fig. 73B). 
 
 
 
 
 
The second step was to check the effect of PPARγ overexpression on the peroxisomal 
genes. The cells transfected with pPPARγ (control) showed a higher expression of 
Fig. 72. Measurements of ROS by dihydroethidium stain following RZG treatment. The cells 
were incubated with either RZG (C&D) or DMSO (A&B) for 24h.  Following the incubation, the cells 
were treated with DMSO (A&C) or CSE (B&D) and then stained with DHE for 30 min. The bars 
represent 10μm. 
 
Fig. 73. PPARγ overexpression promotes PPARγ activation. The cells were either transfected with 
pPPARγ (PCMV Sport PPARγ) or with the pControl (PCMV-GFP3b) for 68h. Thereafter, DMSO or 
CSE stimulation was applied for 4h and the RNA and protein was collected afterwards and the results 
were analysed by qRT-PCR and Western blotting. P values were calculated by the one way ANOVA. 
n=3, *** p≤0.001, **** p≤0.0001. 
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Pex13 mRNA than the cells transfected with the control plasmid (pControl) and then 
treated with CSE suggesting that possibly peroxisomes are highly proliferating in the 
pPPARγ overexpressing cells. The PEX13 protein was only slightly higher in the 
PPARγ overexpression group in comparison to the control group. To our surprise, we 
observed that the additional CSE-treatment of the PPARγ overexpressing group led to 
a down-regulation of the peroxisomal biogenesis gene Pex13 (Fig. 74A) and its 
corresponding protein (Fig. 74B) in comparison to the cells transfected with pPPARγ 
and pControl.  
 
 
 
 
 
The down-regulation of the PEX13 protein could secondarily affect the peroxisomal 
matrix protein import (as was observed above under PEX13 knock-down conditions). 
Our hypothesis was confirmed by real time PCR and Western blot analyses where the 
expression and protein abundance of the peroxisomal antioxidative enzyme catalase 
(Fig. 75A) as well as the expression of peroxisomal β-oxidation (Fig. 75B) and ether 
phospholipid synthesis enzymes (Fig. 75C) was significantly down-regulated in 
pPPARγ overexpressing and then CSE treated cells in comparison to DMSO treated 
cells transfected with either pPPARγ or pControl plasmids.  
 
 
 
 
Fig. 74. PPARγ overexpression induces down-regulation of the peroxisomal membrane 
protein PEX13 in the cells treated with CSE. The cells were either transfected with pPPARγ 
(PCMV Sport PPARγ) or with the pControl (PCMV-GFP3b) for 68h. Thereafter, DMSO or CSE 
stimulation was applied for 4h and the RNA and protein was collected afterwards and the results 
were analysed by qRT-PCR (A) and Western blot (B). Protein levels relative to GAPDH were 
quantified by densitometry with ImageJ. P values were calculated by the one way ANOVA. n=3, * 
p≤0.05, ** p≤0.01, *** p≤0.001. 
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Moreover, we analysed Nrf2, some Nrf2-regulated genes and pro-inflammatory 
cytokines. Interestingly, overexpression of PPARγ followed by CSE treatment as 
shown by qRT-PCR and Western blot analyses downregulated Nrf2 at the mRNA and 
protein level (Fig. 76A) as well as the expression (Fig. 76B) and abundance (Fig. 
76C) of its regulated enzymes in comparison to the control samples. This implies that 
indeed there is no oxidative stress even in the cells that were treated with CSE after 
the PPARγ has been overexpressed. If the results obtained with the Pparγ knock-
down followed by CSE-treatment (Fig. 57-61) are compared to the ones with PPARγ 
overexpression and CSE-treatment (Fig. 73-75), a completely opposite pattern would 
be observed. Whereas Pparγ knock-down induced a significant upregulation of the 
peroxisomal compartment, Nrf2 and its regulated genes accompanied by an oxidative 
stress response and ROS production, overexpression of PPARγ down-regulated these 
genes, proteins and the oxidative stress.  
 
Fig. 75. PPARγ overexpression induces the down-regulation of peroxisomal antioxidative (A), 
β-oxidation (B) and ether phospholipid synthesis enzymes (C) in the cells treated with CSE. 
The cells were either transfected with pPPARγ (PCMV Sport PPARγ) or with the pControl (PCMV-
GFP3b) for 68h. Thereafter, DMSO or CSE stimulation was applied for 4h and the RNA and protein 
was collected afterwards and the results were analysed by qRT-PCR and Western blotting. Protein 
levels relative to GAPDH were quantified by densitometry with ImageJ. P values were calculated by 
the one way ANOVA. n=3, *p≤0.05, ** p≤0.01, *** p≤0.001. 
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Moreover, qRT-PCR (Fig. 77A) and ELISA (Fig. 77B) results revealed that PPARγ 
overexpression attenuated the expression and release of pro-inflammatory cytokines 
in the CSE treated cells. These results again are a confirmation that there is no 
oxidative stress and inflammation in cells with overexpressed PPARγ even after the 
treatment with cigarette smoke extract. To summarize, no antioxidative stress 
response was observed in PPARγ overexpression groups and no stimulation of the 
proinflammatory cytokine release was detected. The PPARγ rather repressed the 
antioxidative enzyme genes to lower levels in CSE-treatment conditions 
(corresponding to control levels without CSE-treatment). 
 
 
 
Fig. 76. PPARγ overexpression provoked a decrease of Nrf2 (A) and of its regulated 
antioxidant enzymes (B&C) in the cells treated with CSE. The cells were either transfected with 
pPPARγ (PCMV Sport PPARγ) or with the pControl (PCMV-GFP3b) for 68h. Thereafter, DMSO or 
CSE stimulation was applied for 4h and the RNA and protein was collected afterwards and the 
results were analysed by qRT-PCR and Western blot analyses. Protein levels relative to GAPDH 
were quantified by densitometry with ImageJ. P values were calculated by the one way ANOVA. 
n=3, * p≤0.05, ** p≤0.01, *** p≤0.001. 
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PPARγ overexpression not only up-regulated peroxisomal genes when no CSE was 
applied, but also induced cells proliferation as was shown by the BrdU assay (Fig. 78). 
 
PPARγ overexpression upon transfection into the cells exerts a preventive effect 
against the harmful CSE-induced proinflammatory cytokine release in the C22 cells 
under basal conditions, that’s probably why the cells were not experiencing oxidative 
stress upon CSE treatment. On the contrary, RZG exerts a protective rather than 
preventive way of action. In another words, RZG protects the cells from oxidative 
stress by increasing antioxidative defence enzymes when the CSE stimulation is 
applied whereas specific PPARγ overexpression could have a preventive effect by 
inhibition or prevention of transcription activation of pro-inflammatory mediators.  
 
 
Fig. 77. PPARγ expression attenuated the mRNA expression (A) and the release (B) of pro-
inflammatory cytokines in the media of CSE treated cells as shown by qRT-PCR and ELISA 
assay. The cells were either transfected with pPPARγ (PCMV Sport PPARγ) or with the pControl 
(PCMV-GFP3b) for 68h. Thereafter, DMSO or CSE stimulation was applied for 4h and the RNA 
supernatant was collected afterwards and the results were analysed by qRT-PCR and ELISA. P 
values were calculated by the one way ANOVA. n=3, *** p≤0.001, **** p≤0.0001.  
 
Fig. 78. Percentage of BrdU positive cells after 
pPPARγ overexpression. The cells were after either 
treated with DMSO or CSE.The extent of cell 
proliferation was measured by absorbance at 450nm. 
P values were calculated by the one way ANOVA. 
n=3, *p≤0.05, ** p≤0.01, *** p≤0.001, **** p≤0.0001. 
 
 
86 
 
5. Discussion 
The prevalence of chronic obstructive pulmonary disease (COPD) is increasing 
worldwide. However, despite the increased prevalence and mortality, there is currently 
no cure available for this disease. It is well known that the most commonly 
encountered risk factor for COPD is cigarette smoking which accounts for 80%-90% of 
COPD cases 21. Peroxisomes are organelles that are present in high numbers in 
secretory cells of bronchioli (club cells) as well as in type II cells of the alveolar region. 
Moreover, these organelles are located in the apical region in ciliated cells bordering 
lung airways. Therefore, peroxisomes could be easily affected in COPD by 
components of cigarette smoke.  However, until the beginning of the experimental 
work of this thesis, no information was available on these cell organelles in the lung of 
COPD patients. It has been demonstrated, in this thesis, that cigarette smoke induces 
strong alterations of the peroxisomal compartment leading to the organelle 
proliferation and its enzyme upregulation in airway epithelial cells of COPD patients as 
well as in a COPD mouse model. Moreover, in order to analyse the role of 
peroxisomes in COPD pathogenesis, siRNA silencing of the mouse peroxisomal 
biogenesis protein PEX13 was applied provoking stronger oxidative stress in CSE 
treated samples. In contrast, the treatment of in vitro model with a PPARγ agonist 
induced the whole peroxisomal compartment and in consequence reduced oxidative 
stress, ROS and inflammatory mediators in the CSE-treated samples.  Similarly, 
PPARγ overexpression attenuated oxidative stress and pro-inflammatory cytokines in 
the CSE treated samples. The results showed that both methods exert different 
mechanisms of action. 
 
The results of this thesis suggest that peroxisomes could be key players in 
amelioration and protection against COPD progression. The discussion will 
concentrate on peroxisome abundance and enzyme composition as well as gene 
regulation in control samples in comparison to human and mouse COPD samples and 
in vitro models. Moreover, the pathological alterations exerted on the in vitro COPD 
models induced by Pex13 and Pparγ gene knock-downs leading to peroxisome 
deficiency and all consequences thereafter will be discussed. Finally, the methods for 
peroxisomal activation in order to possibly reduce the disease progression and 
oxidative stress in COPD will be discussed.  
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5.1. The role of peroxisomes in scavenging ROS and attenuating oxidative 
stress and their possible effects in ameliorating the pathophysiology 
of COPD  
The exposure of lungs to high oxygen concentrations makes them very susceptible to 
injury mediated by oxidative stress 139. Non-enzymatic antioxidants, such as 
glutathione, vitamin C and β-carotene as well as ether lipids (plasmalogens) and 
polyunsaturated fatty acids (PUFA) in the plasma membranes of airway epithelial cells 
or in the surfactant film, covering the alveolar region, are the first line of defence 
against the oxidants 136. Interestingly, the important steps in the synthesis of the 
antioxidant lipids occur in peroxisomes. The second line of defence against the 
oxidants consists of antioxidative enzymes such as superoxide dismutases, catalase, 
glutathione peroxidases and peroxiredoxins. These antioxidative enyzmes are 
degrading various types of ROS and are localized in distinct intracellular sub-
compartments as well as in different pulmonary cell types 137. If the balance between 
the antioxidant defensive mechanism and ROS production is disturbed, pathological 
alterations are induced leading to lung injury. It is well known that oxidative stress is 
central in the pathogenesis of a variety of respiratory diseases like COPD 49, cystic 
fibrosis 198, asthma 199 and idiopathic pulmonary fibrosis 200. Moreover, ROS, which are 
released in the tunica mucosa, lead to oxidative stress in epithelial cells 199. It has 
been shown that the bronchiolar epithelium and AECII in the alveolar region of human 
and murine lungs are rich in peroxisomes 137. Therefore, peroxisomes might protect 
the pulmonary airway epithelium by their high content in different antioxidative 
enzymes, their role in the synthesis of PUFA and plasmalogens and their ability to 
degrade bioactive and toxic lipid derivatives through their β-oxidation systems 136. The 
results of this thesis demonstrate that knocking down of the peroxisomal biogenesis 
gene Pex13 generated a drastic increase in oxidative stress, ROS production and the 
release of inflammatory mediators in C22 cells. In this respect, peroxisomes could 
scavenge ROS induced by the CSE, attenuate oxidative stress and provide protection 
for the lung epithelium thereby possibly reducing the pathophysiology of COPD. 
5.2. The peroxisomal compartment and its corresponding genes are 
activated in COPD patients with high MUC5 expression 
As mentioned above, oxidative stress that arises from increased concentrations of 
reactive oxygen and nitrogen species (ROS/RNS) and from a reduction in their 
detoxification mechanism leads to the initiation and progression of chronic 
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inflammatory diseases such as COPD 23. Numerous studies indicate that peroxisomes 
can respond to oxidative stress and ROS in order to protect the cells against oxidative 
damage 201. Thus, in this thesis, it was first decided to analyse whether there would be 
any alterations in the peroxisomal compartment in COPD patients in comparison to the 
control samples. The selected lung tissue samples from patients were classified 
according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) as 
COPD stage IV 202. All samples were selected according to their morphological 
characteristics and MUC5 abundance. Only tissues with high MUC5 abundance and 
comparable inflammatory reactions were selected. Whole lung homogenates and total 
RNA was analysed for peroxisomal gene expression and abundance.  
 
Many of the peroxisomal genes are regulated by nuclear receptors of the PPAR family, 
the abundance and distribution of which are cell-type dependent. The activation of the 
peroxisome proliferator-activated receptor gamma (PPARγ), which is a ligand-
activated nuclear transcription factor expressed in the lungs, exhibits antioxidative and 
anti-inflammatory effects 45,168,169. Divers results are available from the literature 
concerning PPARγ expression in COPD. Some studies have shown that the activity 
and expression of PPARγ in the bronchial epithelial cells from COPD patients and 
from the CSE-exposed cell model was significantly down-regulated 203. Several other 
studies have shown that the level of PPARγ was reduced in the lungs of patients with 
moderate COPD stages, whereas it was up-regulated in patients with mild COPD 176. 
Another study has revealed that the alveolar macrophages from COPD patients and 
smokers showed a high PPARγ expression in comparison to never-smokers 204,205. It 
was demonstrated, in human peripheral blood mononuclear cells, that PPARγ agonists 
inhibited the production of monocyte inflammatory cytokines such a IL-1β, IL-6 and 
tumour necrosis factor (TNF)-α 167 as well as suppressed COX-2 expression 206, 
reduced cigarette-smoke induced mucin production 170 and increased Nrf2 
transactivation 207-209. Our data revealed a strong upregulation in the expression and 
abundance of PPARγ in the samples of the patients with COPD in comparison to the 
non-COPD samples.  
 
An elevation of the peroxisomal compartment in conditions of stress in the  
mammalian 210,211, yeast 212 and plant systems 213 has been demonstrated in several 
studies suggesting that this may be a common cellular mechanism for dealing with 
various stresses. Hence, cellular oxidative stress and peroxisomal metabolism are 
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intimately linked. The observation that stress increases peroxisomal abundance and 
expression brings the important question up whether this upregulation provides a 
protective effect against oxidative stress.  
 
There is plenty of evidence that disturbance in peroxisomal redox balance puts the 
cells under oxidative stress 214. Moreover, mice deficient in peroxisomes exhibit 
neurodegeneration 215 and show a decline in their motor and cognitive abilities leading 
to an early death 216. In contrast, it was found that PPARγ agonists have the ability to 
increase catalase activity and expression in rat astrocytes 217. Moreover, the results of 
this thesis revealed a significant increase in the expression and abundance of the 
major peroxisomal antioxidative enzyme catalase (CAT) in the lung. In this respect it is 
of interest that the catalase gene is regulated via Nrf2. 
 
The results of this thesis demonstrated that Nrf2, a transcription factor which through 
its binding to the antioxidant response element (ARE) induces the expression of genes 
of antioxidative enzymes, is involved in the activation of the antioxidant response and 
in the protection against oxidative stress 218,219. In unstressed conditions, Nrf2 
transactivation is supressed by Keap1, whereas under oxidative stress conditions, 
Keap1 senses oxidative or electrophilic stress thus liberating Nrf2 which translocates 
into the nucleus and binds to ARE in order to induce the expression of cytoprotective 
genes 220,221. Upon binding to ARE, Nrf2 induces the downstream target genes, such 
as heme oxygenase-1 (Ho-1), superoxide dismutase 1 (Sod1), catalase (Cat) and 
peroxiredoxin 1 (Prxd1) coding for a network of enzymatic antioxidative proteins 
protecting the cells against the oxidative stress as was shown in various in vivo 
220,222,223 and in vitro 224-226 studies. Therefore, catalase which is considered to be a 
rather peroxisome-specific antioxidant enzyme is as well regulated by Nrf2 223. The 
results of this thesis demonstrated that COPD patients exhibit an increase in the gene 
expression and protein abundance of Nrf2 and its downstream target gene and protein 
catalase (CAT), suggesting the induction of the antioxidant response by high oxidative 
stress, as was demonstrated by the DHE-staining in this thesis. 
 
Interestingly, cells that are deficient in the biosynthesis of plasmalogens, are more 
sensitive to ROS damage in comparison to control cells 227. The antioxidative effect of 
plasmalogens has been discussed in various in vitro and in vivo studies 228-230. The 
peroxisomal matrix enzymes glycerone-phosphate O-acyltransferase (GNPAT) and 
alkylglycerone phosphate synthase (AGPS) are the most crucial enzymes for the 
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plasmalogen biosynthesis. The results of this thesis show that the expression and 
abundance of GNPAT and AGPS were as well up-regulated in the patients with 
COPD. 
 
COPD is not only characterized by high oxidative stress, but also by the inflammation 
that affects airways, pulmonary vessels and lung parenchyma. As shown in this thesis, 
this inflammation could be induced by the release of proinflammatory mediators like 
interleukin-8 (IL-8), IL-6 and tumor necrosis factor alpha (TNF-a) by the injured lung 
epithelial cells or from the activated inflammatory cells as shown in the literature 78,189. 
Several studies found that levels of IL-6 are increased in plasma, exhaled breath and 
sputum of COPD patients in comparison to controls 231-234. Similarly, TNF-α levels are 
increased in the induced sputum of patients with COPD and this cytokine was found 
as well to be implicated in cigarette smoke-induced emphysema in mouse models 235-
237. The expression of Il-6, Il-8 and Tnf-α, systemic inflammatory markers associated 
with COPD were analysed by qRT-PCR from the total RNA of COPD patients in 
comparison to the non-COPD lungs. Indeed the results of this thesis showed a 
significant increase in the expression levels of Il-8 and Tnfα mRNA from the COPD 
lungs in comparison to the control samples as well as from CSE treated lung epithelial 
cells. It was suggested that these increased levels of cytokines provide an evidence of 
ongoing inflammatory processes in COPD 191.  
 
Despite the increase of peroxisomes, as shown in the results of this thesis, oxidative 
stress and inflammatory cytokines were still highly elevated in the COPD patients 
suggesting that the net flux of ROS/RNS production exceeded the capacity of 
antioxidative enzymes of these organelles to eliminate harmful oxidants. Therefore, 
the increase of peroxisomes in COPD patients is not sufficient at this point to detoxify 
all potentially injurious oxidants.  
5.3. A similar pattern of peroxisomal induction was detected in a mouse 
COPD model 
Further, we wanted to check whether the pattern of peroxisomal expression in a 
COPD mouse model will be in accordance to the results obtained in the human 
samples. Therefore, paraffin-blocks from WT mice (obtained from Prof. Weissmanns’s 
group, JLU Giessen) exposed to cigarette smoke for up to 3 months were analysed 
178. The samples from COPD mice indeed showed a similar increase in peroxisomal 
biogenesis proteins, antioxidative, β-oxidation, and ether phospholipid synthesis 
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enzymes. Therefore, despite the differences in lung maturation, development and 
anatomy among the species, the pattern of peroxisomal expression and abundance is 
similar in both models suggesting that this upregulation could be a characteristic 
feature of peroxisomes in COPD and that peroxisomes could play an important role in 
protecting the lung against harmful CS effects. 
5.4. Generation of an in vitro cigarette smoke-extract COPD model 
In addition to analysis of the tissue samples, the goal was to establish an in vitro 
model and to determine the effects of cigarette smoke extract (CSE) on peroxisomal 
alterations in cultured cells.  CSE cell culture models could provide vital information on 
the molecular mechanisms taking part in the functional progression of the disease. 
Therefore, to get insights into the pathogenic mechanisms of the disease and to 
maintain as many physiological parameters in vitro as possible, we selected primary 
human bronchial epithelial cells (HBE). In order to determine a proper cigarette smoke 
extract (CSE) concentration, several concentrations were tested and the highest 
concentration which showed no toxicity for cell viability was used for the experimental 
treatment.  The next step was to analyse the peroxisomal expression and abundance 
in order to find out whether this established in vitro model mimics the characteristics of 
the in vivo models. The increase in peroxisomal enzymes with the CSE treatment was 
a confirmation that the generation of the in vitro COPD model was successfully 
established and that it reflects the in situ situation in the lung of patients or in the 
COPD mouse model. 
 
For better understanding of the role of peroxisomes in the pathogenesis of COPD, the 
first step was to disrupt the peroxisomal biogenesis by knocking down PEX13 which is 
a peroxisomal membrane protein that acts as a docking factor for the import of 
peroxisomal matrix proteins 190,195,238. However, to our big disappointment, primary 
HBE cells didn’t survive the siRNA transfection even when the smallest possible 
siRNA concentration was used. Therefore, for the further transfection experiments, the 
C22 mouse bronchial club cell-line was chosen. C22 cells are transformed murine club 
cells which secrete cell-type-specific proteins and possess morphological 
characteristics similar to club cells 239,240. Moreover, our group showed that 
peroxisomes are abundant in C22 cells and that their corresponding gene expression 
and enzyme abundance are comparable to the one found in club cells in the mouse 
lung 241.  
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The CSE-model had to be adjusted for the second time, for C22 cells, in order to 
establish a good COPD model for the analysis of marker genes following the CSE 
treatment. The knock-down of Pex13 in these cells was successful this time. The 
Pex13 gene deletion was verified by a variety of methods in this thesis, such as qRT-
PCR whereas PEX13 protein deletion was confirmed by IF staining and Western blot 
analysis. Real-time PCR analysis showed a strong down-regulation in the Pex13 gene 
expression in the samples transfected with Pex13 siRNA in comparison to the scr-
siRNA samples. In addition to this, Western blot analysis showed a 90% decrease in 
the PEX13 protein abundance in the knock-down samples in comparison to the 
samples transfected with scr-siRNA. Similarly, immunofluorescence staining revealed 
a strong 90% downregulation of the PEX13 protein in the Pex13 knock-down samples. 
In addition to this, the peroxisomal deficiency in the Pex13 knock-down samples was 
confirmed, in immunofluorescence preparations, by the mistargeting of CAT into the 
cytoplasm due to a defect in the import machinery of CAT into peroxisomes upon 
Pex13 deletion 242,243. The cytoplasmic localization of peroxisomal matrix enzymes is a 
well-known phenomenon in cells with peroxisome deficiency 193. 
 
Pex13 gene deletion leads to peroxisomal deficiency. The results of this thesis showed 
that the expression of genes encoding peroxisomal matrix enzymes (Cat, Agps, Acox1 
and Acaa1) and the abundance of the corresponding proteins (CAT and AGPS) were 
significantly down-regulated in Pex13 siRNA transfected samples in comparison to the 
scr-siRNA transfected samples. Since PEX13 is involved in the import of peroxisomal 
matrix proteins with both PTS1 and PTS2 targeting signals, its deletion leads to a 
complete disruption of the peroxisomal matrix protein import leading to the complete 
loss of metabolic functions of these organelles 244. Due to the mistargeting into the 
cytoplasm, most peroxisomal matrix proteins are degraded (most probably via the 
proteasome). However, it is not clear, how the down-regulation of mRNAs for 
peroxisomal proteins occurs. This has to be proven experimentally in future studies. 
Possibly, peroxisomal genes are co-ordinately down-regulated under conditions of 
peroxisomal deficiency in club cells via miRNAs or other molecular mechanisms. 
Moreover, the C22 cells with compromised peroxisomal biogenesis were more 
sensitive to the CSE treatment as was shown by BrdU assay.  
 
Furthermore, silencing of Pex13 followed by CSE treatment drastically increased ROS 
as was visible in fluorescence pictures of DHE-stained cells suggesting that the 
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increase was exerted by the Pex13 knockdown. It is known that an antioxidative 
response is mediated via redox-sensitive transcription factors (e.g. Nrf2 or NfκB), 
which mediate the upregulation of transcription of protective genes, like Pparγ, Ho-1 
and Sod1. We found that Pex13 deletion led to the upregulation of both transcription 
factors PPARγ and Nrf2 as well as it induced the transcription of Nrf2-regulated genes 
and its corresponding proteins HO-1 and SOD1 245,246. This mechanism was especially 
prominent in Pex13 deleted and then CSE treated samples. Moreover, as was shown 
by ARE/luciferase assay, the ARE-driven reporter gene was highly activated when 
CSE stimulation was applied after Pex13 knockdown revealing a strong oxidative 
stress in the knock-down samples, suggesting that peroxisomes are necessary to 
guarantee the cells’ redox homeostasis. 
 
In addition to this, cigarette smoke triggered the release of cytokines, such as TNF-α 
and IL-6 from C22 cells with Pex13 knock-down. Our results demonstrated that Pex13 
knock-down indeed led to a drastic increase in pro-inflammatory cytokines as detected 
by qRT-PCR, Western blot and ELISA. Interestingly, this elevation was 2-3 folds 
higher in the Pex13 siRNA transfected cells treated with CSE in comparison to scr-
siRNA, scr-siRNA transfected cells treated with CSE and only Pex13 siRNA 
transfected cells. Therefore, deletion of Pex13 together with CSE stimulation triggers 
much stronger release of pro-inflammatory mediators like IL-6, TNF-α and COX-2 in 
comparison to scr-siRNA transfected and thereafter CSE treated cells suggesting that 
this upregulation is due to the Pex13 deletion. These cytokines and pro-inflammatory 
mediators might be possibly activated via the Nf-κB pathway due to the oxidative 
stress in C22 cells. It is known that smoke derived oxidants can activate various 
intracellular signalling mechanisms, including the Nf-κB pathway. Nf-κB activation 
leads to its translocation into the nucleus subsequently inducing the production of 
chemokines, cytokines and adhesion molecules 247,248. It was shown that neutrophils of 
COPD patients exhibit increasing Nf-κB signalling after cigarette smoke exposure 249. 
Another study has shown that CSE exposure promotes the recruitment of RelB on pro-
inflammatory gene promoters in the lungs of a COPD mouse model 250. Moreover, it 
has been shown in the literature that the release of IL-6, IL-8 and TNF-α into the 
supernatant from CSE treated type II pneumocytes is mediated via the Nf-κB 
activation 251. The exact mechanism behind the interleukin as well as COX-2 
upregulation in this thesis has to be, however, proven by future experiments. 
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Taken together the results of this thesis suggest that down-regulation of peroxisome 
expression and abundance, as was shown with Pex13 knock-down, exhibits an 
adverse effect on inflammation, wherefore in the pathophysiology of COPD 
peroxisomes could play an important role to protect the pulmonary cells against 
oxidative stress and the release of pro-inflammatory mediators. 
5.6. Peroxisome proliferation can be activated by PPARγ agonists reducing 
inflammation, oxidative stress and ROS release 
In order to show that PEX13 as well as peroxisomal enzymes are regulated by PPARγ 
and that the stimulation of PPARγ receptor by its agonist would trigger the activation of 
peroxisomal biogenesis and metabolism, silencing of Pparγ was performed. Pparγ 
silencing revealed that Pex13 is significantly down-regulated in these cells and that our 
results on oxidative stress, inflammation and ROS, after Pparγ deletion, are in 
accordance with the results we observed following a Pex13 knock-down. The next 
step was to possibly activate the peroxisomal compartment with the PPARγ agonist 
Rosiglitazone (RZG) in order to see whether peroxisomes would counteract the 
oxidative stress and whether this upregulation of peroxisomes would reduce the 
release of inflammatory cytokines.  
 
PPARγ is a member of nuclear hormone receptor family that modifies gene expression 
upon ligand binding. It has been found that PPARγ ligands play an important role in 
the regulation of inflammatory processes and PPARγ agonists might become 
promising anti-inflammatory drugs 252-254. It was shown that PPARγ ligands inhibit the 
M1 and M2 macrophage-activated pro- and anti- inflammatory gene transcription 
respectively 255,256. In addition to this, the PPARγ ligands reduce the inflammatory 
response and regulate macrophage efferocytosis in the lungs of COPD patients 257. 
Moreover, they were found to inhibit cigarette smoke-induced pulmonary neutrophilia 
205,258 and reduce arthritis, colitis, and atherosclerosis in animal models 259-261.  
 
Our results demonstrate that the cells incubated with RZG 24h prior to cigarette smoke 
extract indeed exhibited peroxisomal proliferation and upregulation of (peroxisomal 
proteins in comparison to control cells, cells treated with CSE and cells incubated with 
RZG without CSE treatment. RZG-only treated samples did not show any peroxisomal 
change and were similar to the control samples. Therefore, the peroxisomal 
upregulation was only seen in the samples stimulated with CSE after RZG incubation. 
Moreover, the samples treated with RZG and incubated with CSE showed decreased 
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ROS production, an attenuated cytokine release (IL-6, TNF-α) and an attenuated 
COX-2 increase, suggesting a reduced inflammatory response in the RZG samples 
with high peroxisomal gene expression and peroxisome proliferation. In these 
samples, the activation of Nrf2 based on the ARE luciferase analysis, Western blots 
and qRT-PCRs was demonstrated. Moreover, Nrf2-regulated genes and proteins were 
increased as was shown on the mRNA and protein levels, suggesting that Nrf2 is 
mediating, at least in part, the activation of the antioxidant response. These data 
suggest that PPARγ activation could provide a potential treatment for inflammatory 
airway diseases such as COPD and that this anti-inflammatory and ROS reducing 
action could be mediated through the activation of peroxisomes.  
 
 As was shown above, treatment with CSE activated the Nrf2 pathway but the 
oxidative stress was still present because the peroxisomes weren’t as highly 
upregulated as they were after RZG treatment. However, RZG treatment activated 
peroxisomes and together with up-regulated Nrf2-controlled antioxidant genes 
balanced the antioxidant/oxidant redox homeostasis in the CSE treated samples as 
was confirmed by the DHE staining. This is a confirmation that for the homeostasis of 
the antioxidant/oxidant balance, peroxisomes are indispensable. Yet, since PPARγ 
agonists are implicated in the activation of several other pathways, as was mentioned 
in this discussion, under RZG treatment we can’t exclude that the anti-inflammatory 
and antioxidative effects that we observed in our study were exclusively mediated by 
peroxisomes, but we can say for sure that up-regulated peroxisomes contributed 
strongly to the protective effect. Which other PPARγ dependent pathways contribute to 
the protection against CSE-induced oxidative stress has to be experimentally proven 
in the future. 
 
To exclude non-specific activation by RZG, PPARγ was overexpressed in order to 
check whether this overexpression would corroborate the results obtained by RZG 
treatment. For this purpose, cells were transfected with PPARγ expression plasmid 
(PPARγ-pCMV-Sport6) for 68h and then treated with DMSO. Highly PPARγ 
overexpressing cells demonstrated an increase in peroxisomal gene expression in 
comparison to cells transfected with control plasmid. These results were indeed 
directly the opposite to the results observed with deleted Pparγ followed by DMSO 
treatment (siPparγ 0%CSE). Furthermore, these samples showed upregulation of Nrf2 
and its dependent genes in comparison to PPARγ overexpression and CSE-treated 
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samples, which was as well opposite to what we have seen in the samples treated 
with DMSO following the Pparγ deletion (DMSO only group) and samples treated with 
CSE following the Pparγ knock-down respectively. Moreover, no inflammation was 
observed in these samples as was shown by qRT-PCR and ELISA analysis since the 
cytokine levels did not exceed the concentration of the control samples.  
 
However, in comparison to PPARγ overexpressing cells treated with DMSO, cells with 
strong overexpression of PPARγ and additional CSE treatment, showed a significant 
reduction in peroxisomes, which was as well opposite to the results of Pparγ knock-
down experiments. Similarly, the peroxisome biogenesis protein PEX13 was down-
regulated in samples treated with CSE following PPARγ overexpression. Therefore, 
PTS1 and PTS2 containing peroxisomal antioxidative, β-oxidation and ether 
phospholipid synthesis enzymes were as well down-regulated in these cells. 
Interestingly, Nrf2 and its downstream genes and proteins HO-1 and SOD1 were also 
decreased which is a sign of to-the-control-levels balanced oxidative stress in these 
cells. Our results were confirmed by the decline in cytokine expression suggesting an 
attenuated inflammatory response in the CSE treated cells. The results of PPARγ 
overexpression were completely opposite to the results obtained by the Pparγ knock-
down. Indeed the PPARγ overexpression for 68h exerted a preventive effect by 
attenuating the harmful CSE effects since it upregulated peroxisomes already in the 
samples before the CSE treatment was applied, thus blocking the CSE-driven 
oxidative stress in its initial steps. Overexpression of PPARγ leads, in many cases, to 
ligand-mediated trans-repression of genes by its SUMOylation. This could explain the 
observed down-regulation of peroxisomes, cytokines and Nrf2-driven enzymes. 
Indeed, different effects have been also observed between RZG-pretreated samples 
and the PPARγ overexpression for the regulation of the Nf-κB pathway 262. Moreover, 
differences in overexpression times and high PPARγ protein levels in comparison to 
the RZG-treatment (24h) might also contribute to the distinct effect on the peroxisomal 
compartment. The exact mechanism leading to the different molecular regulation of 
peroxisomal gene transcription must be analysed in details in future experimental 
studies. 
 
The results of this thesis demonstrated that PPARγ activation either by RZG or by 
overexpression plasmid attenuates the release of cytokines and reduces oxidative 
stress and ROS. The mechanism by which PPARγ agonists exert their anti-
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inflammatory effects is poorly understood. Several studies showed that possible ways 
through which PPARγ ligands exert their actions could be by inhibition of TLR4 (toll 
like receptor 4) expression 263, by inhibition of the NF-κB pathway 164 by inhibition of 
ERK1/2 phosphorylation 264 by inhibition of ERK1/2/p38MAPK activation 265 or by 
upregulation of HDAC2 203. This thesis showed an upregulation and proliferation of 
peroxisomes under PPARγ stimulation. However, the exact molecular mechanism 
leading to the effects on the peroxisomal compartment has not yet been clarified. One 
study has shown that a functional cross-talk between NF-κB and Nrf2 exists 266, such 
that the Nrf2-regulated activation of the antioxidant machinery leads to the 
suppression of NF-κB 267. In addition to this, reactive oxygen species activate Nrf2 and 
PPARγ which are linked by a positive feedback loop 268. These interactions in 
connection to the peroxisomes have to be clarified in the further experiments. 
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Fig. 79 Cigarette smoke-extract (CSE) treatment. Cigarette smoke generates ROS which leads to 
the translocation of the oxidative stress-activated Nrf2 transcription factor into the nucleus where it 
binds to ARE and mediates HO-1, SOD1 and CAT activation. In addition to this, cigarette smoke 
leads to a slight induction of the endogenous PPARγ ligands (eg. oxidized lipids) which activate the 
genes responsible for peroxisome proliferation leading to the increased abundance of peroxisomes. 
Furthermore, cigarette smoke induces proinflammatory cytokine production most probably by the 
activation of the NF-κB pathway. Several studies have shown that there is a functional cross-talk 
between NF-κB and Nrf2 
266
, such that the Nrf2 regulated activation of the antioxidant machinery 
leads to the suppression of NF-κB 
267
. In addition to this, ROS and other reactive species activate 
PPAR𝜸 and Nrf2 which are linked by a positive feedback loop. Under control conditions with CSE 
treatment, the expression and abundance of peroxisomes and antioxidative enzymes were probably 
not high enough to counteract the oxidative damage induced by the cigarette smoke extract (as was 
shown by the DHE staining). *Not analysed in this thesis, but known from the literature. 
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Fig. 80 Rosiglitazone treatment. The proposed mechanism is based on the results of the thesis 
and suggests that ROS and the pro-inflammatory cytokines (Ils, Tnfα) which are generated by the 
CSE-induced activation of NF-κB are suppressed by Rosiglitazone. This involves 2 pathways, such 
that 1) Rosiglitazone induces the expression of PPARγ which sustains the expression of Nrf2 via a 
positive feedback loop thus leading to the increased transcription of Nrf2 regulated antioxidative 
enzymes; 2) the strong up-regulation of Nrf2 or PPARγ possibly decrease the activation of NF-κB, 
suppressing the interleukin release. In addition to this, highly expressed PPARγ activates genes 
responsible for peroxisome induction leading to the increased number of peroxisomes as well as an 
increase in their metabolic functions. Peroxisomes, which are rich in antioxidative and β-oxidation 
enzymes and synthesize ROS trapping plasmalogens, reduce the amount of ROS and degrade 
oxidized lipids. The strong expression and abundance of peroxisomes and antioxidative enzymes 
was sufficient to counteract the oxidative damage induced by the cigarette smoke extract as was 
shown in this thesis by the DHE staining. Thus, we hypothesize that Rosiglitazone and peroxisomes 
play a protective role in attenuating the COPD pathophysiology.*Not analysed in this thesis, but 
known from the literature. 
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Fig. 81 Cells with overexpressed PPARγ either stimulated with DMSO (left) or CSE (right). The 
proposed mechanism is based on the results of the thesis and suggests that PPARγ overexpression 
leads to upregulation of peroxisomes and Nrf2-regulated genes thus bringing the level of 
proinflammatory cytokines to the control level as was observed in the absence of CSE treatment. This 
upregulation suggests that with PPARγ overexpression, cells are very rich in the antioxidative enzymes 
thus they are capable of preventing the accumulation of oxidative products even after the CSE-
treatment. Future experiments are necessary to clarify the difference. Under PPARγ overexpression 
followed by CSE-treatment, peroxisomal genes as well as other antioxidant enzymes are 
downregulated. Moreover, Nrf2 is also decreased, suggesting that high PPARγ overexpression reduces 
the activation of the antioxidant and proinflammatory response. *Not analysed in this thesis, but known 
from the literature. 
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6. Summary 
Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality and 
morbidity globally, and its development is mainly associated with tobacco-induced 
oxidative stress. In the lung, pulmonary epithelia are the first targets of cigarette 
smoke components overwhelming the antioxidative capacity of the epithelial cells and 
contributing strongly to COPD pathogenesis.  
 
Peroxisomes are single membrane-bound organelles that possess heterogeneous 
functions and enzyme composition depending on the organ and cell type. Until the 
beginning of experimental work of this thesis, no information was available so far on 
the role of peroxisomes in the molecular pathogenesis of COPD. The fact that 
peroxisomes are abundant in the airway epithelia and that they could be directly 
affected by CS, as they are located underneath the apical surface of the epithelial 
cells, made us hypothesize that they could alter the molecular-pathogenesis of COPD.  
Peroxisomes could protect the pulmonary airway epithelium against ROS and 
lipotoxicity since they are rich in different antioxidative enzymes, they synthesize 
plasmalogens (ROS trapping lipids) and play an important role in β-oxidation of 
eicosanoids. 
 
Therefore, the main goal of the thesis was to analyze the possible alterations of the 
peroxisomal compartment in lung samples of COPD patients and a mouse COPD 
model in comparison to control samples, and to study the functional consequences of 
cigarette smoke extract-treatment on the peroxisomal compartment in human HBE 
cells and mouse C22 cells in culture. Studying the peroxisomal alterations would 
clarify whether the impairment in peroxisomal metabolism could affect the molecular 
pathogenesis of COPD. Moreover, changes in the peroxisomal compartment, 
antioxidative enzymes and cytokines following Pex13 deletion, RZG treatment, PPARγ 
overexpression or knockdown in cigarette smoke-treated cells could be detected. 
 
To get a complete overview of the peroxisomal compartment and its alteration in the 
pathogenesis of COPD, several techniques were used, such as: immunofluorescence 
with a variety of antibodies against peroxisomal and cell marker proteins, cell and lung 
tissue homogenization, Western blot analysis, total RNA isolation, qRT-PCR, 
molecular cloning, transfections, luciferase assays and ELISAs 
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The results of this thesis indicate that a peroxisomal gene expression (Cat, Pex13, 
Pex14, Acox1, Acaa1, Agps, Gnpat) and corresponding protein upregulation occurs in 
human and mouse COPD samples. Moreover, the knock-down of the peroxisomal 
biogenesis gene Pex13 provoked strong oxidative stress and a release of pro-
inflammatory mediators suggesting a protective role of peroxisomes in preventing the 
chronification of inflammation in the disease pathogenesis. Furthermore, treatment 
with the PPARγ agonist Rosiglitazone and PPARγ overexpression were able to 
reverse the effects produced by cigarette smoke extract in C22 cells by inducing 
peroxisome proliferation by PPARγ activation. These results revealed the important 
role of PPARγ and the PPARγ regulated peroxisomal response for the protection 
against chronification and aggravation of the inflammation in COPD. 
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7. Zusammenfassung 
Die Chronisch Obstruktive Lungenkrankheit (Chronic Obstructive Pulmonary 
Disease/COPD) ist eine führende Ursache für Mortalität und Morbidität weltweit, und 
deren Entwicklung ist hauptsächlich mit Tabakrauchen-induziertem oxidativen Stress 
verbunden. In der Lunge stellen pulmonale Epithelien die ersten Schȁdigungsziele von 
Zigarettenrauchbestandteilen dar, die die antioxidative Kapȁzitat der Epithelzellen 
überwȁltigen und stark zur COPD-Pathogenese beitragen. 
 
Peroxisomen sind von einer Einheitsmembran begrenzte Organellen, die je nach 
Organ und Zelltyp unterschiedliche Funktionen und Enzymzusammensetzung 
besitzen. Bis zum Beginn der experimentellen Studien dieser Doktorarbeit lagen 
jedoch keine Informationen über die Rolle der Peroxisomen in der molekularen 
Pathogenese von COPD vor. Die Tatsache, dass die Peroxisomen im apikalen 
Bereich der Atemwegsepithelien reichlich vorhanden sind und dadurch direkt durch 
Zigarettenrauch beeinflusst werden könnten, lässt vermuten, dass sie eine Rolle in der 
molekularen Pathogenese der COPD spielen könnten. Da Peroxisomen außerdem 
reich an verschiedenen antioxidativen Enzymen sind und eine wichtige Rolle in der 
Plasmalogensynthese (ROS-bindende Lipide) sowie bei der β-Oxidation von 
Eicosanoiden spielen, könnten sie die pulmonalen Atemwegsepithelien gegen ROS 
und Lipotoxizität schützen. 
 
Das Hauptziel dieser Doktorarbeit war es, die möglichen Veränderungen des 
peroxisomalen Kompartiments in Lungenproben von COPD-Patienten und einem 
Maus-COPD-Modell im Vergleich zu Kontrollproben zu analysieren und die 
funktionellen Konsequenzen von Zigarettenrauchextrakt auf das peroxisomale 
Kompartiment in humanem HBE-Zellen und Maus-C22-Zellen zu untersuchen. Das 
Studium der peroxisomalen Veränderungen würde zur Klärung beitragen, ob die 
Beeinträchtigung des peroxisomalen Metabolismus die molekulare Pathogenese der 
COPD beeinflussen könnte und um Veränderungen im peroxisomalen Kompartiment, 
antioxidativen Enzymen und Zytokinen entweder nach Pex13-Deletion, Rosiglitazon-
Behandlung, PPARγ-Überexpression oder entsprechendem PPARγ-Knockdown von 
Zigarettenrauch-behandelten Zellen zu erkennen. 
 
 
 
104 
 
Um einen vollständigen Überblick über das peroxisomale Kompartiment und seine 
Veränderungen in der Pathogenese der COPD zu erhalten, wurden verschiedene 
Techniken verwendet: Immunfluoreszenz mit einer Vielzahl von Antikörpern gegen 
peroxisomale und Zellmarkerproteine, Zell- und Lungengewebe-Homogenisierung, 
Western-Blot-Analyse, RNA-Isolierung, qRT-PCR, molekularbiologische Klonierungs-
und Transfektionsverfahren, Luziferase-Assays und ELISAs. 
 
Die Ergebnisse dieser Doktorarbeit zeigen, dass eine peroxisomale Gen- (Cat, Pex13, 
Pex14, Acox1, Acaa1, Agps, Gnpat) und entsprechende Protein-Hochregulierung  in 
menschlichen und Maus-COPD-Proben vorhanden ist. Darüber hinaus führt ein 
Knockdown des peroxisomalen Biogenese-Gens Pex13 zu starkem oxidativen Stress 
und der erhöhten Freisetzung von Entzündungsmediatoren, die auch bei  COPD-
Patienten vorliegen. Deshalb lässt sich bei der Pathogenese dieser Erkrankung auf 
eine schützende Rolle der Peroxisomen schließen. Darüber hinaus konnten die 
Behandlung mit dem PPARγ-Agonisten Rosiglitazon und die PPARγ-Überexpression 
die Effekte, die durch Zigarettenrauchextrakt in C22-Zellen hervorgerufen wurden, 
umkehren, was die wichtige Rolle von PPARγ und der über PPARs-regulierten 
Peroxisomen bei der Protektion gegen die Chronifizierung und Verschlechterung der 
Entzündung bei COPD bestätigte. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
105 
 
8. Appendix 
X. PPARγ Cloning 
X.1 Materials and methods 
X.1.1 PCR reaction   
In order to amplify the insert of interest and to clone it into pGEM-T Easy, a PCR 
reaction was used. The primers (Table 1) for this PCR reaction were designed in order 
to amplify the entire open reading frame. The restriction sites SrfI (forward primer) and 
XhoI (reverse primer) (underlined in Table 1) were inserted in the primer sequence 
and will be subsequently used to clone the fragment into the final vector PCMV-Tag. 
Table 1. Primers used for the amplification of PPARγ 
Oligoname Forward Reverse 
FVmmPPARγ 
3b 
ATAgcccgggcATGGGTGAAACTCTGG TATctcgagCTAATACAAGTCCTTGTAGATCTC 
FVmmPPARγ 
5b 
ATAgcccgggcATGGGTGAAACTCTGG TATctcgagATACAAGTCCTTGTAGATCTCCTG 
 
Table 2. Vector used for the amplification of the PCR-product 
Gene Description I.M.A.G.E. Fully Sequenced cDNA Clone 
Peroxisome proliferator activated receptor gamma IRAVp968E0327D 
For the PCR reaction, two PCR master mixes were prepared using 2 different reverse 
primers as indicated in Table 3. The reactions were mixed and centrifuged before 
being put in the PCR machine. The steps of the program for the PCR are described in 
Table 4.  
Table 3. Components of the PCR reaction  
 
Final concentration Standard reaction 
10X PCR buffer 1X 5µl 
DNA (PCMV sport PPARγ) 10ng or 20 ng it is 100ng 1µl 
Primer (forward – FVmm PPARγ 35b) 2pmol 2µl 
Primer (reverse – RVmm PPARγ 5b or  
                             RVmm PPARγ 3b) 
2pmol 2µl 
dNTP 0.4mM 0.4µl 
Taq polymerase 5u 0.5µl 
Water - Till 50µl 
Total - 50ul 
Table 4. The PCR program 
Step Temperature Time 
Denaturing 95°C 5min 
Denaturing 95°C 30sec 
Annealing 55°C 30sec 
Extension 72°C 1min 
Final extension 72°C 7min 
Final hold 4°C Hold 
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After completion of the program, the PCR reaction was analysed by agarose-gel 
electrophoresis to assess that only one PCR product of the correct size was 
synthesised.  
 
X.1.2 DNA Gel electrophoresis  
X.1.2.1 Preparation of an agarose gel  
For a 1% agarose gel, 0.4g of agarose (SERVA) were dissolved in 40ml 1XTAE buffer 
(1X Tris-Acetate-EDTA). Thereafter, the agarose was melted in the microwave and left 
to cool down (hand-cold). Then, 1.5µl of stain G was added and the agarose was 
poured into a gel tray.  
 
X.1.2.2 Preparation and loading of the DNA samples and gel running  
For a small gel, 4µl of 6X DNA loading dye were added to the DNA sample and mixed 
by pipetting. The gel tray was transferred into a gel running tank and covered with 
1XTAE buffer. Then, the ladder and the samples were loaded and the gel 
electrophoresis (Sub Cell GT, BioRad) was run at 100V for 30min. Finally, the gel was 
examined under UV light (Gel-Doc 2000 gel documentation system). 
 
X.1.3 DNA extraction from the gel  
The DNA fragments were purified by DNA gel electrophoresis followed by DNA 
extraction from the gel. After the electrophoresis, the DNA fragments were excised 
under the UV-light using a scalpel. The excised DNA fragments were placed into 
Eppendorf tubes and weighed. To each 100mg of the agarose gel fragments, 200µl of 
NTI buffer from the gel purification kit were added according to the DNA extraction 
protocol (Macherey-Nagel). The reaction tubes were incubated at 50°C for 10min and 
the samples were vortexed every 3min until the gel was completely dissolved. For 
DNA binding, 700µl of the sample were placed on the NucleoSpin® Column, 
centrifuged twice for 30s at 10,000g and the flow through was discarded. To wash the 
silica membrane, 700µl of Buffer NT3 were added to the NucleoSpin® Gel and PCR 
Clean-up Column, the column was centrifuged at 11,000g for 30s and the flow through 
was discarded. Thereafter, the NucleoSpin® Column was centrifuged twice at 11,000g 
for 1min to remove the buffer NT3 and to dry the column. Finally, the DNA was 
incubated with 30µl of buffer NE for 1min and then eluted by centrifuging twice for 
1min at 11,000g. 
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X.1.3.1 PCR clean-up  
In this thesis the PCR clean-up kit from Macherey-Nagel was used to remove 
enzymes and salts from the restriction enzyme reactions. One volume of the sample 
was mixed with 2 volumes of Buffer NTI. For DNA binding, 700µl of the sample were 
placed on the NucleoSpin® Gel and PCR Clean-up Column, centrifuged twice for 30s 
at 10,000g and the flow-through was discarded. To wash the silica membrane, 700µl 
of Buffer NT3 were added to the NucleoSpin® Gel and PCR Clean-up Column, the 
column was centrifuged at 11,000g for 30s and the flow through was discarded. 
Thereafter, the NucleoSpin® Column was centrifuged twice at 11,000g for 1min to 
remove the buffer NT3 and to dry the column. Finally, the DNA was incubated with 
30µl of buffer NE for 1min and then eluted by centrifuging twice for 1min at 11,000g. 
X.1.4 Ligation reactions 
X.1.4.1 Ligation of the PCR product into pGEM-T Easy  
 
 
 
To facilitate the ligation into the final vector, the purified PCR product was first cloned 
into pGEM-T Easy plasmid vector. For the ligation, the reaction was set up as 
described in Table 5 and incubated at 16°C overnight. The ligation reaction was then 
used to transform competent E.coli DH5 and for positive clones screening. 
  Table 5. Components of the ligation reaction 
 
Standard reaction 
2X ligation buffer 5µl 
pGEM-T easy vector 1µl 
PCR product (gel extracted DNA) 2.5µl or 5µl 
T4 ligase 0.5µl 
Deionized water (LONZA) 1µl or 0µl 
Total volume  10µl or 11.5µl 
Fig. 1. Map of pGEM-T Easy vector. From www.promega.com  
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Fig. 2. The map of 3B and 5B inserts cloned into pGEM-T Easy vector.  The purified PCR 
product was first cloned into pGEM-T Easy. 
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X.1.4.2 Ligation of the PPAR fragment into pCMV-Tag3B and 5B 
The DNA fragments obtained from the restriction enzyme digest of pGEM-T Easy 
containing the PPAR PCR-product were ligated into both the pCMV-Tag 3B and the 
5B expression vectors. The reaction was set-up as described in Table 6 and incubated 
at 16°C overnight. 
Table 6. Components of the ligation reaction 
Components Reaction 1 Reaction 2 Reaction 3 
10X T4 DNA ligase buffer  2µl 2µl 2µl 
PCMV (3b or 5b) 1µl 1µl - 
Insert (3b or 5b) 5µl - 5µl 
T4 DNA ligase 1µl 1µl 1µl 
Deionized water 11µl  16µl 12µl  
Total volume 20µl 20µl 20µl 
 
 
Fig. 3. Vector map and multiple 
cloning site of pCMV-Tag 3. In 
pCMV-Tag 3B an adenosine is 
inserted at the site indicated by 
the asterisk. PPARγ was inserted 
at the restriction enzyme sites 
SrfI/XhoI. N-terminal myc tag. 
From www.yrgene.com 
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X.1.5 Restriction enzyme reactions 
Table 7. Restriction enzymes  
Restriction enzymes Company Buffer Company 
EcoRI R601A, Promega  H buffer R008A, Promega 
XhoI R6161, Promega D buffer R004A, Promega 
SrfI R0629S, New England Biolabs CutSmart® Buffer B7204S, New England Biolabs 
 
The restriction enzyme reactions were set up as described in Table 8, 9 and 10 and 
incubated at 37°C for 3h. Following the incubation, the restriction products were 
separated on a 1% agarose gel.  
Table 8. The restriction enzyme reaction mix 
 Standard reaction 
Plasmid DNA (pGEM-T-Easy) 5µl 
Restriction buffer 5µl 
Enzyme (EcoR1 or XhoI)  1µl 
Deionized water 39µl  
Total volume 50µl 
 
  Table 9. Restriction enzyme reaction mix 
 
Standard reaction 
XhoI restriction enzyme 1µl 
pCMV-tag 30µl 
10X Buffer D 5µl 
Deionized water 14µl 
Total volume 50µl 
 
  Table 10. Restriction enzyme reaction mix 
 
Standard reaction 
SrfI restriction enzyme 1µl 
pCMV-tag or pGEM-T-Easy 15µl 
Fig. 4.  Vector map and multiple cloning site of pCMV-Tag 5. In pCMV-Tag 5B, an adenosine is 
inserted at the site indicated by the asterisk. PPARγ was inserted at the restriction enzyme sites 
SrfI/XhoI. C-terminal myc tag. From www.yrgene.com  
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Restriction enzyme buffer  5µl 
Deionized water 29µl  
Total volume 50µl 
 
X.1.6 Escherichia coli DH5Transformation  
 
Table 11.  Mediums for bacterial growth and transfection 
Transfer buffer 10X (TAE) 40mM Tris base, 20mM acetic acid, 1mM EDTA, pH 7.6 
LB medium 0.17 M sodium chloride, 1% trypton, 0.5% yeast extract, pH 7.0 
LB-Agar LB medium, 1g/50ml agar, 100µg/ml ampicillin or 50µg/ml neomycin 
6X-Agarose loading dye 0.025% (w/v) bromophenol blue without xylene cyanol, 30% (v/v) glycerol 
SOC Tryptone 2% (w/v), yeast extract 0.5% (w/v), NaCl 10mM, KCl 2.5mM, pH 7.0, 
the solution was autoclaved, then 20mM of glucose was added 
 
X.1.6.1 Escherichia coli DH5Electroporation and blue-white screening 
Fifty µl of competent E.coli DH5α were used for one ligation reaction. Five µl of the 
ligation product were added to the tube containing bacteria and incubated for 15min on 
ice. After the incubation, the mixture was transferred to Electroporation Cuvettes and a 
single pulse (Ec2, 2.5kV) was applied (Gene Pulser®/MicroPulser™). As positive 
control, 1µl PUC-Vector was used. Following the electroporation, the mixture was put 
on ice for 10min. Thereafter, 500µl of SOC were added to each cuvette and the 
bacteria were incubated at 37°C for 30min. Then, the bacteria were spread on LB-
ampicillin 100mg/ml (pGEM) or neomycin 50mg/ml (pCMV-Tag) plates and the plates 
were incubated upside-down at 37°C overnight. 
 
X.1.6.2 Escherichia coli DH5blue-white screening 
To identify clones containing pGEM-t easy vector with the correct insert the 
electroporated E.coli DH5α were subjected to blue/white screening. For blue/white 
screening, 100µl of LB medium with 40µl X-Gal (20mg/ml) and 20µl of IPTG (0.8M) 
was prepared. The mixture was spread using glass beads on ampicillin agar plates 
and allowed to dry with half-open lids before plating the transformed bacteria.  
 
X.1.6.3 Transformation of Escherichia coli DH5α by heat shock  
50µl E.coli DH5α were mixed with 1µl PCMV sport PPARγ plasmid (1µl) by gently 
tapping the tube and incubated for 15min on ice. After the incubation, the cells in the 
tube were subjected to a heat-shock at 42°C for 90s and the tube was then placed on 
ice for 2min. Thereafter, 500µl of SOC were added to each tube and the bacteria were 
incubated at 37°C for 30min at 300rpm. Then, the cells were spread on LB-ampicillin 
plates and the plates were incubated upside-down at 37°C overnight. The following 
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day, single colonies were picked and cultured overnight in tubes containing 3ml LB 
media with 3µl neomycin (50mg/ml) at 37°C in a shaking incubator.  
 
X.1.7 Preparation of cultures for the colony PCR  
In order to identify positive clones from the ligation of the PPAR insert into PCMV tag 
vector we have used colony PCR. The PCR master mix was prepared according to 
Table 7 with either 3b or 5b primers, 50µl of the mix were added per PCR tube.  
       Table 12. Components of the PCR reaction 
 
Final concentration Standard reaction 
10X PCR buffer 1X 5µl 
Bacterial DNA from colony ------ ------ 
Primer (forward – FVmm PPARγ 35b) 2pmol 2µl 
Primer (reverse – RVmm PPARγ 5b or  
                             RVmm PPARγ 3b) 
2pmol 2µl 
dNTP 0.4mM 0.4µl 
Taq polymerase 5u 0.5µl 
Water - Till 50µl 
Total - 50µl 
 
The colonies from the overnight culture were picked using a pipette tip (Fig. 5), dipped 
into PCR tubes containing 50µl of PCR master mix, and immersed thereafter into 
tubes containing 100µl of LB media containing 50mg/ml neomycin for 5h at room 
temperature for later culture. Clones resulting to be positive were then incubated in 
3ml of LB media containing 50mg/ml neomycin and cultured at 37°C in a shaker 
overnight and thereafter subjected to miniprep plasmid isolation.  
 
The tubes containing the PCR master mix were subjected to PCR amplification with 
the same conditions as explained in Table 2. The obtained product was separated on 
an agarose gel.  
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X.1.8 Isolation of high-copy plasmid DNA from E. coli 
X.1.8.1 Miniprep plasmid preparation  
For the isolation of the high copy plasmid after ligation procedures the overnight 
cultures derived from positive clones screened by colony PCR were transferred into 
2ml Eppendorf tubes and centrifuged for 30s at 11,000g and the supernatant was 
discarded. The pellet was resuspended (according to the NucleoSpin® Plasmid 
protocol from Macherey-Nagel) in 250µl of Buffer A1, followed by the addition of 250µl 
of buffer A2 and incubated at RT for 5min until the lysate cleared. Thereafter, 300µl of 
buffer A3 were added to neutralize the blue colour and the lysate was clarified by 
centrifugation for 10min at 11,000g at room temperature. Then, the supernatant was 
loaded onto a NucleoSpin® Plasmid/Plasmid Column and centrifuged for 1min at 
11,000g to bind the DNA. In order to wash the membrane, 500µl of Buffer AW were 
pre-warmed to 50°C and added to the column, which was then centrifuged for 1min at 
11,000g. Afterwards 600µl of buffer A4 were added and the column centrifuged for 
1min at 11,000g. The membrane was dried by centrifugation for 2min at 11,000g. 
Finally, the DNA was eluted with 50µl of buffer AE following the incubation for 1min at 
room temperature and centrifugation at 11,000g. 
 
 
 
Fig. 5. Colony PCR procedure 
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X.1.8.2 Midiprep plasmid preparation 
The overnight culture was pelleted by centrifugation at 6,000rpm for 10min at 4°C 
according to the ‘High-copy plasmid purification protocol’ (Macherey-Nagel). The pellet 
was then resuspended in 8ml of Res-EF buffer followed by the addition of 8ml of lysis 
buffer. The mixture was gently inverted for 5 times and the tube was incubated for 
5min at RT. Meanwhile, the NucleoBond® Xtra Column together with the inserted filter 
was equilibrated with 15ml of EQU-EF Buffer. After the incubation, 8ml of the 
neutralization buffer NEU-EF were added to the lysate, which was then gently mixed 
by inverting until the blue sample turned colourless. The lysate was incubated on ice 
for 5min and loaded thereafter onto the column. The column and the filter containing 
the sample were then washed with 5ml of buffer FIL-EF and the filter was removed 
afterwards. The column was then washed twice with 35ml of ENDO-EF buffer followed 
by 15ml of Wash-EF buffer. The DNA was eluted with 5ml of ELU-EF buffer. The 
eluted plasmid was precipitated with 3.5ml of 2-propanol and then centrifuged at 
8,500rpm for 1hr at 4°C. The pellet was washed with 2ml of 70% Ethanol-EF and 
centrifuged at 8,500rpm for 30min at 4°C. After the centrifugation, the ethanol was 
removed and the tube was inverted in order to facilitate the drying of the pellet. At last, 
the pellet was dissolved in an appropriate volume of buffer TE-EF. 
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X.2 Results 
X.2.1 PPARγ Amplification 
In order to overexpress PPARγ in C22 cells and to investigate the role of its 
overexpression in the pathogenesis of COPD, we decided to clone PPARγ into a 
mammalian expression vector bearing a protein-tag. For this purpose, three different 
vectors, pGEM-t Easy and pCMV tag 3B and 5B, were used. pGEM-T Easy is a 
subcloning vector that allows the ligation of the fragment without previous restriction 
enzyme digestion of vector and DNA fragment. It therefore facilitates downstream 
restriction digest and cloning procedures by capturing the PCR product into a “stiff” 
frame. The pCMV tag vectors are the mammalian expression vectors used for this 
cloning procedure. The transfection of these vectors produces a protein product 
bearing a myc-tag at either the N- or C-terminal side of the protein (pCMV 3B and 5B 
respectively). The advantage of using the myc-tag is that the protein can be detected 
with a standard anti myc-tag antibody and that this allows the differentiation between 
the endogenous and the overexpressed protein. We opted further to clone PPAR with 
either C- or N-terminal myc-tag to exclude disturbances of the protein function caused 
by the location of the tag (eg. effects on subcellular localisation or protein folding).  
 
The first step in the cloning procedure was the amplification of PPARγ by PCR. For 
this purpose we designed 2 primers bearing SrfI and XhoI restriction sites, which will 
be required later for the final ligation into PCMV-Tag. As mentioned above, PCMV-Tag 
3B bears the myc-tag at the N-terminus while PCMV-5B at the C-terminus of the 
protein. Therefore, for the PCR-amplification of PPARγ we needed to design two 
different reverse primers, one of which did not contain the natural STOP codon 
present in the PPARγ-cDNA sequence and therefore will be used for the amplification 
of the PPARγ that will be cloned into PCMV-Tag 5B. 
PPARγ was amplified from the original plasmid PCMV-Sport containing PPARγ. To 
make sure that the right amount of DNA was employed during the PCR-reaction, we 
used either 2.5µl or 5µl of the PCMV-Sport PPARγ plasmid corresponding to 
respectively 50ng and 100ng of plasmid DNA. After the PCR reaction, the PPARγ 
product (3b and 5b) containing the added restriction sites was analysed by gel-
electrophoresis on a 1% agarose gel. For this purpose, the whole PCR product was 
loaded on the agarose gel. For both amounts of used PCMV-Sport PPARγ plasmid the 
electrophoresis revealed a single DNA band, of the expected size of 2,000bp (Fig.1), 
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corresponding to our amplified product (for both PPARγ). The fragments 3b and 5b 
were excised under the UV-light using a scalpel and thereafter subjected to the 
purification.  
 
 
 
The purified product was used for ligation into pGEM-T Easy. The pGEM-T Easy 
vector system allows a direct PCR product ligation into a plasmid without previous 
restriction enzyme digestion reactions since it has "T" overhangs at the insertion site. 
The Taq polymerase adds an additional "A" at the end of the amplified DNA in the 
PCR reaction, so that the PCR product is complementary to the vector´s “T” 
overhangs and can ligate directly. The ligation reaction of the purified PCR product 
into pGEM-T Easy was set-up as described in Table 5 and the product used to 
transform competent E. coli DH5α. 
 
X.2.2 Escherichia coli DH5α transformation and blue white screening 
E.coli DH5α were transformed with the ligation product by electroporation (section 
X.1.6.1) in order to identify clones containing pGEM-T Easy vectors with the PPARγ-
insert. The transformed E.coli DH5α were subjected to blue/white screening which 
allows the identification of recombinant bacteria based on their ability to hydrolize X-
Gal by β-galactosidase. Using the pGEM-T Easy system the PPARγ-fragment was 
ligated into the multiple cloning site (MCS) of the vector that contains the coding region 
for the β-galactosidase enzyme. Therefore, if the PPARγ-fragment was correctly 
inserted into the pGEM-T Easy plasmid, the bacteria should not be capable to 
hydrolize X-Gal by β-galactosidase and the colonies appear white (Fig. 2B and C). 
Colonies containing bacteria with active β-galactosidase (pGEM-T Easy without insert) 
can hydrolyze X-Gal and generate a blue product (Fig. 2A). We transformed the E.coli 
DH5α with pUC plasmid containing active β-galactosidase, as the positive control, 
Fig. 1 PCR product from the amplified 3b and 5b PCR reaction. The whole PCR reaction 
was loaded on an agarose gel and subjected to electrophoreses for 30min at 100V. The 
separated fragments corresponded to the expected size of 2,000bp. 
 
 
117 
 
giving, as expected plenty of blue colonies on the agar plate (Fig. 2A). The number of 
colonies on the plates transformed with the pGEM-T easy ligations (Fig 2B and C) 
was 50% lower than the one observed for pUC (Fig. 2A). However, the number of 
white colonies in Fig. 2B and C was much higher than the number of blue colonies. 
This suggested that the PCR product was successfully transformed into E.coli 
disrupting the β-galactosidase gene and rendering the colonies to appear white in 
color. 
 
 
 
X. 2.3 Plasmid isolation and restriction enzyme digestion 
From the white colonies obtained in section X.2.1 overnight cultures were set up and 
subjected to miniprep for the isolation of high copy plasmid. In order to determine 
whether the eluted DNA contains indeed the PPARγ insert, the isolated pGEM-T easy 
plasmids were subjected to restriction enzyme digestion with EcoRI followed by gel-
electrophoresis. pGEM-T Easy contains 2 EcoRI sites flanking the DNA-fragment 
insertion sites. When this enzyme is used for the restriction enzyme digest of pGEM-T-
easy, the inserted fragment is excised form the vector generating two products. In our 
case, the PPARγ insert contained an additional EcoRI site, and therefore 3 products 
were expected from this digest: two bands of approximately 1,000bp each 
representing PPARγ cut in half and one band of 3,000bp corresponding to pGEM-T 
Easy plasmid. The results of the digest are shown in Fig. 3 and display the expected 3 
bands. All clones that we had picked from the blue/white screening proved to be 
positive. For the next step, the digest with the restriction enzymes SrfI and XhoI, we 
therefore picked only one clone for 3B and one for 5B 
Fig. 2 Blue/white screening. Transformed E.coli DH5α were plated on agar plates with LB medium 
containing ampicillin and supplemented with X-gal. Colonies containing the ligated product are white, 
whereas those containing unligated plasmids are blue. A) Positive control, B) 3B clone, C) 5B clone 
 
 
118 
 
 
 
X. 2.4 Restriction enzyme digestion with SrfI and XhoI digestion 
After the confirmation of a successfully ligated PPARγ insert, our next purpose was to 
subclone the insert into the pCMV vector. For this, we had to digest the pGEM-T Easy 
and the pCMV vector with the restriction enzymes SrfI and XhoI. Since the enzymes 
were bought from different companies and required two different restriction enzyme 
buffers, we had to perform the two digestion reactions subsequentially. All the vectors 
were first digested with SrfI and 5µl of this digest were analysed on a gel to assess the 
correct linearization of the plasmids. The SrfI digest resulted, as expected, in one 
single band on the agarose gel representing the linearized vectors of approximately 
4,000 bp (Fig. 4). Following the SrfI digestion, the digested product was subjected to a 
PCR clean-up to remove the previous restriction enzyme buffer. Thereafter, the 
purified products (pGEM-T Easy containing PPARγ and pCMV) were digested using 
XhoI and then analysed on an agarose gel. This digest generated 2 bands (Fig. 5) for 
the pGEM-T Easy digests, eg one for pGEM-T-easy (3,000bp) and one for the PPARγ 
insert (2,000bp). On the other hand, for the pCMV-Tag digest, only one band of 
3,000bp could be detected, corresponding well to the linearized vector. Following the 
electrophoresis, the bands corresponding to pCMV-Tag 3B and 5B and to PPARγ 3B 
and 5B were excised from the gel and purified.  
Fig. 3 Restriction enzyme digestion product Agarose gel electrophoresis after digestion with the 
restriction enzyme EcoRI presenting 3 bands. The band of 3,000bp corresponds to pGEM-T Easy 
and the 2 bands of 1,000bp correspond to the 2 fragments of PPARγ. A) 3B clone, B) 5B clone. 
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X. 2.5 Colony PCR Reaction 
The purified DNA was further used for the final ligation reaction of the PPARγ 
fragments into pCMV-Tag 3B and 5B. The ligation reaction was set-up and then used 
to transform competent E.coli DH5α (section X.1.6.1). pCMV-Tag 3B-GFP was used 
as a positive control. The bacteria were plated on agar plates supplemented with LB 
media and neomycin as a selection marker. The clones containing PPARγ ligated into 
pCMV-Tag as well as clones containing pCMV-Tag without insert (self-ligated plasmid) 
are able to grow on the plates and cannot be differentiated as previously done using 
blue-white screening (Fig. 4B and C). Therefore, the next step was to identify, among 
the grown colonies, the positive clones containing PPARγ ligated into pCMV-Tag; for 
this purpose we used colony PCR. The colony PCR allows the identification of the 
presence or absence of the insert in the plasmid. Whole bacteria were used for the 
colony PCR since the initial 95°C heating step of the PCR reaction allows the release 
of the plasmid DNA from the bacterial cell. The released plasmid DNA containing the 
Fig. 4 SrfI digestion product. Agarose gel 
electrophoresis after digestion with the restriction 
enzyme SrfI presenting 1 band corresponding to pGEM-
T Easy and pCMV vectors. 
Fig. 5 XhoI digestion product. Agarose gel electrophoresis of a product after digestion with the 
restriction enzyme XhoI resulting in 3 bands. The bands correspond to pCMV (3000bp), pGEM-T 
Easy, and PPARγ insert (2000bp).  
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insert is then used as a template for the amplification reaction. Insert-specific primers 
were used for the PCR amplification. Gel electrophoresis of the obtained PCR-
products revealed a single band corresponding to 2,000bp, this suggested that all the 
clones were PPARγ positive. The clones that were positive were incubated in 3ml of 
LB media supplemented with neomycin and cultured at 37°C overnight in a shaker. 
Thereafter, DNA was isolated and purified from the overnight culture by miniprep. 
 
 
 
 
To double-check that indeed the clones contained the right insert, a PCR reaction was 
set-up with the eluted DNA. Following the PCR, the products were separated on the 
agarose. Unfortunately, no bands were observed on the agarose gel and we had to 
conclude that either the isolated DNA was not of good enough quality to perform a 
PCR-reaction or that the results of the colony-PCR were “false positives”. However, 
even after several repetitions of the ligation and screening procedure we were unable 
to obtain the final PCMV-Tag vectors containing PPARγ. We therefore finally decided 
to use the original PCMV sport PPARγ plasmid that we used for the amplification of 
the PPARγ ORF for the transfection and overexpression experiments, despite the fact 
that the PCMV sport vector does not contain a myc tag. 
Fig. 4 Neomycin clones. Transformed E.coli DH5α were plated on agar plates with LB medium 
containing neomycin. Colonies containing the ligated PPARγ fragment into pCMV-tag were 
identified on the plates (B&C). A) Positive control, B) 3B clone, C) 5B clone 
Fig. 5 Colony PCR product. Agarose 
gel electrophoresis of the colony PCR 
presenting 1 band corresponding to 
the pPPARγ insert. 
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